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Abstract 
 
Cancer-associated fibroblasts (CAF) form a heterogenous stromal cell population of 
a solid tumor. They are known to promote tumor growth and survival through 
metabolic reprogramming and inflammation. It is unclear though whether CAF are 
crucial component of tumor initiation and whether CAFs are dispensable altogether 
from the fully developed neoplasm. Tumor suppressor LKB1 regulates AMPK and 
AMPK-related kinases (ARK), and its function is compromised in familial disorder 
Peutz-Jeghers syndrome (PJS). Fibroblast specific haploinsufficiency of LKB1 alone 
is sufficient of initiating gastrointestinal polyposis but the mechanism through which 
LKB1 mediates this is only partially understood. We provide evidence that LKB1 is 
downregulated in multiple human malignancies including high grave serous ovarian 
cancer (HGSOC). Human ovarian cancer is the most lethal gynecological disease, 
characterized by metastasis of omentum. Loss-of LKB1 in ovarian fibroblasts was 
accompanied with metabolic changes associated with CAF-transformation. We 
screened down critical LKB1 substrates through transcriptomic and functional assays 
revealing AMPKa1 and MARK3 as potential downstream effectors of oxidative 
phosphorylation. AMPKa1, MARK1 and SIK-family were the glycolytic counterparts. 
We also took an initiative of cataloguing published human cancer stroma data in order 
to gain more comprehensive look of tumor heterogeneity. Metabolic rewiring was also 
observable in published cancer-stroma datasets. Human cancer-stroma divided into 
metabolically active and highly inflamed subtypes. These results highlights LKB1’s 
role as a conserved metabolic caretaker in fibroblasts. Our data also support 
mechanistic model in which LKB1 and ARKs regulate mitochondrial metabolism, 
essential for CAF transformation. 
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2. Abbreviations 
 
aSMA  a-Smooth muscle actin 
ATP   Adenosine triphosphate 
AMP   Adenosine monophosphate 
AMPK  Adenosine monophosphate kinase 
ARK   AMPK-related kinase 
BC   Breast cancer 
CAF   Cancer-associated fibroblast 
COL   Collagen 
CT   Connective tissue 
ECAR  Extracellular acidification rate 
ECM   Extra cellular matrix 
EMT   Epithelial to mesenchymal transition 
FRT   Female reproductive tract 
GI   Gastrointestinal tract 
GSEA  Gene set enrichment analysis 
HOF   Human ovarian fibroblast 
iHOF   Immortalized human ovarian fibroblast 
HGSOC  High-grade serous ovarian cancer 
LKB1  Liver kinase beta 1 
MARK1-4  Microtubule affinity regulating kinase 1-4 
MEF   Mouse embryonic fibroblast 
MF   Myofibroblast 
MMP   Matrix metalloproteinase 
MOCK  Non-manipulated control sample 
MSC   Mesenchymal stem cell 
mtDNA  Mitochondrial DNA 
NUAK1-2  NUAK-family SNF-like kinase 1-2 
OCR   Oxygen consumption rate 
OXPHOS  Oxidative phosphorylation 
OVCA  Ovarian cancer 
PSC   Pancreatic stellate cell 
PJS   Peutz-Jeghers syndrome 
ROS   Reactive oxygen species 
RT-PCR  Reverse transcription polymerase chain reaction 
shRNA  Short/small hairpin ribonucleic acid 
SIK1-3  Salt-inducible kinase 1-3 
SCR   Scrambled control sample 
SNRK  SNF1-related kinase 
TGFB  Transforming growth factor beta 
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3. Review of Literature 
 
3.1 Cancer-Associated Fibroblast 
Cancer-associated fibroblasts (CAFs) account for a heterogenous stromal cell 
population malignant microenvironment. Though cancer evolution shapes the tumor 
surroundings to enhance tumor growth, the mechanisms are constrained to some 
extent by the homeostatic functions of fibroblasts. Thus, instead of jumping directly 
into the cancer, we will begin by supplying the very basic requisite data from healthy 
tissue. 
 
3.1.1 Fibroblast 
Fibroblasts comprise a major cell type in organism’s connective tissue (CT). CT forms 
the structural frame of all the organs in body scheme. Fibroblasts are often found 
quiescent, nonproliferating and relatively sparse within the CT (Image I). They are 
often identified as small, spindle shaped cells expressing e.g. vimentin, PDGFRa, 
aSMA, FSP1 and N-Cadherin. They are major source of extracellular matrix (ECM). 
ECM supports anchorage, growth and migration of other cells within the tissue. 
Through interactions with ECM, fibroblasts exert mechanical force and tension 
throughout the body. This in order to preserve rigidity even with no muscle contraction 
present [1]. During homeostasis fibroblasts are quiescent. Upon injury, shift in 
balance quickly turns them into activated form. They are heterogenous group of cells 
with potential to transdifferentiate into multiple different stromal lineages following 
activation [2,3]. Fibroblast activation is highly linked to physiological and pathological 
conditions such as wound healing, scarring, granulation tissue formation, cancer 
progression, metastasis and fibrosis.  
 Connective tissue is of mesenchymal origin; connective tissue of a developing 
organism. Mesenchyme on the other hand originates from mesoderm, one of the 
three germ layers in developing embryo. Mesenchymal stem cells (MSC), progenitors 
of mesoderm and mesenchyme, give rise to different stromal cell populations of adult 
connective tissue (Image I, B). Fibroblasts have been shown multipotent and 
indistinguishable from mesenchymal (stem) cells. Even differentiated fibroblasts 
 7 
show marked similarity between MSCs. For example, surface marker expression, 
transcriptome and methylome as MSCs [4,5].  
 MSCs and transdifferentiation are not the only pathways for regeneration of 
fibroblasts. Later in the fully developed organism generation of new fibroblasts can 
result from epithelial cells that transform into fibroblasts, process called epithelial-to-
mesenchymal transition (EMT). Similarly, fibroblasts are able transform into epithelial 
cell through mesenchymal-to-epithelial transition (MET). EMT and MET are naturally 
occurring in development but are also induced during a variety diseases and 
malignancies. Fibroblasts are generated from local MCSs, but they can also migrate 
from bone marrow derived MCSs that spread via circulation.   
 
3.1.2 Characteristics of Fibroblasts 
In addition to localization of fibroblasts within the connective tissue, there are several 
molecular markers and functions that can be used to distinguish them from other cell 
types. 
 
3.1.2.1 Molecular Characteristics: Extracellular Matrix 
Extracellular matrix functions as a structural component of connective tissue. It is 
responsible for the elasticity, tension and impact resistance of CT. It also serves as 
docking platform for resident stromal cells and signaling molecules secreted by them. 
Fibroblasts are responsible for generation and modification of ECM. They are not the 
only ECM modifying cells, but they have their own responsibilities and tissue specific 
functions in it. CT is traditionally divided into loose and thick according to the fraction 
ECM present in the tissue. 
 Despite its enormous heterogeneity, ECM’s structural components shear some 
common molecular features. Microscopic analysis of ECM shows enrichment of 
filamentous mesh proteins. These mesh-components are often extremely long 
polypeptide chains. They form fibrous protein structures by attaching to each other 
through e.g. conserved aminoacids repeats. The long stretches of ECM components 
are often modified by degradation or post-translational modifications. Components 
secreted by fibroblasts comprise of collagens (COLI, COLII, COLIII, COLIV, COLV, 
COLVI), fibronectin, laminin, proteoglycans (perlecan), glycoproteins (nidogen), 
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glycosaminoglycans, polysaccharides and elastin [6]. In order to further modify 
the secreted components, fibroblasts release certain modifying enzymes. Matrix 
metalloproteinases, such as MMP1 and MMP3, work by degrading certain ECM 
components, thus modifying the environment suitable for predetermined purposes 
[7]. Different MMPs are specific against certain types of collagens for example. This 
type of specificity originates from the repetitive, signature sequences in the 
corresponding collagen aminoacids or though post-translational modifications.  
 ECM of normal tissue is usually soft, with the exception to bone. The fibers are 
elastic and bend in response to mechanical stress. In pathologic circumstances 
however, the ECM is found to get stiffer and more linearized compared to 
homeostatis [8,9,10]. This is proposed to give e.g. cancer cells opportunities for 
metastasis and vascularization: degraded ECM and liberated growth factors promote 
vascularization. 
 
Image I. Different 
fibroblast populations. A) 
Adult murine female uterine 
tube: serial sections stained with 
aSMA (muscle layer, right), 
vimentin (fibroblasts, middle) 
and E-Cadherin (epithelia, 
right). Note clear separation 
between the aSMA+; Vim- 
muscle and aSMA-; Vim+ 
fibroblasts. B) Developing 
(E13.5) mouse small intestine. 
Mesenchymal fibroblasts locate 
between thin smooth muscle 
layer (red) and epithelial cell layer (dotted line). Highly proliferative embryonic tissue has also 
multiple EdU+ fibroblasts. Note, development of intestinal villi begins only after E13.5. C) Adult 
murine intestine villi show aSMA expressive myofibroblasts inside the villus structures in addition to 
smooth muscle layers (bottom). Stem cell supporting pericyptal myofibroblasts locate at the bottom 
crypt (not visible). D) Primary mouse embryonic fibroblasts cultured on plastic and stained with 
phalloidin and mitochondrial outer membrane marker Tom20. Note the size and morphological 
variation among the cells. C) is 2x higher magnification than A), B) and D). Scale bar 200µm. Source 
Päivinen P.J.P. 
 
Phalloidin (Actin)
TOM20 (Mitochondria)
Hoechst (DNA/Nucleus)
!SMA (Smooth muscle)
EdU (Proliferating/DNA synthetizing cells)"III-Tubulin (Neurons)
Hoechst (DNA/Nucleus)
!SMA Vimentin E-Cadherin
A)
B) C) D)!SMA (Smooth muscle)Hoechst (DNA/Nucleus)
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3.1.2.2 Functional Characteristics: Wound healing 
Wound healing is one of major physiological responses highlighting the role of 
fibroblasts and CT. During the tissue injury, connective tissue produces granulation 
tissue at the site of trauma. Granulation tissue is a specialized site which supports 
wound closure, vascularization and immune response. It aims to keep the trauma 
localized and prevent it from spreading. Granulation tissue is also high in fibroblast 
content. Granulation tissue’s environmental factors (ECM tension, secreted growth 
factors, cytokines and chemokines) promotes fibroblast differentiation towards so-
called activated fibroblasts, myofibroblasts (MF) [11,12]. Myofibroblasts are smooth-
muscle-like cells with high expression of alpha-smooth muscle actin (ACTA2, protein 
a-SMA) [1]. They are differentiated fibroblasts that promote wound contraction, 
scarring and fibrosis. MFs share characteristics of fibroblasts of solid tumors, cancer-
associated fibroblasts. 
 Fully differentiated MFs sense the surrounding environment through mechano-
transduction. Intracellular actin stress fiber apparatus is connected to extracellular 
fibronectin. This connection transmits signals from changes in the ECM structure 
during tissue repair and embryogenesis. Stress fibers are associated with non-
muscle myosin which is one discrimination between myofibroblasts and 
smooth/skeletal muscle. Proto-myofibroblasts are so-called premature 
myofibroblasts which lack a-SMA expression [13]. As the wound heals, the proto-
myofibroblasts differentiate to myofibroblasts which are capable of producing 
increasing amounts of tension and helps sealing the wound [11].  
 
3.1.3 Central Stromal Pathways 
In the following sections we will describe some well-established signaling pathways 
that have been shown to play critical roles both in normal fibroblast differentiation, 
connective tissue remodeling and cancer-associated-fibroblast-transformation. 
 
3.1.3.1 Epithelial to Mesenchymal Transition  
Epithelial to mesenchymal transition (EMT) is a process of transformation of epithelial 
cells into more mesenchymal type. The process involves multiple complicated 
signaling pathways, many of which converge finally into reduction of epithelial 
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markers and induction of mesenchymal markers. EMT is a natural process that is 
required for proper development and homeostasis. It is a dynamic, reversible 
process, and also the opposite, mesenchymal to epithelial transition (MET) is 
described.  
 Epithelial cells are characterized by apical-basal polarity, that e.g. situates 
different intracellular effectors accordingly within the cytosol for enhanced signal 
transduction. The epithelial cells harbor tight, gap and adherent junctions between 
the neighboring cells. Epithelial markers such as E-cadherin (CDH1), claudin 
(CLDN1), occludin (OCLN), desmoplakin (DSP) and plakophilin (PKP1) are epithelial 
proteins associated within these junctions. The downregulation of these protein is 
also used as a readout of ongoing EMT. Downregulation of epithelial markers, and 
subsequent induction of fibroblast markers, is accompanied by phenotypic changes. 
These include fibroblast-like phenotype and detachment from epithelial layer.  
 EMT is important for cancer invasiveness. Normal epithelial cells are not able 
to penetrate the basement membrane, on top of which they sat on. During EMT 
however, they acquire stromal features that enable them to do so. In addition to 
invasiveness, EMT helps cancer cell migration, supplies more stromal cells, 
promotes their proliferation and most importantly helps the cancer cells to adapt to 
the changing environment.   
 
3.1.3.2 TGFB-signaling 
Transforming growth factor beta 1 (gene TGFB1; protein TGFB1) is a well 
characterized growth factor that is capable of inducing fibroblast differentiation into 
myofibroblast in favorable environment [12]. In homeostasis it inhibits proliferation. 
Paracrine and autocrine secretion of TGFB-substrates (TGF-B1, -2 and -3) 
accumulate in ECM during wound healing. It is secreted from a variety of sources 
most notably from platelets, macrophages and epithelial cells. In order to activate 
TGFB gets cleaved from LTF (lactoferrin). Active form of TGFB can signal through 
TGFB receptors I/II (TGFBR1/2, TGFBR-1/2).  
 TGF-B1/3 homodimers bind to the TGFBR-2. This ligand-receptor complex has 
high affinity towards the TGFBR-1. TGFBR-1 can thus associate to TGFBR-2. 
Furthermore, it will bind the unoccupied TGF-B1-3 monomer. This way, ligand 
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binding brings the two receptor types in close proximity and transduces the 
extracellular signal across plasma membrane. Intracellular Ser/Thr-kinase subunit of 
TGFB-R2 phosphorylates the TGFB-R1 and thus activates this. The signal is further 
transmitted as phosphorylation series of downstream effectors: phosphorylation 
promotes association of CO-SMAD (SMAD4) and R-SMADs (SMAD1,2,3,5,8). CO-
SMAD/R-SMAD complex migrates to the nucleus. Functioning as a transcription 
factors it promotes TGFB-responsive gene expression. This is mediated either 
directly from the membrane or via early endosome: TGFB-R1-2 complexes can be 
internalized, and the signalosome can be thus targeted somewhere else. Signaling 
can also be blocked through I-SMAD/caveolin-1 mediated endocytosis followed by 
proteosomal degradation. I-SMADs (SMAD6,7) directly compete with R-SMADs in 
TGFB-RI phosphorylation site74,129 [14,15]. Caveolin-1 (CAV1, CAV1) inhibition acts 
though TGFB-receptor dynamics. Caveolae are membrane bound proteins required 
for membrane invagination. CAV1 inhibits TGFB-signaling via promoting TGFBR-1 
degradation: TGFB receptors are bound to CAV1 localized lipid-rafts that are 
internalized. Regulating CAV-1 expression also regulates TGFB-receptor turn-over 
[14]. Therefore, silencing CAV1 results in alleviated TGFB-signaling and fibroblast 
activation. Also, RAS is able to convey silencing phosphorylation of R-SMADs though 
MAPK-pathway and thus inhibiting TGFb signaling [15].  
 SMADs control transcription of a range of pathways. Upregulation of SNAI1/2, 
TWIST1, COL-VI, VIM, FN1 and downregulation of CDH1 and OCLN are either direct 
or indirect outcomes of TGFB-signaling, but they are direct in sense of EMT [16]. 
TGFB can also control EMT through pathways outside SMADs like PI3K-AKT, RAS 
and GSK3b. It is noteworthy that TGFB-signaling works in concert with b-catenin 
(WNT-independent). b-catenin enables e.g. aSMA induction following TGFB 
activation. Loss-of b-catenin does not however compromise e.g. SMAD2 mediated 
transcription [17].  
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3.1.3.3 Integrin-signaling 
Epithelial cells observe and anchor to their surroundings (bottom basement 
membrane and neighboring epithelial cells) through dimeric integrin molecules. 
Integrin dimers form from a and b subunits. Diversity of integrin subunits (18 a’s and 
8 b’s) gives these dimeric receptors vast ability to interact with a variety of ECM 
components. These components include collagens, fibronectin and laminin. How 
epithelial integrin signaling is intertwined to fibroblasts and stroma comes through 
EMT. Integrin signaling works in concert with b-catenin to regulate TGFB. a3b1-
integrin mediates TGFB-R1 internalization specifically at E-cadherin foci. 
Furthermore, this association is necessary for SMAD2 and b-catenin 
phosphorylation. Indeed, expression of dominant-negative b-catenin, effectively 
block the aSMA expression induced by TGFB1, also justifying the role of b-catenin 
in EMT [17]. 
 Another integrin mediated E-cadherin disruption is mediated through b1-integrin 
(ITGB1, CD29). b1-integrin recognizes type I collagens and activates FAK (focal 
adhesion kinase) through Scr. FAK phosphorylates (again) b-catenin, but in contrast 
to earlier a3b1 induced b-catenin phosphorylation (Tyr654), this phospho-b-catenin 
migrates to nucleus and affects transcription (Ref155, small notion) [18]. Thus, it is 
possible that these two b1-mediated integrin pathways are divergent.     
 
3.1.3.4 Mechanotransduction: YAP/TAZ, HH and Myocardin 
Transcription factors YAP and TAZ are regulated independently through conserved 
Hippo-signaling and direct mechanical cues from ECM and cytoskeleton. They are 
vital part of cellular mechanotransduction [19].  
 Hippo-signaling starts from MST1/2 which control the activity of LATS1/2. 
LATS’s are responsible of regulation of Hippo pathways effectors YAP and TAZ: 
LATS phosphorylates YAP (Ser127) and TAZ thus inducing their cytoplasmic 
retention and degradation. When unphosphorylated, YAP/TAZ are transported to the 
nucleus. There they regulated transcription of Hippo-targets by associating with their 
TEAD effector proteins. Together they genes regulate proliferation, stemness and 
survival.  
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 Outside-in, ECM has a profound role in inducing tension and force through the 
focal adhesions to the cytoskeleton, and thus promoting stiff matrix responsive genes 
such as a-SMA and YAP-targets. By depleting YAP from cancer-associated 
fibroblasts effectively blocks this mechanotransductive pathway and reduces the 
cancer invasiveness. Depletion of TAZ on the other hand has less pronounced effect. 
Importantly, also TGFB is able to induce nuclear localization of YAP though indirect 
ECM remodeling [20]. Additionally, this cancer supporting function of YAP can be 
induced by means independent of mechanotransduction, namely Hippo-signaling 
[20]. This could mean that despite stiff ECM, active Hippo could potentially be 
sufficient driver of cancer-associated fibroblast expansion. 
 Interesting observation from mammalian development connects YAP/TAZ, 
Hedgehog and myofibroblast differentiation: YAP is an inhibitor of MF differentiation 
[21]. It suppresses the MF gatekeeper MYOCD (myocardin) transcription. MYOCD 
belongs to a family of transcription factors responsible for myofibroblast differentiation 
[22]. This suppressive effect is mediated though YAP/TAZ’s tissue mechanic’s 
sensing properties and HH-signaling pathway [21].  
 Hedgehog signaling is a conserved signaling pathways with important 
implications in basic development. HH-ligand (SonicHH, IndiaHH) binding to its 
membrane receptor PTCH. This relieves HH-effector, Smoothened (SMO) from 
retainment mediated by PTCH. SMO migrates to primary cilium, were it again 
activates and relieves GLI transcription factors from SUFU. SUFU restricts GLIs 
spatially and functionally, and thus prevents HH mediated transcription. GLIs (GLI1 
and GLI2) are transported to nucleus where they promote HH-responsive gene 
transcription. Hedgehog can contribute to cancer associated EMT. Gli1 promotes 
expression of Snai1 followed by reduction of E-cadherin in epithelial system and 
basal cell carcinoma-like expansion in vivo. The transcriptomic changes do not 
however seem to translate into morphologically mesenchymal cells, thus it is possible 
that HH mediates EMT only to a certain degree [23]. 
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3.1.3.5 Cytokines, Chemokines and Inflammation 
Pro-inflammatory response of the fibroblasts is a hallmark of cancer initiation and 
progression [24]. Fibroblast inflammatory responses are different from one cancer 
type to another. Skins, breast and pancreas for example show marked upregulation 
of inflammation whereas cervical cancer does not. The time-course of tumor 
inflammation can also change. The early inflammatory response enhances the 
macrophage recruitment, angiogenesis and survival of cancer cells. Mechanistically, 
inflammatory cytokines induced by the CAFs (COX-2, CXCL1, CXCL2, CXCL5, IL-6, 
IL-1b) could mediate more systemic inflammation of the tumor tissue through e.g. 
NF-kB-signaling [24].  
 IL-6 is one particularly interesting and well described inflammatory cytokine. IL-
6 acts through binding to its membrane receptor IL6Ra. Receptor binding follows 
receptor dimerization and signal transduction via GP130 and STAT3 transcription 
factor. Forced IL-6 expression in breast cancer cells, degrades E-cadherin and 
induces the expression of stromal N-cadherin, SNAI, TWIST and vimentin, 
collectively induces EMT [25]. In human patients it is actually the stromal CAFs who 
are responsible for secreting IL-6. Stromal IL-6 recapitulates the EMT phenotypes 
but also confers significant chemoprotection to the cancer cells [26]. However, IL-6 
mediated EMT seems to be mediated by other means than after loss-of a1-integrin: 
there the protein levels of E-cadherin remain stable but rather the localization 
changes [17,25,26].  
 
3.1.4 Cancer-Associated Fibroblast 
Cancer stroma comprises the micro-milieu surrounding the solid tumor. This tumor 
microenvironment comprises of the same stromal cells as connective tissue in 
general, but with tumor promoting properties. This is also the origin of cancer-
associated fibroblasts (CAFs). Currently the role of CAFs (carcinoma-associated-, 
tumor-associated-), is well acknowledged in multiple neoplasms. Generally, CAFs 
are taken as tumor supporting population of stromal cells. Yet, still their exact 
functions are heterogenous and not well understood in detail. 
 As in wound healing, during tumor formation, changing environmental factors 
directs fibroblast transformation to CAFs. Key players in transformation are the 
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secreted chemokines, cytokines, growth factors and other biochemically active 
molecules (see above) [27]. Transformed fibroblasts modify the ECM for more 
suitable for the new acquired state [6,28]. This can further support the activation of 
normal fibroblast through tissue mechanics. Since the circumstances however are 
not the same as in e.g. wound healing this can be taken as misinterpretation of the 
surroundings. In context of CAFs one often hears, ‘cancer is a wound that does not 
heal’. 
 All organs have their own specialized connective tissues and fibroblast 
subpopulations [29]. Because of this, cancer can have extremely specific 
characteristics when it comes to initiation, progression and metastasis. To appreciate 
this complexity, we will go through some of best-studied organs and their 
malignancies: vasculature, skin, stomach and intestine, breast, pancreas and 
ovaries. We give explain some detailed mechanisms which apply many of the 
abovementioned pathways.  
 
3.1.4.1 Vasculature 
Capillary pericytes are proposed to possess MSC properties. They are a population 
of perivascular mesenchymal cells. Pericytes account for the capillary functions by 
communicating with vascular endothelial cells through paracrine signaling. This 
signaling accounts for capillary flow rate and permeability, trough interactions with 
endothelial cells. Endothelial cells form the luminal surface epithelia of blood vessels. 
Since all the connective tissue is also vascularized, pericytes and endothelial cells 
are common for all the organs. There are however tissue-specific differences in how 
pericytes actually colonize vessels in difference tissues at different conditions e.g. 
lung capillaries are more abundantly colonized by pericytes than on average. Though 
not fibroblasts, pericytes and endothelial cells account for disease progression 
through differentiation. More specifically through pericyte-fibroblast-transition (PFT) 
and endothelial-to-mesenchymal transition (EndoMT) respectively.  
 Pericytes dissociate from the vasculature after trauma or stromal cues, and 
subsequently acquire fibroblast-like phenotype [29,30]. PFT is augmented by PDGF-
signaling: PDGF-PP binding to PDGFR-b is efficient driver for pericytes to migrate 
away from the vessels. This is counterbalanced by transforming the pericytes into 
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CAFs. Importantly, this is driven primarily through PDGFR-b and receptor type -a is 
not accounting for it [31]. Blocking PDGFR-b signaling, the tumor growth and 
angiogenesis are significantly compromised, associated with reduced PFT. 
Interestingly, similarly as in PFT in cancer, during spinal cord injury, resident pericytes 
are forming the vital part of scarring tissue. Following the injury, there is a substantial 
increase in vasculature followed by migration of a specific pericytes away from the 
vessels to form the scarring tissue. Interestingly, these scar-forming fibroblasts are 
positive for PDGFR-b but lose the expression of PDGFR-a. They also begin to 
express a-SMA and fibronectin [30]. EndoMT on the other hand, is driven through 
more classical EMT by TGFB-signaling. TGFB1 in the endothelial cells promotes 
transdifferentiation by increasing stromal gene expression and dampening the 
epithelial genes [32].  
 
3.1.4.2 Skin 
 
Skin fibroblasts (dermal fibroblasts) have been extensively characterized. So far 
there are at least 8 fibroblast subpopulations discovered: papillary1 (CD26+, BLIMP1-
, LRIG1+, SCA1-), reticular2 (DLK1+, SCA1-), hypodermal fibroblasts3, hair follicle 
dermal papilla fibroblasts4 (SOX2+, CD133+), dermal sheath fibroblasts5 (SOX2+, 
CD133+), myofibroblasts6, preadipocytes7 (CD24+, CD36+, SCA1+, ZFP423+) and 
pericytes [33,34,35]. These populations are separated from epithelial cell layer by 
basement membrane (BM), as are all the other mesenchymal compartments in the 
body. Only the fibroblasts in dermal papilla are situated in the epithelial side of BM. 
 During wound healing the α-SMA+ myofibroblasts from neighboring dermal 
tissue colonize the wounded area. Immune cells take care of inflammatory response 
initiation while fibroblasts begin to exert tension to the granulation tissue and seal the 
wound. Lineage tracing studies have given insight into which one of the fibroblast 
populations participate the most. So far it seems that reticular fibroblasts are a major 
contributor for wound healing, whereas FDBF’s not so much. Also, preadipocytes 
contribute to dermal healing process [34].  
 Studies on dermal squamous cell carcinomas (SCC) have given important 
insight into skin cancer and its resident CAFs. Notch signaling has gained special 
attention [36,37]. In physiological circumstances, Notch is regulating e.g. keratinocyte 
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differentiation. Stromal deletion of RBPJ (also called CBF-1 in human, RBP-Jk/CLS 
in mouse, component of NOTCH-RBP-AP1 axis) results in CAF marker gene 
upregulation, dermal thinning, fibroblast senescence and development of 
keratinocyte tumors, type of skin SCC [36]. This effect could be effectively blocked 
with inhibition of AP1 and/or c-Fos/c-Jun signaling [36]. Interestingly, RBPJ also 
physically interacts and inhibits TP53 and thus apoptosis and senescence [37]. Thus, 
blocking RBPJ alone would result in CAF-target upregulation but also induced 
senescence and CAF exhaustion. On the other hand, inhibiting both RBPJ and TP53 
would enable CAFs to circumvent TP53 mediated apoptosis and proliferate [37]. It is 
however possible that CAF genes regulated by loss-of RBPJ, would mediate 
coincidental inhibition of TP53. Indeed, FGF receptors and ligands are capable of 
inhibiting TP53: their expression is elevated in CAFs and more recently observed 
upregulated in human cancers also [37].  
 
3.1.4.3 Lung 
Pulmonary stroma comprises mostly pericytes, resident fibroblasts, myofibroblasts, 
mesothelial cells, lipofibroblasts, adipocytes and mesenchymal stem cells (ABCG2+) 
[38,39]. Quantities of different fibroblast subtypes varies temporally which makes the 
classification challenging. Pericytes are responsible for maintaining sufficient gas 
exchange in extensively vascularized lungs. Resident fibroblasts localize to the 
interstitial compartment and differentiate to myofibroblasts [40]. Also bone marrow 
derived MSC supply to the pool of myofibroblasts [37].  
 In lung pathology, non-small cell lung cancer (SNCLC), interstitial lung disease 
and idiopathic pulmonary disease (IPD or IPF, idiopathic pulmonary fibrosis) are the 
most studied diseases with respect to surrounding stroma. IPF is a fatal lung disease 
in which normal tissue is replaced by increasing amounts of ECM due to stromal 
activation. Though not a cancer, we designate fibrotic fibroblasts of IPF also CAFs. 
The disease has no cure. In mouse, IPF is possible to induce by intratracheal injection 
of bleomycin. Following a month or-so, lesions arise, characterized by fibrotic 
activation. In addition to resident fibroblast activation, CAF reservoir is supplied at 
least through bone marrow and pericytes [39,41]. Regarding EMT, reports are either 
in favor or against [39,41,42]. For example, bone marrow derived CAFs (in IFP 
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context) do not respond to TGFB-stimulation by upregulating aSMA [41]. Then again, 
AECs (alveolar epithelial cells) are either commencing or not commencing EMT in 
vivo. Explanation for this might lay within temporal dynamics in CAF transformation: 
signature CAF markers seem to fluctuate during the course of fibrosis, thus e.g. 
aSMA may not be stably expressed [39].  
 Lung cancer is the deadliest neoplasm, accounting up to millions of affections 
and deaths each year. Mutations in K-RAS and STK11 are often identified, the former 
acting as a potent driver.  NSCLC can be categorized in adenocarcinoma (ADC) and 
squamous carcinoma (SCC). A number of reports has studied lung cancer-stroma 
cross-talk with focus on metabolism. In late stage of ADC, CAFs are characterized 
by induced glycolytic capacity and decreased oxidative phosphorylation, consistent 
with the general hypothesis of reverse Warburg effect [43]. These changes are 
mediated through epithelia-stroma signaling and affects also the cancer cell’s 
metabolism [44]. Stromal metabolism has a big role also in delineating the differences 
between the lung ADC and SCC. ADC-CAFs are more glycolytic compared to SCC. 
In SCC it is the cancer cells who are glycolytic [44]. Hexamine biosynthesis enzyme 
GFAT2 (gene GFPT2) shows high association CAF glucose uptake and EMT/TGFB-
signaling in ADC, whereas SLC2A1 and G6PD are more prognostic for SCC [44]. 
 
3.1.4.4 Gastrointestinal Tract 
Stomach, intestine and colon stromal cells are situated in the intestinal connective 
tissue, lamina propria within mucosal layer. Gastrointestinal (GI) tract consists of 
multiple different mesenchymal cell populations: fibroblasts, mesenchymal stem cells 
from bone marrow, pericytes, myofibroblasts and interstitial cells of Cajal. Intestinal 
fibroblasts develop from mesoderm derived mesothelium but also from neural crest 
cells [45]. Adipocytes, epithelial and smooth muscle cells and have also been 
considered to supply stromal cells though EMT and dedifferentiation [46,47]. 
 Intestinal mesenchymal cells and fibroblasts have profounding roles in tissue 
homeostasis. Through pathways such as WNT, BMP, HH and antigen presenting, 
they contribute to stem cell niche stability and immune modulatory functions of 
intestine [47]. For example, human and murine stromal cells express toll-like 
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receptors and MHC-I/-II and in this way also contribute to the innate and adaptive 
immune homeostasis.   
 There are multiple GI malignancies related to stromal impairment such as 
intestinal and colon cancer, intestinal polyposis, colitis-associated cancer (CAC), 
inflammatory bowel disease, Crohn’s disease and senescence related 
parainflammation of intestine. Similar principles related to wound healing are 
applicable when intestinal epithelia get disrupted. Resident fibroblasts activate and 
transdifferentiate to CAFs through TGFB mediated transformation. CAFs are 
supplied through EMT and EndoMT. Importantly, also bone marrow (BM) derived 
MSC contribute to CAF supply in inflammation induced gastric cancer mouse model 
[48]. BM-MSC differentiate to aSMA expressing MFs, which again support the stem 
cells niche within the bone marrow. Upon tumorigenesis, the BM residing MFs supply 
to the CAFs in the tumor. TGFB and CXCR4 mediate the expansion and recruitment 
respectively. Eventually, BM derived CAFs constitute up to 20% of total CAFs. 
Interestingly, these BM-CAFs are proinflammatory (expressing IL-6, IL-33, IL1b and 
TNFa) compared to resident myofibroblasts [48]. This could indicate, that the actual 
proinflammatory hallmark is due to migratory BM-CAFs and not because of resident 
CAFs.  
 BM-CAFs could also contribute to further activating the tumor stroma. Resident 
fibroblasts of the intestine are responsive to IGF-1 and TNFa, the latter induced in 
expression of BM-CAFs. Stimulated by TNFa and IGF-1, intestinal fibroblasts induce 
production of procollagen a1 and TIPM-1. This TNFa induced matrix remodeling is 
independent on AP-1 and NF-kB, but reliant on TNFR2/STAT3 signaling [49]. 
Furthermore, TIMP-1 functions as a prognostic marker of colon and pancreatic 
cancer stroma and promotes CAF accumulation [50]. Given that no somatic 
alterations are not observed in at least in a subset of cancer, it is interesting to see 
that DNA of BM-CAFs is hypomethylated following transformation [48,51]. This could 
emphasize means by which CAFs’ genomic DNA could be manipulated without 
mutational burden.  
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3.1.4.5 Breast 
Mammary gland development is mediated through epithelia-mesenchymal cross-
talk and branching morphogenesis, as are lung and GI tract. In addition, mammary 
glands continue developing during the organism’s life and adapts to new 
physiological conditions after pregnancy, lactation, involution and puberty. Mature 
mammary gland mesenchyme comprises sub-populations of estrogen receptor alpha 
expressing (ERa) stromal cells. Quiescent fibroblasts can be located in inter (CD105-
/CD26+/TGFA+/DPP-IV+)- and intralobular (CD105+/CD26-/TGFA-/DPP-IV-) spaces. 
These two cell types show different transcriptomic profiles: intralobular presenting 
more myofibroblastic related signature whereas interlobular fibroblasts represent 
more proinflammatory profile [52,53]. This type of separation is not visible in murine 
mammary glands however, thus showing limitations in animal models [53]. Later 
during embryogenesis also adipose tissue (secondary mammary mesenchyme) 
invades this mesenchyme. This will give rise to the mature fat pad [54]. Fat pad 
comprises a distinctive connective tissue due to high fraction of adipocytes in it. It 
also contains normal fibroblasts, endothelial cells and inflammatory cells.  
 Breast cancer (BC) is among the most prevalent cancers with millions affected 
annually. The disease holds major genetic risk. Mutations in genes such as BRCA1, 
BRCA2, TP53, STK11 and PTEN are often identified. BC subtypes are divided 
according to increasing aggressiveness: basal-like, luminal-A (Lum-A), HER2 
amplified and triple negative (TN, for estrogen, progesterone and HER2 receptors). 
We have learnt a great deal about CAF heterogeneity from studies about BC [55,56]. 
In human BC tumors, stromal MF proportion positively correlates with disease 
aggressiveness whereas the overall stromal size shows decreasing correlation with 
aggressive subtypes [55,57]. Within the stroma, any compartment (resident stromal, 
fat pad and bone marrow) exhibit a possible source of CAFs. Multiple hypothesis has 
been proposed for the causal fibroblast population. Once again, mesenchymal stem 
cells are suspected to represent at least one suspect [58]. Adipose tissue next to 
mammary gland is being investigated as a source of these MSCs though bone 
marrow and breast-intrinsic MSCs are equally feasible sources.  
 BC-CAFs are characterized by increased MF marker aSMA (independent of 
TGFB), induction of HIF1a-CXCL12 pathway and oxidative stress [57]. Specific 
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subtype of CAFs (CD10+ and GRP77+), is capable of supporting cancer stem cell 
(CSC) niche through secreted interleukin [56]. They also promoted the BC resistance 
against immunotherapy. Importantly these CAFs are not of bone marrow MSC origin 
but rather activated resident fibroblasts [56]. 
 In addition to earlier specific subtype of BC-CAF, at least four different CAF 
subtypes are characterized in great detail, revealing their functions in tumor survival, 
proliferation and inflammatory response [55,56]. All four are identified in all disease 
states, at different proportions. Two of these CAF-types, other negative for all 
markers (1st), the other positive for PDGFRa and FSP1 (2nd), were more enriched 
in the healthy, juxtaposing tumor. The remaining two aSMA+ groups, were associated 
with more aggressive TN disease and situated towards the tumors. The other (3rd), 
inflammatory type of aSMA+ CAFs, are situated close to the solid tumor and attracts 
regulatory T-cells. They usher T-cells to differentiation thus enhancing 
immunosuppression. The remaining (4th) aSMA+ subtype is more metabolically 
compromised. It is plausible to assume that BC-CAFs exhibit at least inflammatory 
and myofibroblastic subtypes which pose different roles in disease progression 
[55,56,57].  
 Inflammatory breast cancer (IBC) is yet another disease subtype with lower 
survival compared to normal BC [58]. Differences between inflammatory and non-
inflammatory breast cancers have been attempted to dissect by using transcriptomic 
profiling. IBM shows upregulation of inflammatory pathways that is correlated with 
downregulation of e.g. endoplasmic reticulum stress signature. ER stress is typically 
considered anti-oncogenic. It would be of particular interest if the above mentioned 
inflammatory-aSMA+ CAFs would actually play a role in IBC. 
  
3.1.4.6 Pancreas 
Pancreas can be divided into exocrine and endocrine compartments. The exocrine 
compartment is responsible for hormone secreting properties of pancreas and is 
colonized by special type of fibroblasts: pancreatic stellate cells (PSC) [59]. During 
homeostasis, PSC contain fat droplets and express desmin, vimentin and GFAP (glial 
fibrillary acidic protein) [59]. They have fibroblastic phenotype and respond to injuries 
as fibroblasts do: activate and turn myofibroblastic. Activation PSCs can be induced 
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by multiple different ways most notably inflammatory cytokines, growth factors 
(PDGF, FGF, TGFB/A, TNFa) and reactive oxygen species [59,60]. Also, culturing 
PSC (just as any fibroblasts) on plastic is sometimes enough to induce activation. 
Activated PSCs decrease the fat droplet content, induce expression of aSMA and 
PDGFRa/b, and secrete COL-I, COL-III, fibronectin and laminin [59,60,61]. 
Interestingly, co-culturing PSC together with different pancreatic cancer cell lines 
induces PCS proliferation, observation that is not a self-evident indicator of fibroblast 
activation [62]. Indeed, activated fibroblasts do not necessarily proliferate more than 
non-active counter-ones [63]. Nevertheless, the hallmarks of PSC activation can be 
partially reversed by culturing them in three-dimensional environment [64]. 
 Chronic pancreatitis (CP) and pancreatic ductal adenocarcinoma (PDA) both 
emphasize the role of PSC activation. In acute pancreatitis, injury in pancreatic 
stroma or ducts results in necrosis, inflammation and PSC activation. Upon 
continuous injuring (e.g. reactive oxygen species from alcohol abuse), the activation 
might evolve into chronic pancreatitis [65]. Interestingly, even though the etiology and 
pathology of CP and PDA differ from one another, the stromal transcriptomics of them 
show greater similarity than might be expected [66].  
 Pancreatic cancer belongs to the malignancies of worst survival rates. 
Mutations in K-RAS, TP53, p16INK4A, SMAD4, STK11 and MEN1 are often observed. 
PDA can be modeled in mouse with K-Ras and p53 mutations conditionally in 
pancreas. Cancer cells are able to induce CAF transformation also in pancreas. 
Proximal to cancer cells, PSC induce their aSMA expression, thus differentiating into 
myofibroblastic type of CAF (myCAF). Acting through distance, cancer cells were 
able to induce generation of yet another type of CAF: aSMAlow, IL-6high and IL-11high 
inflammatory CAF, iCAF. Cytokines secreted by iCAFs, induced the JAK/STAT3 
pathway within cancer cells, thus promoting the survival and proliferation [64]. A third 
distinct CAF population in murine PDA model is an antigen presenting CAF, apCAF 
[67].  Antigen presenting CAFs are CD74+, HA-Aa+ and HA-Ab1+, and capable of 
forming functional MHC-II complex. Through the MHC-II, apCAFs are able to 
communicate with resident T-helper cells. It will be of special interest to see if these 
apCAFs would pose immunomodulatory effects in PDA in similar way as their 
counter-CAFs in breast cancer (see above).  
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 These differentiated states of PSCs are not static. The iCAF and apCAF 
phenotype can be effectively reverse by plating them from 3D-cultures into 2D which 
resulted in aSMAhigh; IL-6low, myCAF phenotype. Importantly, stellate cells are normal 
resident stromal cells in a variety of organs. It is still only the pancreatic stellate cells 
that have been actively studied as a potential CAF-source.   
 
3.1.4.7 Ovary 
Ovaries are part of internal female reproductive system. Ovarian stroma is highly 
vascularized and densely populated with fibroblast-like stromal cells. During normal 
ovulation cycle these fibroblasts differentiate to generate the follicle surrounding cell 
layers theca interna (androgen producing compartment) and theca externa [68].  
 Ovarian cancer is reported the deadliest gynecological malignancy. 
Classification of the disease is based on histology and mutation burden: high- (TP53, 
BRCA1, PIK3CA) and low-grade serous ovarian cancer (KRAS, BRAF), high (TP53, 
BRCA1, PIK3CA)- and low-grade endometroid cancer (CTNNB1, PTEN), clear cell 
cancer (PTEN, PIK3CA) and mucinous cancer (KRAS, TP53). The high-grade 
serous ovarian cancer (HGSOC) is the most lethal subtype. A variety of hereditary 
disorders such as Peutz-Jeghers syndrome and Lynch-syndrome, are known to 
predispose for ovarian cancer. Disease is characterized metastasis primarily to 
omentum and peritoneum (disease stage III/IV). Fibroblasts have been identified 
regulating the ovarian cancer invasion [28], metabolism [69,70], invasion [71] and 
survival (chemoresistance) [69].  
 The question of mechanistic relationship between CAF’s metabolism and 
patient’s immune system, has been troubling the field for a while. In ovarian cancer, 
CAFs actively supply glutathione (GSH) and cysteine for the cancer cells which 
enables them to escape platinum-based chemotherapy [69]. Cytotoxic (CD8+) T-cells 
(TC) regulate CAF’s GSH metabolism through INFg: INFg induces GGT5 transcription 
and enzymatic activity, thus promoting the GSH turnover. Additionally, INFg hindered 
the cysteine metabolism by preventing cystine transportation though CAF plasma 
membrane: INFg induced JAK/STAT1 dependent transcriptional repression of cystine 
transporter component, xCT. Interestingly, these observations are only effective in 
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the fibroblasts. Without TC, CAFs supply GSH for the cancer cells, which they again 
utilize in order to chelate the chemo reagents such as cisplatin [69].  
 CAFs are also key players in regulating cancer cell’s glycolytic switch. CAFs 
promote cancer cell glycolytic capacity, inhibit glycogenesis and induce 
glycogenolysis [70]. Pathway begins from cancer cell secreted TGFB1. This induces 
p38a MAPK dependent flux of IL-6 and CXCL10 from CAFs, which is responded as 
phosphoglycomutase-1 (PGM1) phosphorylation and enhancement of glycolysis in 
cancer cells. Glycolysis positively correlates with metastatic potential of in vivo tumor 
models. Importantly, these results were not exclusive for ovarian cancer but rather 
global effects in a variety of CAF-cancer cell combinations [70].   
 Another important, yet uncovered CAF hallmark are micro RNAs (miRNA). 
miRNAs are proven important in ovarian cancer development [71]. miR-214 was 
discovered as a potent inducer of CCL5, CCL7, CCL8 and CXCL10 production and 
secretion. Cancer cells were found specifically primed for detecting CCL5 in their 
surroundings: it effectively enhances cancer cell survival and invasiveness.  
 Ovarian cancer cells are also able to promote transdifferentiation of not only 
fibroblasts, but also MSCs, stromal population present in HGSOC’s metastatic site, 
omentum [63]. HOXA9 expression in cancer cells induces expression and secretion 
of TGFB2. This in effect, induces CAF transformation and upregulation of several 
mentioned CAF marker genes in resident fibroblasts and MSCs: IL-6, CXCL12, 
VEGFA, aSMA, FAP, TGFB1 and TGFB2 [63]. Importantly, cancer cells themselves 
do not supply to the CAF number through autocrine, TGFB2-mediated EMT.  
 
3.1.4.8 Cancer-Associated Stroma 
Just as a notion: CAFs represent the majority of stroma in the tumor. It is still 
important not to omit other stromal cell types. Also, the stromal cells might change 
dynamically depending on the disease stage, therapy phase and disease type.  
 Fibroblasts are known to be able to differentiate into adipocytes. In the context 
of breast cancer and mammary gland as a whole, new population of differentiated 
adipocytes has emerged. Breast cancer cells can initiate adipocyte differentiation 
driven through Wnt-signaling. This results firstly to generation of cancer-associated 
adipocytes and later on adipocyte-derived fibroblasts: adipocyte population 
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characterized by smaller lipid droplets and gain of (activated-)fibroblast markers such 
as FSP1, aSMA and morphology [72,73,74]. It is highly probable that this type of 
transdifferentiation of adipocytes, due to proximity of cancer cells, may also play a 
role in other cancers. Especially when there is prominent resource of adipocytes. As 
there is in the omentum for example, area associated with ovarian cancer metastasis.  
 
3.1.4.9 Pro-or-Anti-tumorigenic CAFs? 
CAFs have been shown beneficial for cancer cells in many respects. Still, one cannot 
kill the cancer just by removing them. In pancreatic ductal adenocarcinoma, depletion 
of aSMA-positive myofibroblasts after tumor initiation significantly decreases the 
overall survival [75]. MF-depletion affects most notably in ECM-remodeling, necrosis 
and cancer stemness. Interestingly, also vascularization is found reduced in these 
CAF-depleted tumors. Decreased survival is also associated with reduced number of 
effector T cells and increase in regulatory T cells. This immunocompromised disease 
can be rescued to some extent by inducing immunoresponse with anti-CTLA4 
antibody [75].  
 CAF’s role as a tumor initiating component is also slightly controversial. 
Performing xenograft experiments, it is generally accepted that fibroblasts (NFs or 
CAFs) are not able to induce tumorigenesis by themselves. Rather cancer cells 
together with fibroblasts are able to do so. Then again, stromal specific deletion of 
genes such as TGFB-R2 or LKB1 in stromal fibroblasts is potent inducer of neoplasia 
of prostate, forestomach, intestine and endometrium [76,77,78,79].  
 These experiments emphasize that CAFs might actually pose a dual role in 
tumor evolution: I) they have causal role in cancer initiation but II) they hinder cancer 
progression once it has initiated. The above experiments are however too drastic to 
recapitulate the effects in wider perspective. CAFs in breast and ovarian cancer are 
reported not to encounter genetic alterations during tumorigenesis [51]. In support of 
this idea is the above-mentioned model of myCAF-iCAF in PDAC: rather than 
committing to terminally differentiated CAF, activated PSCs are able to 
transdifferentiate dynamically. That is why complete depletion of them would not 
resemble the effects that would be met if CAFs were simply transdifferentiated back 
to normal fibroblasts. Surely CAF-transformation is accompanied with a range of 
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changes in the CT, but by trying to block this differentiation process could possibly 
repress or even reverse the effect. Tissue requires the resident fibroblasts for many 
reasons thus it is not surprising to see cancer-ignition after removal of them. It is also 
possible that cancer cells promote epigenetic changes in the CAFs that would 
permanently change fibroblast genome.       
 
3.2 Mitochondria and Bioenergetics  
Mitochondria are membranous organelles evolved after symbiotic events prior to 
engulfment of oxygen utilizing bacterial by eukaryotic cell. They function as energy 
producing units of cell. Utilizing localized membrane potential (ΔΨ) differences and 
charge carrier proteins, mitochondrial membrane enzymes catalyzes production of 
high-energy content intermediates. The ΔΨ is stored as chemical energy within the 
high-energy bonds of molecules such as NADPH, NADH, FADH, ATP (adenosine 
triphosphate) and GTP (guanosine triphosphate). By enzymatic reactions these 
bonds can be broken into smaller, lower energy states and the free energy released 
can be utilized in downstream reactions. Mitochondrial structure is tightly linked to its 
functions. This is why mitochondrial dynamics are also interconnected to pathologies 
associated with the mitochondrial metabolism. Alzheimer’s disease, Parkinson’s 
disease, Charcot-Marie-Tooth neuropathy and type-2 diabetes are just a fraction of 
diseases characterized by mitochondrial dysfunction. 
 
3.2.1 Mitochondrial dynamics 
Taken the origin of mitochondria, one may not be surprised by how mitochondrial 
turn-over is regulated by dynamic fission and fusion events; similar processes as cell 
division and membrane fusion in normal eukaryotes and prokaryotes. Mitochondria 
are double membranous organelles, consisting of outer and inner mitochondrial 
membranes (OMM, IMM respectively). The space left between the two membranes 
is called matrix and space within IMM is called inter-/inner membrane space. 
Mitochondria have their own (maternally derived) mitochondrial DNA (mtDNA), 
replicated by DNA polymerase-g. During homeostasis mitochondria are fused and 
fractionated according to cell’s needs. Long stretching strands of mitochondria 
(increased fusion) supports the needs for high energy metabolism whereas more 
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dispersed and grainy pattern of mitochondria is typical during cell division to facilitate 
equal division of mitochondrial mass and mtDNA between the daughter cells.  
 Mitochondrial fusion is a process in which outer and inner membranes of 
different mitochondria fuse together. OMM fusion is mediated by MITOFUSIN-1 and 
-2 (MFN1/-2) and IMM fusion by optic ATROPY-1 (OPA-1) [80]. They are all 
GTPases, catalyzing the reaction: GTP ® GDP + P. OMM fusion is mediated by the 
alignment of mitofusins’ heptad regions (HR2, HR1 not participating to this) from 
opposing membranes.  This will form coiled-coils between the mitofusins and tether 
the membranes before the actual fusion [81]. IMM fusion is acquired through OPA-1 
and more specifically its proteolytically cleaved long and short isoforms. Activity of 
the isoforms is mediated by co-expression, mitochondrial membrane potential and 
Yme1L [82,83].  
 Fission of the membranes is mediated by dynamin related protein 1 (DRP-1) 
and close association of mitochondria and endoplasmic reticulum (ER). Inverted 
formin-2 (INF-2) works as an initiator of this fission. INF-2 is recruited to the ER once 
it is prenylated. From here it can initiate actin polymerization and constriction of 
mitochondria. Once the constriction reaches DRP-1 threshold this will take over and 
continue up to its dynamic range [84]. Fission is complete by dynamin 2 (Dyn-2) [85]. 
DRP-1 itself is recruited to the mitochondrial membrane by FIS1, MFF and MiD49/-
51.  
 
3.2.2 Citric Acid Cycle 
Mitochondria are specialized in producing energy in aerobic conditions. Aerobic 
energy production is far more efficient compared to anaerobic glycolysis and 
fermentation. Cell is capable of producing 2 molecules of ATP through glycolysis 
whereas the oxidative phosphorylation (aerobic) yield 32-36 molecules. Molecular 
oxygen forms the basis of mitochondrial reactions such as oxidative phosphorylation 
(OXPHOS), electron transport chain and beta-oxidation.  
 In citric acid cycle (tricarboxylic acid cycle, TCA) group of metabolic enzymes 
work in sequence passing the previous end-product as a source material for the next 
enzyme. These enzymes are located mitochondrial matrix. The overall starting 
material is acetyl-coenzyme-A (Acetyl-CoA) derived from pyruvate, end product of 
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glycolysis for example. The sequence 9 enzymatic reactions work in order to oxidize 
the Acetyl-CoA and reducing the high-energy cofactor NADP+ (nicotinamide adenine 
nucleotide phosphate) into its NADPH+H form. The cycle also produces reduced 
forms of FADH2 (flavin adenine dinucleotide) and GTP (guanosine triphosphate), 
which will further improve the energetic efficiency of TCA.  
 
3.2.3 Electron Transport Chain and Oxidative Phosphorylation 
Reduced NADPH can act as an electron donor for the electron transport chain 
enzymes (ETC). These enzymes are located in the IMM. The electrons from NADPH 
are passed through a sequence of redox pairs situated as prosthetic groups 
(covalently joined cofactors) in the core electron transport enzymes (mostly 
different types of cytochromes). These enzymes work in such a way that the electrons 
flow according to decreasing electronegativity from donor to acceptor. This is 
accompanied by transport of protons (H+) across the mitochondrial membrane into 
the intermembranes space. This is what generates ΔΨ, electrochemical potential 
(pH) difference across the membrane. This chemiosmotic potential is harnessed for 
driving force for ATP production. There the biologically relevant energy is stored as 
a high energy bond between the g- and b-phosphates as P-O-P bond. 
 ETC begins with passage of electrons form NADHP to the ubiquinone located 
in the mitochondrial complex I, and thereby reducing it. Complex I is able to act as 
an proton pump transferring 4 protons across the intermembrane to the matrix. In 
Complex III electrons are transferred from earlier ubiquinone to the cytochrome C. 
From the cyt-C electrons are used to further reducing steps eventually leading to 
additional 4 protons crossing the membrane. Complex IV transfers electrons from 
cyt-C to molecular oxygen, generating water and transferring more protons across 
the membrane. Complex II adds up electrons to the overall pool of 
ubiquinone/ubiquinol in Complex I, but does not contain proton pump properties as 
the other complexes.  
 Oxidative phosphorylation is a process where potential energy generated as 
an electro-chemical gradient during electron transport chain is harnessed for ATP 
synthesis. ATP synthase is a membrane protein by which the proton flow from the 
intermembrane space is channeled through to the mitochondrial matrix. As the 
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protons move they create proton-motive force that is used as free energy for the 
generation of the g- and b-phosphate bond in ATP.  
  
3.2.4 Beta-oxidation 
The third mitochondrial metabolic pathway, beta-oxidation, yields also Acetyl-CoA 
which can be further supplied to TCA and electron transport chain. Beta-oxidation is 
a catabolic pathway for fatty-acid oxidation and breakdown. Beta-oxidation 
performing enzymes are located in the inner mitochondrial membranes. The pathway 
begins with translocations of cytosolic free fatty acids in to the mitochondrial matrix 
(inside the inner membranes). This is dependent of carnitine shuttle. Long chain fatty 
acids are first converted into fatty Acyl-CoA. Acyl-CoA then reacts with carnitine 
palmitoyltranferase (I/II) which is transported into the cristae of mitochondria. A 
second round of carnitine palmitoyltranferase reactions occur in order to bring the 
Acyl-CoA into the matrix. 
 Now the beta-oxidation can begin. During a series of reducing steps the fatty 
acid (Acyl-CoA) gets cleaved by 2-carbons, generating a molecule of Acetyl-CoA and 
reduced cofactors FADH2 and NADH+H. There is a slight difference in the reaction 
chain when an odd numbered Acyl-chain enters the beta-oxidation, in comparison to 
even-numbered chain. The reaction chain chews Acetyl-CoA pieces of the body of 
fatty acid as long as it is possible (in even numbered this will go all the way through 
the structure). But in odd-numbered the last product of the reactions, propionyl-CoA 
is transformed into succinyl-CoA which can then feed the TCA.  
 The pathway is also able to handle both unsaturated and saturated fatty acids. 
With unsaturated starting material pathway includes specific steps in order to transfer 
the fatty acid into more suitable stereoisomer that is suitable for cleavage. cis-D3/4 
bonds within fatty acid would cause problems with the formation of trans-D2-bond. 
This is overcome by the usage of 2 additional enzymes enoyl CoA isomerase and 
2,4 Dienoyl CoA reductase. These enzymes help to modify the bonding conformation 
in such a way that beta-oxidation can proceed.  Beta-oxidation is also performed in 
peroxisomes. 
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3.2.5 Reactive Oxygen Species 
Reactive oxygen species are naturally occurring cellular components, originating 
from pretty much all oxygen consuming events: mitochondrial respiration, hydrolysis, 
oxidation/reduction reactions and peroxisomal degradation: 
 
  O2 + e- ® O2•- ® H2O2 + e- ® • OH + e- ® H2O 
 
The above reaction shows three commonly produced ROS compound: superoxide 
radical (2nd), hydrogen peroxide (middle) and hydroxyl radical (4th). Depending on 
the cellular pH, the protonation state and reactivity of ROS can change. Cellular ROS 
and free radical especially are extremely potent electron acceptors/oxidizers. It is 
thus not surprising that they can easily disrupt e.g. mitochondrial ETC. Importantly, 
OXPHOS itself acts as a ROS-source. ROS function also as a natural signaling 
molecules. Endogenous antioxidant enzymes balance the effects of ROS-mediated 
damage and desirable ROS-signaling. Examples of these enzymes account 
superoxide dismutase, glutathione peroxide and reductase and Vitamins A, C and E.  
 
3.2.6 Mitochondria in Cancer 
Cancer cells and stromal cells within tumor microenvironment form a tumor-
promoting symbiotic relationship between each-other. With para- and autocrine 
signaling, cells aim to influence each other with the common objective of optimal 
growth (metastasis), given the input energy reservoir (vasculature). By fine-tuning 
their metabolism, cancer cells are thought to optimize this cross-talk. The seminal 
theory from O.H. Warburg presented how cancer cells were characterized by 
increased glycolysis compared to healthy cells. Due to reduced and inefficient 
vascularization and following hypoxia in solid tumors, increased glycolysis was seen 
as a way-out from metabolic crisis. However, glycolysis is far less efficient way of 
producing energy compared to mitochondrial oxidative phosphorylation. There are 
multiple hypothesis’ again how and why cancer cells acquire this type of energy 
reprogramming. Possible explanations such as adaptation to hypoxia, mitochondrial 
stress and dysfunction, chemoresistance, mutational burden and metabolic 
intermediates as signaling molecules are all attractive and intertwining options. 
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 Currently the so-called reverse Warburg effect has gained more support. This 
model proposes that cancer cells would actually possess high OXPHOS levels. This 
is augmented by intermediates supplied by the activated stroma, which on the other 
hand is characterized by enhanced glucose uptake, high glycolytic levels and low 
OXPHOS; normal Warburg one might say [86,87]. Glycolytic CAFs are able to direct 
their metabolism towards production of metabolites, such as lactate, glutamine (Gln) 
and glutamate (Glu), which they can feed to cancer cells [87]. Interestingly, the 
lactate-shuttle functions through ROS-induced mitochondrial dysfunction in both 
CAFs and cancer cells, whereas Gln/Glu was associated with decreased ROS-
production [87,88]. Cancer cells again use lactate to fuel their own TCA [88].  
 The molecular mechanisms of this type of dual-Warburg are slowly being 
unraveled. Cancer cell are able to reduce IDH3a expression in adjacent fibroblasts 
through PDGF and TGFB mediated CAF-transformation [86]. More specifically, 
IDH3a reduction is achieved through micro RNA-424 mediated silencing of IDH3a. 
Reduction in IDH3a is countered by induction of HIF-1a and observed as increase in 
glycolytic capacity [86].  
 Another reprogramming mechanism works in breast cancer but also through 
micro-RNAs. Cancer cells produce extracellular vesicles (EV) packed with another 
type of micro RNA, miR-105 [89]. These vesicles delivered to the adjacent CAFs 
which respond by changing towards glycolytic metabolism. This increases 
intracellular levels of lactate, acetate, glutamate, pyruvate and aminoacids. 
Interestingly, miR-105-CAFs show dynamic adjustment of their metabolism according 
to the available nutrients. For example, during starvation miR-105-CAFs are able to 
detoxify the tissue from ammonium by metabolizing it to Glu and Gln. Changes 
following miR-105 are not associated with changes in fatty acid metabolism [89].  
 As mentioned above, mammary gland is evidently special tissue due to adjacent 
connective tissue with fat pad. Fat pad functions as an enriched source of energy for 
the surrounding cells. Through lipolysis, the adipocytes can secrete free fatty acids 
into the surroundings which the neighboring cells can utilize for beta-oxidation and 
oxidative phosphorylation. In breast cancer, cancer cells take advantage of this 
pathway by reprogramming the adipocytes into cancer-associated adipocytes (CAA). 
Production of FFAs by CAAs act as a source of nutrition for OXPHOSHIGH cancer 
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cells. This has been also reported to induce fat depletion of adipocytes and 
transdifferentiation of them into CAFs. Interestingly, shear mitochondrial uncoupling 
with FCCP was shown to decrease lipid content of 3T3-L1 adipocytes [90]. Though 
the study lacked evidence to prove direct transdifferentiation of adipocytes it showed 
how mild mitochondrial membrane potential manipulation had effect of lipid synthesis 
and beta-oxidation related genes such as Scd1/2, DHAPAT, CPT-2 and MCAD. It 
also highlights that though b-oxidation is not necessarily established in CAFs it does 
play a role in the cancer stroma. 
 Cancer stroma is stiffened during the course of tumor evolution but could tissue 
rigidity solely mediate metabolic changes. Indeed, growing cancer cells and CAFs on 
rigid substrate increases levels of glycolysis and OXPHOS [91]. Stiffening of ECM is 
associated with reciprocal release and uptake of Gln, Glu and aspartate (Asp) among 
CAFs and cancer cells. These aminoacids drive biosynthetic pathways for 
nucleotides and glutathione and are driven by YAP/TAZ mechanotransduction [91]. It 
is not however known how this type of matrix stiffening would affect normal cells. 
Could the rigidity be causal for CAF- or cancer cell transformation? 
 These metabolic alterations also provide important opportunities for 
intervention. Cancer cells could be for example targeted as OXPHOSHIGH cell 
population. On the other hand, once the metabolome of tumor is well enough 
established it could be possible to direct it though limiting nutrients or engineered 
metabolites. Could the CAF transformation and cancer cell metabolism be reverted 
by somehow softening the tissue? 
 
3.3 LKB1 and AMPK-related protein kinases 
LKB1 is a serine/threonine kinase encoded by human gene STK11. It is a tumor 
suppressor, mutated in Peutz-Jeghers syndrome (PJS) [92]. LKB1 functions as key 
regulator of development, stemness, metabolism and homeostasis in a variety of 
tissue and cell types and pathological and physiological conditions [93,94,95,96,97]. 
Together with coactivators STRADa/b and MO25a/b, LKB1 forms a catalytically 
active complex that is capable of phosphorylating and thus activating its substrates 
[98]. LKB1 mediates its cellular functions through its 14 downstream kinase 
substrates: AMPKa1/2, MARK1-4, NUAK1-2, SIK1-3, SNRK and BRSK1-2 
 33 
[98,99,100,101]. These kinases belong AMPK-related protein kinases (ARK) family. 
ARKs share specific T-loop within their amino acid sequence. LKB1 is responsible 
for phosphorylating each substrate on a specific threonine residue within the T-loop, 
thus inducing the activation [98]. The association of LKB1 and STRAD25a is critical 
for kinase activities of substrates [98]. Each substrate again has different roles in 
different signaling pathways, in different organs at different developmental time 
points. 
 LKB1 functions as a key gatekeeper in signaling pathways such as mTOR, 
energy stress, apoptosis, TP53 and TGFB. For example, through AMPK-
phosphorylation and sequential TSC2-activation, LKB1 mediates its inhibitory effect 
on mTOR and growth [102]. On the other hand, LKB1 physically associates with 
TP53, induces its phosphorylation and enable apoptosis [100,103]. LKB1 is a TGFB-
pathway inhibitor. In epithelial cells, LKB1 inhibits TGFB-signaling and EMT in 
cooperation with LKB1-interacting protein 1 (LIP1) [104]. Also, in the mouse 
embryonic fibroblasts and PJS, loss-of LKB1 results in marked reduction in TGFB1 
mRNA, secreted TGFB and TGFB-signaling, measured as MF differentiation and 
SMAD2/3 transcription [105,106].  
 
3.3.1 LKB1 in Peutz-Jeghers Syndrome 
The tumor suppressive function of LKB1 (liver kinase B1) was first discovered 
Peutz-Jeghers syndrome [92]. PJS is dominantly inherited autosomal syndrome 
which is manifested as hamartomatous polyposis of gastrointestinal tract. PJS is 
also linked to other malignancies such as breast, colon, small intestine, pancreatic, 
ovarian, cervical and lung cancer [107,108]. 
 Of all of the LKB1-related pathologies, the PJS stands out in the perspective 
of cancer-associated fibroblasts and tumor stroma. Stromal specific deletions of 
LKB1 in the smooth muscle cells, mesenchymal progenitor cells, fibroblasts or even 
in T-cells are efficient drivers or polyposis [77,105,109]. Stromal deletion of LKB1 
results in transformation of fibroblasts and concomitant expansion of the 
neighboring epithelia. Loss-of LKB1 results in reduced stromal TGFB-signaling, 
which would otherwise suppress epithelial growth [77,105]. In addition to TGFB, 
also IL-11/STAT3 pathway is implicated: stroma secreted IL-11 results in induction 
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STAT3, inflammation and polyposis of the adjacent epithelia. Importantly, polyposis 
could be effectively blocked by JAK1/2-inhibitor [105]. Interestingly, deletion of 
heterozygosity of LKB1 in T-cells is also able to induce polyposis [109]. T-cell 
mediated polyposis is associated with pronounced immune cell infiltration, IL-6 
expression and activation of JAK/STAT3 similarly as in fibroblast specific deletion. 
Once again, polyposis could be blocked though JAK2 inhibition [109]. 
 
3.3.2 LKB1, Mitochondria & Metabolism  
LKB1 has been proposed an important role in mitochondrial function and energy 
metabolism. The first evidence about LKB1’s association with mitochondria was by 
observing LKB1 localizing to the mitochondria, following initial steps of apoptosis 
[103]. More metabolically relevant results came later: in hematopoietic stem cells 
(HSC) LKB1 maintains mitochondrial integrity which is associated with overall 
survival of the lineage. These changes are partially independent of AMPKa1/a2 axis 
thus mediated through other substrates [94,95,96].  
 Interestingly LKB1 deletion in regulatory T-cells (Treg) shows similar effects. 
LKB1 deletion in Tregs compromise the immune cell survival, which results in TH2-
dominant inflammatory disorder and severe autoimmune disorder [97,110]. These 
syndromes are associated with mitochondrial dysfunction and metabolic imbalance: 
decreases in oxidative phosphorylation capacity, mitochondrial mass, mitochondrial 
membrane potential, mitochondrial DNA content, dysregulated lipid and 
triacylglycerol metabolism. Even more, pathways regulating unsaturated fatty acids 
where upregulated along with lipid accumulation. These mechanisms further 
strengthen the association of metabolism-survival-axis, but the absolute pathways 
are still missing. Histamine has been suggested as a regulator of Treg function. In 
LKB1-null Tregs, histidine decarboxylase (HDC) and histamine levels were 
upregulated. The metabolic pathway in Tregs is possibly carried out though MARK 
and SIK-family substrates.  
 Partially explaining the mitochondrial dysfunction following loss-of LKB1 is 
induction ROS [111]. Deletion of Stk11 in mouse embryonic fibroblasts results in 
significant induction of cellular ROS – characteristic that is not recapitulated by loss-
of AMPKa’s. Importantly, this ROS pathways seems to be different in fibroblasts and 
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hematopoietic cells: loss-of LKB1 in HSCs did not induce ROS production and neither 
did AMPKa’s.  
 
3.3.3 LKB1 Substrates 
In the following section we will describe some hallmarks of each kinase substrate 
family. We try to be open minded about LKB1 dependency since in many of the 
studies have not thoroughly evaluated this. From here onwards we denote all LKB1 
substrates collectively as ARKs (AMPK-related kinases); including AMPKs. 
 
3.3.3.1 AMPKa1 & AMPKa2 
AMPK (5’-adenosine monophosphate-activated protein kinase) catalytic subunits, a1 
and a2 (encoded by genes PRKAA1 and PRKAA2 respectively), are most reputable 
for their function in cellular energy sensing. Functional heterotrimeric AMPK is 
assembled from a1-2, b1-2 and g1-3 subunits. Regulatory g1-3 subunits are responsible 
for sensing the AMP:ATP ration. Cellular AMP and ATP compete in binding the 
Bateman domain of g-subunit, thus allosterically regulating it. When activated by 
binding of AMP, conformational changes expose the T-loop Thr172 in a1-2-subunits 
subjecting it for phosphorylation and further activation. AMPK is phosphorylated by 
LKB1 and CAMKK2, the latter of which is responsible for Ca2+ mediated AMPK 
activation [99,100,112]. Also, CAMKK2 mediated activation is shown independent of 
cellular energy status, since ADP:ATP ratios wouldn’t significantly alter the activation. 
Thus, the LKB1 mediated and ADP:ATP initiated activation of AMPK is the pathway 
that aims to ensure the energy homeostasis under low energy level. 
 AMPK has numerous downstream effectors, but the most fundamental is the 
regulation of mTORC1. AMPK phosphorylates and activates TSC2 which 
consequently inhibits mTORC1 via RHEB-GDP/GTP switch [102]. Both LKB1 and 
AMPK also regulate TP53. AMPK, as LKB1, physically associates with TP53, 
promotes the phosphorylation of Ser15 and cellular senescence [113]. The 
interdependency here is not necessarily direct though. In NSCLC for example it has 
been shown how deletion of LKB1 or AMPKa1/2 in TP53-null background, are 
manifested in opposing outcomes [114]. This might suggest of divergent regulation 
of TP53 by LKB1 and AMPK. Interestingly, TP53 can also act upstream of AMPK. In 
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mouse embryonic fibroblasts, TP53 responsive gene SESTRIN-2 phosphorylates 
AMPK and through that, regulates mTORC1 [115].  
 Other metabolic effects of AMPK are mediated by inactivating phosphorylation 
of ACC1 at Ser79 and HMGR which inhibits the fatty acid and cholesterol synthesis 
and induced b-oxidation [116]. Overall, AMPK activation attempts to shot down 
cellular anabolic, energy consuming pathways and promote catabolic, energy 
producing pathways.     
 
3.3.3.2 MARK1-4 
MARK1-4 (also called PAR1C, PAR1B, PAR1A, PAR1D or collectively PAR-
1/MARKs) are LKB1 substrates functioning in cell polarity acquisition and regulation 
of WNT-signaling. They control the microtubular dynamics via MAPs (microtubule 
associated protein). Their role has been extensively studied in polarity of epithelial 
cell, fibroblasts and neurons, using non-mammalian model organisms.  
 aPKC (atypical protein kinase C), component of PAR-3/PAR-6/aPKC master 
polarity complex, has been shown to inhibits MARK2’s and MARK3’s kinase activities 
by phosphorylating their Thr595 and Thr564 respectively. Phosphorylation, in concert 
with recruitment of 14-3-3, re-localizes MARK away from lateral tight junctions 
[117,118]. As a consequence, MARK2 and MARK3 are translocated away from 
lateral membranes to the cytoplasm [118]. 
 Downstream of MARKs include Dishevelled (DSH), an important WNT-signal 
transducer [119,120]. However, this DSH phosphorylation by MARKs isn’t really 
required for canonical b-catenin mediated WNT-signaling, but rather for PCP-non-
canonical pathway [120]. Interestingly, DSH is also required for aPKC stability [121]. 
This sustains aPKC activity, leading further to phosphorylation and downregulation 
of MARK2. 
 Polarity is also regulated in LKB1-dependent MARK-phosphorylation. LKB1 
phosphorylates MARK2 at Thr208. Phosphorylated MARK2 further phosphorylates 
MAP called Tau (Ser262/Ser356) and subjects it for degradation. This inhibits tubulin 
polymerization and microtubular regrowth and thus regulates the polarity acquisition 
[122]. MARK3 again phosphorylates ARHGEF2, yet another cellular polarity related 
component, at Ser151 in LKB1-dependent manner [123]. ARHGEF2 phosphorylation 
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relieves it from CYNLT1 sequester, promotes its 14-3-3 mediated translocation, and 
regulates actin stress fiber and focal adhesion complex dynamics.  
 LKB1-MARK signaling axis is regulating also the Hippo-YAP/TAZ pathway. 
MARKs 1, 3 and 4 are critical in LATS1/2 mediated YAP phosphorylation and 
cytoplasmic retention [124]. This regulation was mediated through Scribble (SCRIB), 
critical Hippo-effector. Importantly, LKB1 is known to suppress YAP-mediated 
transcription also in LATS1/2-independent means [125]. This inhibition is 
independent on mechanotransduction and AMPK/mTOR-signaling.   
 Animal models of MARK2, MARK3 and MARK4 have homeostatic changes 
such as: decreased body weight, resistance for high fat diet, improved glucose 
tolerance, reduced brown and white adipose tissue mass and overall increased 
metabolism [126,127,128]. No information about the tumorigenesis or polyposis was 
acquired. Moreover, these association studies are not strong enough to implicate 
LKB1’s role in these profounding traits. 
 
3.3.3.3 NUAK1-2 
NUAK1 and NUAK2 (ARK5 and SNARK (Sucrose nonfermenting AMPK-related 
kinase) respectively) form a pair of ARKs participating in cellular adhesion, 
senescence, survival and metabolism. In addition to LKB1, also AKT and NDR2 are 
capable of phosphorylating NUAK1 (Ser600 and Thr211 respectively) but not NUAK2 
[129,130]. NDR2 phosphorylation is happening on same site as LKB1’s, but in this 
setting (SW480 cells), LKB1 mRNA was reported low which might explain 
redundancy [130]. Transcriptionally NUAK2 is modulated by TGFB-SMAD2/3 and 
Hippo pathways [131,132], both of which are highly associated in CAF transformation.  
 LKB1 activated NUAK1 and NUAK2 phosphorylates MYPT1, a regulatory 
subunit of the myosin light chain phosphatase [133,134,135]. MYPT1 
phosphorylation at Ser445, Ser472 and Ser910 is accomplished via formation of 
NUAK1-PP1b-MYPT1 complex. Such complex formation is still to be confirmed with 
NUAK2, though phosphorylation of MYPT1 is already established [135]. 
Phosphorylation recruits 14-3-3 to the complex which results to overall sustained 
phosphorylation of MLC2 and cell adhesion.  
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 Importantly, there is strong evidence that LKB1 dependent TP53 regulation is 
in part accomplished through NUAK1 [136]. In epithelial cells, NUAK1 
phosphorylation of TP53 (Ser15 and Ser392) resulted in cell cycle arrest in G0/G1, 
and it was reliant on prior phosphorylation of NUAK1-Thr211 by LKB1. This might 
partially explain the gap in LKB1-TP53-AMPK regulation. It is also worth mentioning 
that though NUAK2 has not yet proven to control TP53, LKB1 has about 100 times 
higher enzymatic activity towards NUAK2 T-loop compared to for example AMPKa1 
[98]. Thus, taken the extreme similarity between NUAK1 and -2 amino acid sequence, 
it could very well be that this preference to NUAKs over AMPK at the level of T-loop, 
would conduct to the level of TP53 regulation.   
 NUAK1 is also able to restrain cell cycle in without TP53, through Hippo-effector 
LATS1 [137]. In fibroblasts, NUAK1/2 phosphorylates LATS1 in Ser464, following 
LKB1 mediated activation. As we discussed in mechanotransduction, Hippo-pathway 
is responsible for the non-mechanical inhibition of YAP/TAZ.  
  NUAK1 also restrains cell cycle in concert with MYC [135,138]. This is reliant 
on the intact LKB1-phosphosite, Thr211, though LKB1-dependency is not technically 
proven. Here, in U2OS cells, NUAK1 knock-down inhibits mitochondrial electron 
transport chain and overall mitochondrial membrane potential, both affecting 
oxidative capacity. In HeLa cells (thus LKB1 independent), this, MYC-controlled 
NUAK1 and NUAK2 activation is Ca2+ sensitive [135]. MYC drives PKCa/b 
(conventional PKC) expression. PCKa is key player in sustaining NUAK1 and NUAK2 
protein stability and activity [135]. NUAK1 and NUAK2 also regulate mTORC1 in this 
setting, both independently and dependently on AMPK. More specifically, Ca2+-
dependent AMPK activation in HeLa cells is dependent on intact NUAK1: knocking 
down NUAK1 results in proteosomal degradation of both a1- and b1-subunits, 
followed by induced mTORC1/RAPTOR activation [135].  
 In central nervous system, NUAK1 has been demonstrated to carry crucial 
functions in axon specification in LKB1 dependent manner [139]. In utero deletion of 
cortical LKB1 results in failure in ipsi-/contralateral axon branching. Knock-down of 
LKB1 and/or NUAK1 in isolated neurons reduces the axonal growth, initiation and 
stability, without affecting the dendritic tree development. The finding that the axonal 
defects originates from increased mitochondrial motility within axonal microtubules, 
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emphasizes the LKB1-(substrate)-mitochondria axis also in CNS. Importantly, these 
functions where shown independent of LKB1’s brain specific substrates BRSK1/2 
and also NUAK2.  
 
3.3.3.4 SIK1-3 
 
Salt-inducible kinases, SIKs, are of LKB1 substrates which respond cAMP signaling, 
participates in epigenetic modifications, gluconeogenesis, lipid metabolism, sleep 
behavior and ‘internal clock’ adjustment. 
 Perhaps the most established role of SIKs comes from their tight association 
with cAMP signaling and CREB (cAMP response element binding protein). SIK1 was 
identified as a class II histone deacetylase (HDAC) and a CREB target gene [140]. 
The two CREB binding sites in SIK1 promoter are occupied during cAMP induction 
(e.g. forskolin). Activated SIK1 is able to directly phosphorylate and inhibit other 
HDACs, HDAC5 and HDAC4 at Ser259 and Ser489. This again relays as reduced 
silencing of MEF2C transcription factors, which are vital for (smooth) muscle 
development [22,140,141]. However, cAMP has a dual role in regulating SIK activity. 
In long-term, increased cAMP enhances SIK transcription through CREB, but 
acutely it also induces PKA mediated inhibitory SIK-phosphorylation (SIK1-Ser577 
and SIK2-Ser587) [140,141].  
 Also, CREB regulation of SIKs is based deeper than direct phosphorylation. 
TORCs (TORC1-3, CREB coactivators) have been identified as assistants of CREB. 
They help establishing the transcriptional machinery for CREB [142]. SIKs mediate 
CREB regulation also at this level. Specifically, SIK1 and SIK2 (QSK, Qin-induced 
kinase) phosphorylates CRTC2 (TORC2) on Ser171, subjecting it to 14-3-3 mediated 
cytoplasmic retention [142,143]. PKA mediated phosphorylation of SIK2-Ser587 is 
again able to inhibit this retention. It is noteworthy that also AMPK is capable of 
phosphorylating TORC2 at the same site as SIK1. 
 SIKs provide also a link between LKB1 and TGFB-signaling. SIK1 expression 
is induced following TGFB-signaling activation. In cooperation with SMAD7, SIK1 
associates with TGFB-R1, thus promoting its proteosomal degradation through 
ubiquitylation [144]. Thus, LKB1 could inhibit TGFB by 1) activating SIK1 directly, 2) 
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directly inhibiting TGFB itself or 3) indirectly by 3.1) inducing TGFB which 3.2) 
induces SIK-mediated TGFB-silencing.  
 SIKs convey homeostasis also in central nervous system. Sleeping is a 
conserved behavior which aims for energetic balance/replenishment and CSN 
recovery. SIK3 has important role in sleep dynamics regulation (non-REM sleep, 
sleep need, waking duration). Specifically, point mutation at Ser551 of SIK3 (so-
called Sleepy-variant) causes increased sleep need and NREM duration [145,146]. 
This behavior was traced to well-established interaction of SIK3 and PKA. At SIK3, 
PKA mediates its phosphorylation at Thr469, Ser551 and Ser674. The middle 
phosphosite (Ser551) is important in PKA mediated 14-3-3 recognition and 
translocation. This highlight SIK3’s role at more systemic level and it will be 
interesting to see if LKB1 plays a role in this.  
 A real bombshell came about ovarian cancer metastasis and SIK2’s role there 
[147]. In this scenario, autophosphorylation of SIK2 (Ser90, Ser343 and Ser358) 
actually had the lion’s share in overall activity of SIK2, NOT due to LKB1 nor PKA! 
indeed, Ser358 is also putative AKT2 and PKA phosphosite. SIK2 activation in 
ovarian cancer cells was actually mediated via FFA-PLC-Ca2+ signaling. In addition, 
SIK2 was reported directly phosphorylating ACC1 and p85α (Ser156, regulatory 
subunit of PI3K), and these were essential for lipid signaling-controlled ovarian 
cancer metastases. 
 
3.3.3.5 BRSK1-2 
BRSK1/2 (SAD-B/A) are AMPK-Rs specifically expressed in neurons and pancreas.  
Though single knock-outs of BRSKs show no observable phenotype, double-knock-
outs show defects in CNS development. Ventricular enlargement, cortical thinning 
and axonal/dendritic misorientation as hallmarks, notably similar together with 
pyramidal-specific deletion of LKB1 [148]. BRSK-null neurons are unable to polarize 
and subsequently failed in developing functional axons or dendrites, again similar to 
LKB1 phenotype in CNS [149]. interestingly, LKB1-null pyramidal progenitors, fail in 
axon/dendritic development but not in radial migration [148]. Overall, BRSK1/2 
phenotypes in the cortex appear in LKB1 dependent manner, though direct genetic 
evidence is still lacking [148].  
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 However, there are clear LKB1-independent phenotypes also. Careful analysis 
of BRSK1/2 (double knock-out) and LKB1 (NestinCre, progenitor specific knock-out) 
knock-animal’s neuroanatomy shows differences in peripheral nervous tissues [150]. 
Here BRSKs cause defective development of ventral horns [150]. These 
developmental defects were found LKB1-independent and more similar to 
neurotrophin-3 deficiency related phenotypes. More-over, BRSK-specific phenotypes 
were linked to NT-3 dependent posttranscriptional modifications within BRSK1 [150]. 
 Within a neuron, BRSK2 has been detected in synaptic boutons (presynaptic 
terminal endings), where it associates with synaptic vesicles. At functional level 
BRSK2 seems to have a role in conveying signal across synapse, as measured in 
increase of frequency in excitatory postsynaptic potentials (EPSP) after 
overexpression. On the contrary, the kinase-dead mutant of BRSK2 showed 
decreased frequency in EPSPs. Together this implicates BRSK2s role in kinase 
dependent synaptic vesicle fusion within the synaptic bouton [151].  
 In pancreas BRSK2 has a role reminiscent to other ARKs: regulation of glucose 
and insulin sensitivity. Pancreatic specific BRSK2 knock-out mouse show 
hypoinsulemia, defective insulin secretion following glucose stimulation, decreased 
b-cells and pancreatic islet size. Further experimentation showed that glucose pulse 
stimulated the transcription of BRSK2 in mTOR1 dependent manner [152]. Given 
such a high association of BRSKs in energy metabolism, it would be interesting to 
explore possible link between BKRS-metabolism and BRKS-neural regulation.   
 Generally, BRSKs are phosphorylated by at least LKB1, TAK1 and CDK5 
[98,149]. BRSKs again phosphorylate at least Tau and RIM1. The latter represents 
the mechanistic link of BRSK and synaptic vesicle fusion [149,151].  
 
3.3.3.6 SNRK 
In the phylogeny of AMPK-Rs, SNRK is found to diverge way earlier from others 
discussed here. Functional studies of SNRK (sucrose non-fermenting related kinase) 
are relatively limited to date. Published reports show SNRK functioning in vasculature 
and adipose tissue homeostasis. Expression-wise SNRK is highly expressed in 
testis, placenta, vasculature, including endothelial and hematopoietic cells and 
adipose tissue [101,153,154].  
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 SNRK functions as a NOTCH signaling component in zebrafish vasculature 
development [153]. In adipose tissue SNRK is speculated to function in similar 
pathways associated with other ARKs: glucose uptake, fasting and insulin sensing 
[154]. Macrophage derived inflammatory factors are able to restrain SNRK 
transcription [154]. Phosphoproteomics of SNRK-depleted adipocytes revealed 
hypophosporylation of mTORC1, ACC1 and multiple mitochondrial proteins, whereas 
components of inflammatory signals showed increased phosphorylation [154].  
 These scattered results imply SNRKs functions associate with other ARKs, but 
the LKB1-dependency remains largely unexplored.  
 
Overall, many of the ARKs have intertwining functions. They account for LKB1-
dependent and independent functions. Because of the experimental variation 
(mouse/human, fibroblast/epithelial, ATP/AMP, LKB1/no-LKB1 etc.), the conclusion 
is very difficult to wrap up. What is currently missing mostly is the evaluation of the 
ARK functions in functionally relevant scenario. They are all AMP-activation 
related, thus it would be critical to examine their functions always in metabolic 
stress.  
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4. Aim of the Study 
Main goal of the study was to explore whether LKB1 levels are changed in human 
cancer stroma. Another more mechanistic aim was to see if LKB1 mediates metabolic 
changes in fibroblasts as in immune cells. If yes, whether these could be connected 
to the cancer-associated fibroblast transformation. In no, by what other means LKB1 
could mediate its tumor suppressive functions. We were also interested in studying 
the hierarchy between the LKB1 substrates in fibroblasts. This could potentially 
explain something about downstream effectors in CAF-transformation and help in 
dissecting the further mechanisms.   
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5. Results 
5.1 Stromal LKB1 is Reduced in Ovarian Cancer LKB1 is mutated in many 
human malignancies, and Peutz-Jeghers syndrome predisposes patient for other 
disease aside of polyposis, such as breast, lung and ovarian cancer [92,108]. Since 
stromal deletion of LKB1 is sufficient driver of gastrointestinal polyposis, we wanted 
look if LKB1 levels are changed in other neoplasms’ stroma [77,105,109]. We 
performed an exhaustive literature search and catalogued transcriptomic data from 
published datasets from cancers’ stroma (Appendix I). (We catalogued additional 
~200 comparisons to cover other activated stromal from a variety of human 
malignancies and in vitro experimentations. Not discussed further in this report.) Data 
sets did not include any published polyp-transcriptomes or sarcomas.  Surprisingly, 
only a handful of datasets showed significant changes in LKB1 levels. Out of 78 
datasets, only 7 had statistically significant (adjusted p-value £ 0.05) changes 
(Fig1A). One colon and one breast cancer data had stroma with high LKB1 whereas 
2 ovaria cancer, another breast, one lung and one pancreatic cancer stroma samples 
had LKB1 levels significantly reduced in the stroma. LKB1 levels experienced the 
deepest drop in ovarian cancer dataset (Fig1A, B). Because of this and the fact that 
loss-of LKB1 in mouse oviductal fibroblasts is sufficient to drive endometrial cancer, 
we focused our following experimentation to human ovarian stroma and female 
reproductive tract (FRT) [78,79].  
 LKB1 is observed to be homo-deleted in 1.8-4% in cases of human ovarian 
cancer (cBioPortal, Nature 2014 and TCGA;PanCancerAtlas) and we did not 
observe reduction in epithelial LKB1 levels ovarian cancer (Fig1B). In attempt to 
rationalize stromal LKB1’s role in ovarian cancer, we performed low-through-put PCR 
screen on ovarian cancer stroma markers. These markers included 57 most up- and 
down regulated genes in GSE40595 dataset. We generated human ovarian fibroblast 
cell lines (iHOF) with small hairpin RNA (shRNA) mediated knock-down of LKB1 
(Fig1C). In the iHOFs, we saw large changes in 26 out of 57 targets (log fold change 
³ ±1.5 £) following LKB1 knock-down. Out of these 26 genes, 16 were directionally 
similar to ovarian cancer stroma. Out of all 57, 33 genes were directionally similar. 
This suggests us, that indeed LKB1 may play a role in CAF transformation in human 
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disease. Additionally, these genes represent a novel LKB1 responsive genes in 
human ovarian fibroblasts. From now on, all the knock-down samples are designated 
as protein identifiers in CAPITALS, regardless of species (e.g. knock-down of Prkaa2 
mRNA in MEFs is written AMPKa2). RT-PCR and WB targets are designated as 
species specific mRNA and protein identifiers respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. LKB1 levels are reduced in human ovarian cancer. A) Log-2-fold changes of 78 
published cancer stroma datasets. Datasets with statistically significant changes (adjusted p-value < 
0.05) are marked with their GSE-repository identifiers. B) Stromal and epithelial LKB1 mRNA levels 
in GSE40595. C) Low-throughput RT-PCR of human ovarian cancer stroma genes in LKB1 null iHOFs 
(top). Knock-down efficiencies of LKB1-iHOFs (bottom). D) LKB1 mRNA level (top) and protein level 
(bottom) of a single pair of human adnexal benign and ovarian cancer CAFs. What are also probed on 
western are, CAF-markers MMP-9, CAV-1 and aSMA. NDUFB8 was analyzed for mitochondrial 
biogenesis, also associated CAF-transformation. 3rd row ponceau as a loading control for LKB1, 
NDUFB8 and MMP-9 and bottom row Vinculin as a loading control for aSMA and CAV-1. 
GSE17978
GSE9014
GSE40595
GSE115635
GSE35364
GSE35602
GSE101665
−1
0
1
Lo
g2
 F
ol
d 
Ch
an
ge
CAF Origin
Bladder
Breast
Dermis
GI−tract
Lung
Ovary and Cervix
Pancreas
Prostate
LKB1 Levels in Publicly Available Datasets
TGFBI
COL1A1
DKK3
STAT2
SNAI2
THY1
COL6A2
PKD2
C3
PTGS1
SLPI
COL11A1
RABL6
TNFMP6
VDR
MXRA5
SLC40A1
SERPINB9
CDOA3
ADAMTS5
SLC7A7
CXCL14
CXCR4
CCL11 MAL2
IL10RA
−3.00
−2.00
−1.00
−0.59
0.00
0.59
1.00
2.00
3.00
20 25 30 35
SCR Average Expression (Cycle) Value
Lo
g2
 F
ol
d 
Ch
an
ge
OVCA Stroma Associated Genes in LKB1−null iHOFs
A
C
1.00
0.63
0
0.2
0.4
0.6
0.8
1
1.2
Adnex CAF
Re
la
tiv
e 
ex
pr
es
si
on
 v
al
ue
 n
or
m
al
ize
d 
to
 G
AP
DH
LKB1 in Human Ovarian 
Cancer CAFsD
Log2FC: -0.88
Adjusted p-value: 0.00053
B
0.29
0.38
0.18
0.92
1.00
0 0.2 0.4 0.6 0.8 1 1.2
LKB1_3
LKB1_2
LKB1_1
SCR_2
SCR_1
Relative expression value normalizedGAPDH
iHOF LKB1 Levels
 46 
Since the ovarian cancer dataset (GSE40595) represented the all stromal cell 
populations, not only fibroblasts, we evaluated LKB1 levels (along with other 
markers) in single pair of adnexal benign fibroblasts and CAFs derived from ovarian 
cancer patient. We observed ~40% reduction in STK11 mRNA and somewhat similar 
reduction in protein level (Fig1D). We also observed induction in CAF-markers MMP-
9 and aSMA. Slight decreases were observed in mitochondrial complex I component 
NDUFB8 and a third CAF-marker CAV-1, markers for mitochondrial biogenesis and 
caveolae signaling respectively. Mitochondrial biogenesis and caveolae mediated 
membrane trafficking are contributing to CAF-transformation (see the literature 
review). These data highlight that LKB1 levels are reduced de novo in human ovarian 
cancer and that this downregulation is associated with human cancer related 
transcriptomic signature.  
 
In murine model of endometrial cancer, epithelial heterozygosity of LKB1 does not 
drive tumorigenesis [170]. On the other hand, whole-body heterozygosity and 
epithelial or mesenchymal homozygous deletion of LKB1 do progress into 
endometrial adenocarcinoma and oviductal adenomas [78,79,170]. Stromal 
heterozygosity of LKB1 is known to be sufficient driver of gastrointestinal polyposis, 
but whether same holds true for FRT is not yet reported. Given the opportunity, we 
analyzed murine ovaries, fallopian tubes and uterine tubes of Peutz-Jeghers mouse 
model at the age of 11 months (Twist2Cre/+; Stk11+/flox = Lkb1Twist2KO/+). Importantly, 
mutant mice were fertile and by the time of collection, GI-polyposis was fully penetrant 
in the heterozygous animals. We did not observe noticeable difference in the size or 
external appearance of the ovaries, fallopian or uterine tubes between the genotypes 
of 2 versus 2 animals (4 versus 4 ovaries) (FigS1).  
 HGSOC is known to initiate through from either fallopian tubes or ovarian 
surface epithelia [155,156]. Thus, we analyzed these anatomical regions in closer 
detail. We also analyzed uterine for extra-ovarian growth. Recombination was evident 
in the stroma and muscle layers through-out the mouse FRT (FigS1). LKB1 
downregulation was assessed by immunohistochemical analysis. aSMA was highly 
expressed in uterine muscle layer and fallopian tubes with no differences between 
the genotypes. Epithelial cell layer overlaying the tubular structures and ovarian 
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follicular structures was uniform in both genotypes. We observed significantly less E-
Cadherin expression in ovarian structures of LKB1-heterozygotes which might imply 
ongoing EMT. To asses this, we visualized active TGFB-signaling by staining 
phospho-SMAD3. We did not however observe any difference: p-SMAD3 stained 
similarly in both genotypes, follicular epithelial layer. This ruled out active TGFB as a 
source of this E-Cadherin pattern. This suggested that in the FRT, LKB1 
heterozygosity requires further reduction and/or concomitant oncogenic signal(s) 
from neighboring epithelia or stroma, in order to initiate stromal expansion and cancer 
progression.  
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Supplementary Figure 1. Stromal heterozygosity of LKB1 does not induce ovarian 
cancer in Peutz-Jeghers mouse model. No general differences in gross anatomy (top row) or in 
fine structures of heterozygous (left) and wild type (right) mouse female reproductive tracts. 
Recombination was assessed with TdTomato reporter (4th row) and LKB1 staining (6th and 7th rows). 
Wild type ovaries (Rows 3-11, column 4) were from different mouse than fallopian and uterine tube 
(Rows 1-11, columns 5-6).  1st row in same scale. 2nd row scale bar 2000µm. Rows 3-10 scalebar 200µm. 
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5.2 AMPK and AMPK-Related Kinases Contribute Significantly and 
Hierarchically to LKB1 Transcriptome in Fibroblasts We began dissecting 
the role of LKB1 in ovarian cancer evolution and CAF-transformation by evaluating 
though which substrates LKB1 mediates its functions in fibroblasts. LKB1 regulates 
14 kinases belonging to family of AMPK-related protein kinases [98]. As a model of 
stromal fibroblasts, we used primary mouse embryonic fibroblasts (MEF). Because 
of inherent heterogeneity of MEF’s they also provided us an opportunity to circumvent 
and model endogenous variability of tissue stroma [29,157]. Also, as a primary cell 
line, MEFs do not experience somatic modifications related to immortalization or 
extended culture conditions. LKB1 and 12 of its kinase substrates where silenced 
using short hairpin RNA (shRNA) mediated interference [158]. We did not induce 
knock-down of BRKS1 or BRSK2 due to their low expression and functional 
unrelatedness in fibroblasts (FigS2A).  
 Author of the thesis was responsible of producing sequencing batch 4: 
AMPKa1, AMPKa2 and LKB1 (2nd replicate). Thus, validation data is only supplied 
for the corresponding batch! Hairpins were validated according to knock-down 
efficiency (Data not shown). Knock-down efficiencies of sequencing samples were 
validated with RT-PCR and western blotting (FigS2B, C). Levels of AMPKa1, 
AMPKa2 and LKB1 reached >90% compared to SCR control in mRNA level. 
Importantly, we observed reproducible upregulation of AMPKa2 following AMPKa1 
knock-down. This might speak for underlying hairpin effect or compensatory 
mechanism within AMPKs. Also, upregulation of LKB1 was observed after 
AMPKa1/a2 knock-downs. On the other hand, AMPKa2 levels experienced ~50% 
drop, following LKB1 knock-down.  
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Supplementary Figure 2. 
Validation of RNA-sequencing 
batch #2: AMPKa1, AMPKa2 and 
LKB1 (2nd replicate) samples. A) 
LKB1, AMPK and ARK expression in 
primary MEFs as represented in 
average read counts from SCR-control 
samples. B) RT-PCR analyses of 
knock-down efficiencies. C) Western-
blot analyses of protein levels of 
knock-down samples. AICAR (AMPK-
activator) samples were also 
generated though not sequenced. 
Ponceau stainings as a loading 
control: top-ponceau for AMPKa1 and 
bottom for p-ACC1, AMPKa2 and 
LKB1 (Batch 1 & 3). Note the shift in 
sample order in p-ACC, AMPKa2 and 
LKB1 in sample batch 4. No ponceau-
control for Batch 2 available. 
 
 
After quality check and library preparation, MEF transcriptomes were generated with 
single-end RNA-sequencing. Sequencing was performed in four batches (FigS3A). 
All batches were included with scrambled (SCR) control. Each batch included 2 to 6 
biological replicates, specifically embryos. Looking into the similarity of significant 
genes, we observed good overlap between the two LKB1 batches (>71% directional 
similarity). For further analyses we combined the two LKB1 data (FigS3B). Also, 
without going deeper into the directionality, we could readily observe how of the ARK 
subfamilies related to each other (FigS3C). For example, among SIK-family, SIK2 
and SIK3 were the most distant. In MARKs, MARK4 seemed the most distant 
showing highest amount of similarity together with MARK3. MARK2 shared plenty 
with MARK1 and MARK3 but it also had a huge number of exclusive genes. The 
absolute shared genes between AMPKa’s and NUAK’s were higher, though they still 
retained high number of exclusive genes.  
 We also tried to identify feed-back-loops by analyzing expression values of 
substrate paralogs following ARK-knock-downs (FigS3D). NUAKs, SIK1/2, 
MARK1/3/4 had no significant effect on each other’s expressions. The previously 
observed AMPKa-feed-back was present also in the sequencing data, but we also 
saw changes in paralog expressions following MARK2 and SIK3 knock-downs: 
MARK2 knock-down induced expression of MARK1 and SIK3 induced SIK1 but 
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silenced SIK2. Whether these are true biological effects or rather hairpin-dependent 
will require further inspection. Interestingly, we did not observe the reported AMPKa1 
reduction following NUAK1 knock-down in mRNA level [135,138]. 
 
 
Supplementary Figure 3 
RNA-sequencing batch 
information and ARK-
paralog cross-talk. A) 
Information about the 
sequencing batches. B) 
Aggregation of two LKB1-MEF 
batches. Combined LKB1-
dataset included (I) 
significantly altered* common 
genes and, (II) genes which 
were significantly altered* in 
the other and directionally 
similar in the other. Thick 
circles represent the 
significantly altered fraction (*) 
and thin circles the non-
significant fraction. C) Venn-
diagrams representing the 
common significantly changed* 
between the ARK-paralogs. 
Directionality was not assessed 
between the paralogs. D) Table 
with knockdown (rows) 
induced changes in the other 
ARK’s mRNA levels (columns). 
(*) = Adjusted p-value < 0.05 
and Log-2-fold change  £∓1.5³.  
 
 
 
 
After data processing, hierarchical clustering revealed LKB1 batches forming a 
separate branch together with previously published LKB1 polyp-data from Peutz-
Jeghers mouse model (Fig2A) [105]. MARK3 and MARK4 clustered closest among 
the substrates to LKB1 datasets. SIKs and SNRK formed distinct cluster of four. 
AMPKa1, AMPKa2, MARK1, MARK2, NUAK1 and NUAK2 formed a third 
distinguishable group, which was closer to LKB1s than SIK-SNRK.  
 In order to get more detailed view on substrate contribution on LKB1 
transcriptome, we analyzed gene-by-gene similarity of substrates with genes most 
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AMPK!2 4 IV -4.22
MARK1 3 II -1.25
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SIK1 3 III -0.98
SIK2 2 III -1.69
SIK3 3 III -2.52
SNRK 3 III -2.13
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significantly regulated by LKB1. By applying fold change and adjusted p-value 
thresholds we saw 693 common genes regulated after LKB1 knock-down (FigS3B, 
underlined). From these MARK2, NUAK1 and AMPKa2 took the lion’s share (Fig2B). 
Adjusting these changes to the whole transcriptomic changes, showed that AMPKa2 
and NUAK2 and NUAK1 had the highest LKB1-related transcriptomic fingerprint 
(Fig2C). Also, looking at genes changing solely after knocking down a single 
substrate showed MARK2, NUAK1, AMPKa1 and AMPKa2 having the highest 
number of exclusive genes (Fig2D). Overall, sequenced ARKs covered ~77% of 
significantly altered transcriptome of LKB1.  
 LKB1 is known regulator of cellular pathways ranging from cell polarity, 
proliferation, differentiation and metabolism [93,94,103,122]. To see if our in silico 
model could capture some of these functions, we performed gene set enrichment 
analysis (GSEA) for LKB1 and the substrates. LKB1-MEFs showed positive 
enrichment of pathways such as JAK/STAT3, glycolysis and interferon responses 
(Fig2E). On the other hand, hallmarks such as TGFB-signaling and myogenesis were 
negatively enriched, which is in agreement with the function of LKB1 as a TGFB 
inhibitor [104]. Generally, LKB1 replicates were highly enriched in inflammatory 
related pathways. Looking down the substrates it seemed that more pathways were 
negatively than positively enriched. None of the GSEA hallmarks were shared with 
all the samples. 
 LKB1 and ARKs maintain metabolic equilibrium [94,95,96,97]. Thus, we 
focused our further GSEA more specifically on metabolic pathways. LKB1 replicates 
were differentially deregulated among oxidative phosphorylation. This was interesting 
in 2 ways: there is increasing evidence of decreased oxidative phosphorylation 
following loss-of LKB1 AND activated fibroblasts in cancer stroma are described to 
maintain low OXPHOS and to cancer progression [86,87,88]. Seeing this difference 
in OXPHOS, we conducted more detailed leading-edge analysis without being able 
to resolve the origin of difference (Data not shown). LKB1 replicate(s) shared positive 
enrichment in glycolysis, xenobiotic, and cholesterol metabolism. Thus, loss-of LKB1 
results in changes in oxidative phosphorylation which could be compensated by 
upregulation of multiple other metabolic pathways. ARK knock-downs resulted 
generally in decreased glycolysis and fatty-acid metabolism. Oxidative 
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phosphorylation was more dispersed among them. Thus, we hypothesize that LKB1 
regulates mitochondrial metabolism also in fibroblasts, and that some of its 
substrates possibly functions downstream of it in this pathway.  
 
 
Figure 2. Sequencing analyses of MEFs with LKB1, AMPKa’s and AMPK-related kinase 
knock-downs. A) Unbiased hierarchical clustering of LKB1-/ARK knock-down MEFs and published 
Peutz-Jeghers mouse model polyps.  B) Directional similarity of LKB1 (FigS3B) and substrates: Up 
(blue), down (yellow) and total (red) among significant genes*. C) Fraction of total genes (B, red) from 
all the significantly differentially expressed genes within a substrate*. D) Number of exclusively, 
significantly expressed genes from LKB1 (FigS3B) following substrate knock-down. E) GSEA analysis 
of Molecular Signatures Database (MSigDB) hallmarks of LKB1-/ARK knock-down MEFs. (*) = 
Adjusted p-value £ 0.05 and Log-2-fold change £∓1.5³.  
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5.3 Cancer-Associated Fibroblast Classification Unveils Inflammatory 
and Myofibroblastic CAF Subtypes Before going deeper into the mechanism 
driving the possible CAF-transformation, we wanted to improve our confidence about 
LKB1-MEFs as a good surrogate for CAFs. There is not a single all-inclusive CAF-
marker that we could use as a universal identifier. CAFs are rather identified by a 
cluster of markers. By utilizing curated CAF-gene set [37,159], we first aimed to see 
how LKB1 and ARKs segregate/merge in terms of CAF-markers. By limiting the 
clustering to ~120 CAF-markers, did not see drastic changes in the clustering 
compared to initial clustering (Fig2A). MARK1 switched to LKB1-MARK3/4 cluster 
(FigS4A). SIK/SNRK clustered as an outgroup and AMPK-NUAK were closer to 
MARK-LKB1. This could indicate that SIK, AMPK-NUAK and MARK-LKB1 represents 
different CAF subtypes. We also performed GSEA analysis with the same CAF-gene 
set in order to normalize the value of these CAF-markers over to the whole 
transcriptome. Surprisingly, majority of the ARKs showed negative enrichment 
against the markers. LKB1 together with SIK3 and NUAK2 were positively enriched 
(FigS4B). This highlights that not all the genes within these CAF-markers are equally 
highly altered in all the knock-downs. Thus, the markers give a different weight for 
depending on the sample. 
Supplementary Figure 4. Association of Curated CAF-markers in LKB1-ARK-MEFs. A) 
Unbiased hierarchical clustering of LKB1- and ARK-MEFs based of 166 CAF-markers. B) GSEA 
analysis of LKB1- and ARK-MEFs against gene set constructed from curated CAF-markers. Asterix (*) 
signifies statistical significance (nominal p-value £ 0.05). 
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Despite the CAF-markers are curated, the directionality and biological purpose of 
them is often unknown. Thus, we wanted to deepen our understanding in CAF-
heterogeneity to the level of whole transcriptome using actual patient material. To 
achieve this and really benchmark our MEF-model, we took advantage of our 
previous literature search (Fig1A, Appendix I). We divided the samples into two 
distinct categories. Direct (29pc) samples were acquired though microdissection or 
FACS-sorting and were considered to represent the actual stromal signature present 
at the time of dissection. Indirect (51pc) samples were patient derived cell lines which 
may have lost some of their pathogenic phenotypes through prolonged in vitro culture 
conditions but included only fibroblasts. Hierarchical clustering was performed for the 
two groups separately which identified brute segregation of another two groups in 
both direct and indirect (Fig3A, B). Samples from identified clusters (Patient Derived 
Direct/Indirect 1 & 2 ® 4 clusters) were further merged as a representative of the 
whole cluster.  
 CAFs represent heterogeneity which can roughly divide then into two 
fundamentally different subtypes: myofibroblast-like and inflammatory-like [64]. The 
former is more myogenic and metabolically active whereas the latter represents more 
inflamed phenotype. To see if our identified clusters could capture some of this 
heterogeneity, we performed GSEA analysis on the merged clusters. The direct 
clusters were somewhat similar, differing only in pathways such as hypoxia, oxidative 
phosphorylation and MYC targets (Fig3C). This was probably due to noise originating 
through other stromal cell types present in majority of samples. This would also 
suggest that the pathways that actually show difference, are very strong since they 
pop-out despite this noise. Thus, e.g. OXPHOS would highlight an important hallmark 
discriminating these two groups.  
 Surprisingly, indirect clusters represented more dramatic differences among 
each other. Cluster one was positively enriched in oxidative phosphorylation, 
glycolysis and myogenesis and generally negative in inflammation associated 
hallmarks. Indirect cluster 2 on the other hand was positively enriched in ALL 
inflammatory hallmarks and negative in myogenesis and oxidative phosphorylation. 
This would suggest that dissecting the noise originating from other stromal cells, 
effectively revealed additional, fibroblast-specific differences. The results are also in 
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agreement with the hypothesis of two difference CAF subtypes namely myCAF and 
iCAF. 
 To clarify the confusion around the directionality among 166 CAF-markers used 
earlier, we performed GSEA analysis of newly identified CAF-clusters against these 
same CAF-markers. Results showed that the markers are indeed preferentially 
upregulated in human CAFs (Fig3D). This implies that LKB1, NUAK2 and SIK3 
actually shows strongest similarity towards human CAFs with respect to these marker 
genes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Clustering of Published Stromal Data Sets Dissects CAF-Heterogeneity. A) 
Unbiased hierarchical clustering of top/bottom 1000 genes of stromal samples directly dissected from 
patients. B) Unbiased hierarchical clustering of top/bottom 1000 genes of fibroblasts outgrown from 
patient derived stromal samples. Grey boxes in A) and B) represent the identifies clusters I and II in 
both. C) GSEA analysis of MSigDB hallmarks of averaged clusters (grey boxes in A) and B)). Color-
coding divides hallmarks into inflammatory (grey), metabolic (yellow), myofibroblast (red) and other 
(green). D) GSEA analysis of patient derived clusters against gene set constructed from curated CAF-
markers.  
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Next we sought to see how the MEF-data compared against the identified clusters 
themselves. LKB1 datasets represented highest association with direct cluster 1 and 
indirect cluster 2 (FigS5). This pattern was shared with SIK1, SIK3 and SNRK in the 
direct, and AMPKa1, AMPKa2 and NUAK2 in the indirect clusters respectively. 
Importantly, both of the clusters (Direct1 & Indirect2) were low in oxidative 
phosphorylation and partially glycolytic, which is consistent with initial observations 
with LKB1-MEFs (Fig2E). In light of this data we conclude that, though not proven a 
CAF, LKB1-null MEFs preferentially associate together with certain CAF subtypes 
over others. Namely, LKB1-MEFs are associated with highly inflammatory, low-
OXPHOS and low-MYOGENESIS CAF subtypes. 
 
  
Supplementary Figure 
5. GSEA Analysis of 
LKB1-ARK-MEFs 
Against Gene Sets 
Constructed from 
Patient Derived 
clusters. A) MEF 
sequencing samples 
against Patient Derived 
Direct Cluster 1. B) MEF 
sequencing samples 
against Patient Derived 
Direct Cluster 2. C) MEF 
sequencing samples 
against Patient Derived 
Indirect Cluster 1. D) 
MEF sequencing samples 
against Patient Derived 
Indirect Cluster 2. 
Asterix signifies statistical 
significance (nominal p-
value £ 0.05).  
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5.4 LKB1 and ARKs Regulate MEF Oxidative Metabolism and 
Mitochondrial Biogenesis We have thus far collected two independent 
transcriptomic evidence of LKB1 functioning in mitochondrial metabolism: unbiased 
GSEA hallmark analyses and association with low-OXPHOS CAF subtypes. There is 
also increasing line of evidence supporting LKB1’s role as a metabolic caretaker in 
other cell types [94,95,96,97]. Thus, we hypothesize that LKB1 function as a 
metabolic regulator is conserved in fibroblasts. More specifically, we asked whether 
these transcriptomic signatures would translate into physiological responses and 
further, which one of the kinase substrates might be responsible for it. This metabolic 
rewiring could potentially help explaining LKB1’s role also in ovarian cancer 
development. There is currently no all-inclusive measure of oxidative phosphorylation 
or glycolysis. To answer our questions, we began by measuring the MEF oxygen 
consumption rate (ORC) and extracellular acidification rate (ECAR) of the knock-
down primary cell lines. OCR and ECAR are generally taken as surrogates for 
oxidative phosphorylation and glycolysis respectively.  
 Due to the sensitivity of OCR measurement to cell density, and in order to rule 
out density-dependent effects, we measured it once in low (FigS6B) and twice at high 
(Fig4A, FigS6A) cell densities. Regardless of plating density, knock-down of LKB1 
resulted in reproducibly reduction in OCR levels, reflecting the decreased OXPHOS 
capacity (Fig4A, upper time course). More specifically, knock-down of LKB1 resulted 
in decrease in maximum and spare respiratory capacities, having minimal effects in 
other OCR-measures (Fig4A, Blue barplots). Interestingly the ATP derived through 
OXPHOS was not altered after LKB1 knock-down, suggesting LKB1-null MEF are 
still at energetic equilibrium. From the substrates, AMPKa1 and MARK3 were the 
most consistent with LKB1. NUAK1 and SIK1 also showed somewhat similar trends 
as LKB1 but so far, we only captured 2 replicates from them. AMPKa2 and MARK2 
were similar in 2 out of 3 measurements but contrasting in one compared to LKB1. 
MARK4 and SNRK had increased OCR levels compared to SCR-control.  
 ECAR levels of LKB1-null MEFs were generally not changed (2/3) but high 
glycolytic levels were observed in a single measurement (1/3) (Fig4A, lower time 
course, yellow barplots; FigS6C). Looking for substrates in-between these LKB1-
observations we identified AMPKa1, MARK1 and SIK-family as the most similar to 
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LKB1. Once again, MARK4 and SNRK showed the highest ECAR levels (Fig4A). 
These results suggested that LKB1 might actually regulate oxidative and anaerobic 
metabolism through different substrates. Also, MARK4 and SNRK seemed the 
strongest LKB1-independent substrates with respect to metabolic control implicated 
by both extremely high OCR and ECAR measures. Nevertheless, additional 
experimentation is required to dissect LKB1-dependent ARK with high confidence.  
 Reactive oxygen species are known to originate as a by-product of 
mitochondrial respiration but also by mitochondria-independent means. Regardless 
of its origin, ROS can potently cause mitochondrial dysfunction and oxidative stress 
resulting in vicious cycle fueling more and more ROS further reducing the 
mitochondrial function.  Importantly, loss of LKB1 in MEFs is described to induce 
ROS production [111]. Interestingly, this is independent of AMPKa1/2 [111]. We 
measured ROS production from knock-down of LKB1 and substrates in MEFs. 
Importantly, loss-of LKB1 resulted in reproducible ~2-fold increase in ROS (Fig4B, 
FigS6D). Loss-of AMPKs did not increase the ROS production consistent with earlier 
report. MARK1, MARK4, NUAK1, SIK2 and SNRK knock-downs increased ROS and 
thus represents potential candidates for LKB1-antioxidant effectors.   
 Next, we went to the level of mitochondria to see if loss-of LKB1 or ARKs affects 
mitochondrial biogenesis. We measured mitochondrial DNA (mtDNA) content and 
quantified the mitochondrial organelle content. Knocking down LKB1 resulted in 20-
40% reduction in cellular mitochondrial DNA content (Fig4C, FigS6E). AMPKa2, 
MARK2, SIK2 and SIK3 were the most similar in their mtDNA contents. MARK4 and 
SNRK showed increase in mitochondrial DNA. Somewhat surprisingly, also AMPKa1 
showed induction of mtDNA content, which is in agreement with the report describing 
AMPK as an activator of mitochondrial biogenesis [160].  
 Similar reduction in mitochondrial protein content (~25%) was also observed in 
LKB1-MEFs with microscopy (Fig4D). Importantly, we did not observe difference in 
mitochondrial particle number, suggesting that LKB1-dependent reduction in 
mitochondrial content is not due to disruption of fission/fusion dynamics. Though not 
quantified for the ARKs, we did observe considerable fractionation of mitochondria 
following knock-downs of MARK3 and NUAK1 (FigS7). Also, a different type of 
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mitochondrial phenotype, a pearl-necklace type was observed in AMPKa2-null MEFs 
(FigS7). 
  Knock-down efficiencies were evaluated by RT-PCR, at the end of the 
experiments (FigS8). We didn’t observe large differences between the SCR and 
MOCK-controls in OCR, ECAR, ROS or mtDNA analyses.  
 Taken together, our data suggests that LKB1 is regulating mitochondrial 
metabolism and biogenesis in fibroblasts. Moreover, LKB1 may mediate its glycolytic, 
oxidative phosphorylation and mitochondrial biogenetics effects through distinct 
substrates. Mitochondrial dysfunction following LKB1-loss was readily observable 
through multiple levels of inspection. Thus, we feel confident to say LKB1-MEFs are 
indeed low-OXPHOS. This also clarifies the confusion after seeing conflicting results 
in LKB1-transcritomes and GSEA (Fig2E).    
 
Figure 4. LKB1 and Critical 
Kinase Substrates Regulate 
Mitochondrial Metabolism in 
MEFs. A) Extracellular flux assays 
of LKB1-ARK-MEFs. 
Representative time course plots of 
LKB1 and SCR-/MOCK-controls (2 
independent biological replicates 
from both) in OCR (up) and ECAR 
(bottom). Barplots representing 
the OCR (blue) and ECAR (yellow) 
measures derived from the time 
course assay. B) Representative 
barplots from ROS-assay using the 
same cells as in A). DCF+NAC and 
NAC represent technical controls. 
C) Mitochondrial DNA content 
measurement form the same cells 
as in A) and B). D) Mitochondrial 
mass analysis from single pair of 
LKB1 and SCR cells using the same 
cells as in A), B) and C). 
Representative images and 
quantification of mitochondrial 
surface area per total area (left) and 
mitochondrial particle number per 
total area (right). Each dot in 
boxplots represents a single cell. 
Scalebar 50µm. Asterix signifies 
statistical significance ((*) = p-
value £ 0.05, (**) = p-value £ 
0.0001) calculated with unpaired 
student’s T-test. Cross signifies the 
control samples. No statistics were 
applied on mtDNA amounts. 
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Supplementary Figure 6. Data from OCR/ECAR Replicated Experiments. A) OCR 
measures derived from another high cell density flux assay. B) OCR measures derived from low cell 
density flux assay. C) ECAR measures using the same cells as in A). D) ROS-assay using the same cells 
as in B). Mitochondrial DNA quantification from the same cells as in A)/C) (left) and B) (right) 
respectively. Asterix signifies statistical significance ((*) = p-value £ 0.05, (**) = p-value £ 0.0001) 
calculated with unpaired student’s T-test. Cross signifies the control samples. No statistics were 
applied on mtDNA amounts. 
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Supplementary Figure 7. Mitochondrial Phenotypes of ARKs. 1st Column representing 
uniform SCR-control mitochondria. 2nd and 4th Columns highlights the mitochondrial fractionation 
following knock-downs of MARK3 and NUAK1 respectively. 3rd Column represents the pearl-string 
phenotype of AMPKa2 knock-down. Cells were the same as in Fig4. Scalebar 50µm. 
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Supplementary Figure 8. Knock-down Efficiencies of Cells Used in Mitochondrial 
Assays. Left) Cells used in Fig4. Middle) Cells used in FigS6A, C and E (left). Right) Cells used in 
FigS6B, D and E (right). Cross signifies the control samples. 
 
5.5 LKB1 Regulates Mitochondrial Metabolism of Ovarian Fibroblasts 
Despite Lkb1Twist2KO/+ was incapable of initiating FRT tumorigenesis, complete 
stromal deletion of LKB1 succeeds in it [78]. The molecular mechanism is however 
only partially understood, especially from the perspective of CAFs. We have already 
provided evidence that loss-of LKB1 or ARKs regulate CAF-associated metabolic 
changes. To see if similar changes occur in human ovarian fibroblasts, we measured 
OCR and ECAR fluxes from LKB1 knock-down iHOF cell lines. As in the case of 
MEFs, loss-of LKB1 in iHOFs resulted in significant decrease in maximum and spare 
respiratory capacities and a slight increase in glycolytic responses (Fig5A). 
Compensating for the reduced OXPHOS, LKB1-null iHOFs increased their glycolysis 
and glycolytic capacity (Fig5B). Importantly, knocking-down LKB1 from iHOFs didn’t 
increase the proliferation rate compared to SCR control (Data not shown). Thus, this 
suggests mitochondrial metabolism as a LKB1-mediated mechanism supporting 
ovarian cancer development. 
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Figure 5. LKB1 Mediates Mitochondrial Metabolism in Human Ovarian Fibroblasts. A) 
Extracellular OCR assay of LKB1-iHOFs and SCR-control. Representative time course plot (left) and 
barplots representing OCR measures derived from time course assay (right). B) Extracellular ECAR 
assay of LKB1-iHOFs and SCR-control. Representative time course plot (left) and barplots 
representing ECAR measures derived from time course assay (right). Both A) and B) are from same 
cells. Knock-down was validated in Fig1C (LKB1_3). Asterix (*) signifies statistical significance (p-
value £ 0.05) calculated with unpaired student’s T-test.  
 
Collectively, our data suggests that LKB1 levels are de novo down-regulated in 
human ovarian cancer. Though LKB1-heterozygosity was not sufficient to drive 
tumorigenesis, near complete loss-of LKB1 in iHOFs resulted in transcriptomic profile 
reminiscent to ovarian cancer stroma. We also provide evidence that LKB1 regulates 
cancer-associated metabolic changes also in both murine and human ovarian 
fibroblasts. This could help explaining the molecular mechanism through which CAFs 
promote ovarian cancer. These data also suggest more conserved function of LKB1 
as a metabolic caretaker in fibroblasts. Whether these metabolic changes are actually 
causal for cancer initiation or whether they are driven through LKB1 substrates, our 
data is not strong enough to prove. From the MEF-transcriptomic analyses we can 
however say that majority of LKB1 functions are driven through small subset of 
substrates (MARK2, AMPKa2 and NUAK1). Thus, it is plausible to hypothesize 
(some of) them as actual metabolic effectors of LKB1 that could potentially function 
also downstream of LKB1 in ovarian cancer.  
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 In light of this data, we propose a model in which I) LKB1 function is 
compromised by yet undescribed mechanism in e.g. ovarian stromal fibroblasts. II) 
This loss-of-function results in deficient activation of LKB1 substrates and III) is 
relayed as mitochondrial dysfunction. IV) This again is critical for stromal activation 
and cancer-associated fibroblast transformation (Model).  
 
 
Model: Ovarian cancer reduces stromal LKB1 levels. This results in insufficient 
activation of LKB1’s downstream substrates which again causes mitochondrial 
dysfunction, ROS-production, inflammation, fibroblast activation and transformation 
into myofibroblast (MF) and/or CAFs. Red arrows indicate direct mechanism by which cancer 
cells downregulate stromal LKB1. Blue arrows indicate indirect mechanism, in this case through 
cancer-associated immune cells. Yellow arrows indicate CAF-transformation though both LKB1-
dependent and -independent (mitochondrial fractionation). Purple arrows indicate the crosstalk 
between CAFs and tumor cells through established mechanisms such as aminoacids biosynthesis and 
lactate shuttle. What is not visible in the model of the signaling from non-invading cancer-cells to the 
stroma which is also possible. Epithelial color-coding from green to red represents the corresponding 
increase in malignant potential. Fibroblast intracellular organelles (yellow) represent mitochondria. 
Brown spiral material underneath the basement membrane represent fibrous ECM which tends to 
linearize towards the more cancerous region. 
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6. Discussion 
 
With the data provided, I hope we have convinced the reader that I) ARKs contribute 
to LKB1’s functions in hierarchical fashion and that majority of LKB1’s functions are 
covered through its 12 kinase substrates, II) Cancer-associated fibroblasts 
experience profounding heterogeneity which makes their categorization challenging, 
III) LKB1 and some ARK knock-down fibroblasts are activated and share CAF-like 
phenotypes, IV) LKB1 and ARKs regulate stromal oxidative metabolism and lastly V) 
stromal LKB1 regulates functions relevant towards human diseases such as ovarian 
cancer. 
 Despite AMPK’s historical role as a pivotal target of LKB1, the field is gradually 
beginning to appreciate the spectrum of its other substrates [162]. AMPK may be 
highly expressed and central in many cellular pathways but as we have already seen, 
the sheer expression value does not necessarily translate to the functional relevance. 
This is also why it might be a good idea to include the BRSK1/2 in later transcriptomic-
screenings. It would also be interesting to explore the substrates-independent ~30% 
of LKB1 transcriptome. It is possible that by evaluating the transcriptomes in more 
physiologically relevant conditions (e.g. energy deprivation) would recover some of 
this missing fraction. In the lab we have generated transcriptomic data using AMPK-
activators. It will be interesting to see how that will compare to LKB1. Additionally, it 
is possible that some of the remaining 23% is not covered due to paralog-
compensatory mechanism. Of note, since LKB1-heterozygosity can already cause 
neoplasm, it might be worth wile to evaluate the coverage of LKB1-/+ MEFs versus 
complete knock-down.  
 ARK nomenclature suggests, though hardly proves, inter-substrate functional 
relatedness. Phylogenetic separation of the substrates is based on protein sequence 
similarities, which do carry functional information. Functional relatedness can further 
lead to inter-substrate feed-back/forward loops that can possible affect paralog 
transcription when another paralog is reduced. We do observe one such loop in case 
of knocking down AMPKa1, which results boost in a2 expression. This could be taken 
into account by adding a1/a2 double knock-out to the analysis. Substrate paralogs 
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also contain additive effects among each other [162]. We have also generated 
AMPKa1/a2 double knock-out transcriptomic data which is planned to include in the 
later analyses.  
 It is interesting to see that AMPKa1 and a2 contribute so much to LKB1’s 
fibroblast signature, even though they cluster far away. Even more, since they are 
dispensable in GI-polyposis [105]. If it would turn out that AMPKa1/a2 would conduct 
LKB1’s metabolic functions, this would mean the OXPHOS/glycolysis are not critical 
for polyposis initiation. But this could of course underlie differences between the 
model systems. Importantly, our model is lacking natural epithelial-to-mesenchyme 
signaling hub, which plays a role in the living organism. Temporal dynamics in GI-
polyposis are relatively long (months/>1 year). Thus, it is more than probable that our 
brief in vitro experimentation is not able to capture real malignant state of polyposis. 
Rather it measures more natural and homeostatic substrate contribution. It could also 
be that AMPKa’s would mediate other cancer mechanisms aside from initiation. They 
could for example have role in metastasis and PJS’s association to other 
malignancies. 
 Outside LKB1, it would be very interesting to look what the substrate’s LKB1-
independent functions are. Could we e.g. confirm some of the previously identified 
substrate-specific pathways merely from the transcriptomes? As we have shown, 
given a substrate, LKB1 maximally covers only 16% of the differentially expressed 
genes. Naturally, LKB1 sits above the substrate and thus the transcriptomic changes 
will fade away moving further from the substrate-of-interest. This probably explains 
why we see such a small LKB1-dependent fraction. Additionally, after seeing this high 
coverage (77%) in such a heterogenous in vitro model, it will be extremely exciting to 
see what kind of changes in substrate contributions we will see in more 
clonal/homogenous cell populations such as iHOFs. If a group of substrates could be 
linked to certain cellular function of LKB1, it would make it easier to rationalize what 
substrates might be underlying certain phenotype. Here we argue, that underneath 
one such phenotype, metabolic regulation, there is already a group of substrates 
emerging. If indeed, AMPKa1 and MARK2 would be the crucial kinases carrying out 
LKB1’s functions, they would serve as plausible candidates for e.g. pharmacological 
targets. Of course, LKB1’s effects could very well be counter balanced through its 
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independent substrates such as SNRK and MARK4. As is visible from the results, 
the metabolic behavior is still very noisy, and requires further characterization and 
rescue-experiments to actually identify the causal substrates.  
  
Despite LKB1-MEFs were exhausted, visible as reductions in maximal and spare 
respiratory capacities, we do not see any changes in the OXPHOS derived ATP. This 
might be explained that following LKB1 knock-down, other changes support ATP 
production such as glycolysis and b-oxidation. Importantly, basal respiration was kept 
in the level of SCR-control, thus this compensatory ATP production would be 
anaerobic. Interestingly though, in 2 out of 3 measures we observed less leakiness 
of protons following LKB1-loss. Thus, we argue that despite loss-of LKB1 and 
exhaustion of mitochondria, the cell manages to tighten/restrict the leakiness of 
mitochondrial membranes and thus increasing the mitochondrial membrane 
potential. To prove this hypothesis, easy experiment would be just to measure the Y. 
This would also explain the lack of compensatory glycolysis: since, the cell can 
handle loss-of LKB1 and following exhaustion by just adjusting its mitochondrial 
leakiness, it is not necessary to induce glycolysis. Still, since we do observe some 
degree of increased ECAR in MEFs, this might suggest us an additional backup 
compensation. To gain insight into this it would be interesting to measure pathways 
such as b-oxidation/lipid metabolism, glutamine (SEAHORSE Mito Fuel Flex assay) 
and other aminoacids biosynthetic pathways. 
 Reactive oxygen species originate in principle through all oxygen related 
metabolism in the cell. Our data suggests that ROS does not directly correlate with 
mitochondrial dysfunction. Thus, mitochondria seem to be protected to some extent 
from intracellular ROS. Data also suggests that mitochondrial dysfunction would be 
only partially responsible for ROS. Increased ROS could potentially originate through 
mitochondrial dysfunction or by mitochondria-independent means such as 
peroxisome and antioxidant dysregulations. In case of MARK4 for example, we 
observe high OXPHOS and glycolysis, high metabolic activity overall. This could act 
a potent source of metabolically derived ROS that could in principle relay back to 
mitochondria and disrupt OXPHOS. Importantly, OXPHOS derived ROS would 
actually develop inside the mitochondria and has thus shorter distance to the site of 
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disruption compared to mitochondrial-independent ROS. Loss of LKB1 results in 
induction of the latter type of ROS. This ROS however conveys to mitochondria, due 
to extremely high proportions, and only then disrupt the electron transport chain. The 
fact that loss of LKB1 is still more potent ROS inducer than e.g. MARK2/3 is 
supporting this idea of two independent but intertwining ROS pathways. To fit this 
hypothesis to the data, it would mean that probably this excess ROS production 
would be independent of the 10 substrates. This since none of substrates reach ROS 
levels of LKB1. This is also suggested by the published report [111]. This would 
suggest that if LKB1 mediates its OCR effects through AMPKa1, it would be ROS-
independent. Importantly, the original report argued that both a1 and a2 were able to 
rescue the effect, which our data is not strong enough to say. LKB1 is known to 
activate AMPK-TSC2 mediated cellular damage response following ROS-induction 
[162]. This could potentially implicate many interesting scenarios where LKB1-AMPK 
axis would try to provide fail-safe for mTORC1 regulation during e.g. mitochondrial 
dysfunction. MARK4 and SNRK produced ROS originates probably through LKB1 
independent means, suggested by the differences in OCR/ECAR measures. To really 
dissect the origin of intracellular ROS we could perform mitochondrial specific ROS-
assay.  
 
 Mitochondrial DNA contains genetic information about the OXPHOS enzymes. 
Thus, the absolute mtDNA amount sets the limit for mitochondrial components, mass 
and eventually to function (OXPHOS). In our experiments, we hold on to the model 
in which mtDNA gets degraded as a result from prior mitochondrial dysfunction. 
Following mitochondrial impairment, process of coordinated mitochondrial 
destruction, mitophagy, takes place. Along with the mitochondrial proteins, also the 
mtDNA gets degraded. This mitochondrial degradation can be observed as e.g. 
decreased OXPHOS.  
 Though mtDNA and OXPHOS/glycolysis did not absolutely correlate through-
out our experiments, we did observe association of lower mtDNA level and low-
OXPHOS in multiple samples. However, the proposed model does not explain how 
AMPKa1 experience 1.2-1.4 increase mtDNA load, even though the cells are low on 
OXPHOS. In other words, AMPKa1 could regulate mitochondrial function and 
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structure independently. It will be interesting to see if the latter is mediated through 
the reported mechanism [160]. Moreover, since only the functional half is similar to 
the case of LKB1 suggests that the structural regulation could be mediated through 
LKB1-independent mechanisms, such as CAMKK2-pathway. Also, seeing this effect 
only after knocking down a1-subunit, yearns for the effect of double knock-down 
(DKO). Whether the mtDNA amount would be compensated or potentiated following 
loss-of additional catalytic subunit could speak in favor or against AMPK-
compensatory mechanism. Importantly, in U2OS cells either a1 or a2 reconstitution 
to DKO-cells was efficient to restore the mitochondrial fission capacity. It is also 
possible that LKB1 et co. regulated mtDNA through its replication. mtDNA is 
polymerized by DNA polymerase gamma (Polg1). We didn’t observe big changes in 
the Polg1 mRNA levels in RNA-sequencing though.  
 We are left puzzled how might MARK4 and SNRK have such a big effect in 
LKB1-independent cellular metabolism. This was of course suggested in wider 
perspective at some of the transcriptomic level results. One might speculate that 
LKB1 promotes oxidative phosphorylation through AMPKs, MARK2/3 and SIK2, 
whereas MARK4 and SNRK balances this by restraining OXPHOS and glycolysis by 
LKB1-independent means.  
 
CAF heterogeneity is already established in a variety of human cancers [55,56,64]. 
Though novel single-cell based approaches will undoubtedly increase the resolution 
in this field, it is encouraging to see that some of this diversity is possible to capture 
even by more traditional and easy-access means. As a quick-and-dirty exploration, 
our CAF datasets seem to capture many relevant biological processes such as 
myogenesis, metabolism and inflammation. We sought to just take the raw 
expression values from individual datasets with no further filtering applied. Given a 
certain gene, adjusting to standard deviation within a cluster may or may not make 
sense depending on the question. For our purposes we were only interested in the 
brute ranking of the genes within a cluster so averaging the expression values should 
work equally fine. If the exact expression value would be important, then 
normalization would absolutely be in place. Further adjusting of the data might also 
be possible by means applied from modern single-cell sequencing techniques: by 
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recording external variables and using them as covariates, could possibly help in 
reducing the dimensionality of the data. Also including some positive and negative 
controls in the training such as myofibroblasts, fibroblasts activated by inflammatory 
cytokines or mitochondrial complex inhibitors, could further help in clustering.  
 We were surprised how homogenous the direct clusters were in terms of 
enriched hallmarks. The direct samples were mostly acquired through laser-capture 
microdissection. Only a handful of FACS sorted fibroblast samples were included. 
Thus, these clusters represent more or less the total stromal cell heterogeneity: 
fibroblasts, myofibroblasts, pericytes, immune cells, stellate cells, mesenchymal stem 
cells etc. This highlights that, though the stromal fibroblasts may differ quite 
drastically, the stroma as a whole can actually possess striking homology. This even 
though the that the stroma were dissected form a variety of tissues and tissues 
specific fibroblast heterogeneity is an acknowledged phenotype in mammalian 
systems [29]. Most probably this additional layer of stromal heterogeneity could be 
observed through higher principal components. It might be however possible that 
regardless of the site of cancer, the stroma that it sculptures would end up looking 
quite homogenous.   
 From the indirect clusters it was encouraging to see how to myCAF and iCAF 
subpopulations were readily visible. In the study describing them, these two subtypes 
were observed dynamically differentiating between each other, merely through 
exchanging the culture condition form 2D (myCAF) to 3D (iCAF) [64]. Importantly, in 
our datasets majority of the indirect samples were cultured in 2D and might thus be 
expected to represent the myCAF population. Apparently, the differences between 
the clusters where so fundamental that the enrichment analysis was capable of 
capturing them.  
 The observation that LKB1-MEFs actually show high association towards any 
of the clusters, already argues that the phenotypes that we see there, are associated 
with human malignancies. Though the data is not strong enough to identify LKB1-
MEFs as CAFs, we are positive that they are activated. And by activated, we mean 
active in CAF-related biological processes. Indeed, the inflammation and energy 
metabolism are already described as hallmark of loss-of LKB1 in the stroma. 
Restricting the LKB1 and ARK grouping to curated CAF-markers proposes also 
 72 
interesting model. It is suggesting that though each member has a prevalence 
towards certain CAF subtype identified, it is only the LKB1, NUAK2 and SIK3 that 
show positive correlation with regards the CAF-markers. This would suggest that 
other ARKs would drive other cellular pathways, outside these CAF-markers. Of 
course, now since we have generated these new CAF-clusters, it would make sense 
to update this CAF-marker list into more comprehensive version.   
 Since all the identified clusters were still CAFs, it was actually surprising to see 
how few hallmarks were shared between them. EMT, KRAS, HEDGEHOG, TGFb 
and protein secretion being the only ones and all of them enriched positively. These 
could be thus utilized as a more general characteristic of CAFs. Instead of using a 
single molecular marker, such as aSMA, one should rather probe at least a single 
marker from all the above-mentioned hallmarks. It would also make sense trying to 
classify the genes responsible for the divergence of the clades. By k-means clustering 
it might be possible to virtually dissect the biologically active pathways in separate 
clusters. This would also help in identifying single molecular markers for different 
biological processes such as the above-mentioned hallmarks. 
 We did not include data on other, non-cancer-but-activated fibroblasts we 
collected. Nevertheless, in the future they might help dissecting similar associations 
as in case of CAFs. Also, with the help of more controlled in vitro experiment it might 
be possible to investigate the precise molecular mechanism in detain. They could 
also be used in attempt to dissect the biological process activated in specific CAF-
dataset. For example, one could generate an IL-6 gene set form in vitro conditioning 
of fibroblasts with IL-6. This can be probed against all the CAF-datasets to see which 
of them seem high or low in IL-6 responsive genes. This way we hope we can further 
develop our collection of data into more versatile tools for people to use to quickly 
see how their data compares against the published.                
 
There have been numerous attempts figuring out LKB1’s role in reproductive tract 
development due to increased incidence of ovarian, endometrial and cervical in PJS 
patients. Still, there is not a single report explaining LKB1’s role in ovarian cancer 
specifically. We have shown for the first time that endogenous level of LKB1 is 
decreased in the stroma of human HGSOC and it is unchanged in the tumor epithelia. 
 73 
We also provide evidence suggesting loss-of LKB1 in ovarian fibroblasts results in 
CAF-like metabolic phenotype. 
 The fact that we did not observe malignant transformation in Lkb1Twist2KO/+ mice 
ovaries, fallopian tubes of uterus is in agreement with earlier reports. It is likely that 
rather functioning as a driver of initiation, stromal loss of LKB1 enhances the cancer 
cell survival. It is also possible that the low sample number was not able to capture 
the phenotype. Indeed, whole-body heterozygous mice are reported to exhibit 
endometrial cancer only in ~30% of cases [79]. Since LKB1 heterozygosity was not 
fully penetrant in cancer development, further speaks for additional driver mutations. 
Complete loss of LKB1 in the endometrium is efficient to induce fully penetrant 
endometrial adenocarcinoma [79]. This however does not happen in human patients. 
  Looking closely at the levels of changes in different experiments gives us also 
important perspective. Looking at the stroma as a whole, we observe ~50% reduction 
at mRNA level. At the level of fibroblasts this is about 40% (only a single sample). 
Since we have no information about the stromal cell composition of ovarian cancer, 
we are not able to say if LKB1 is reduced in other cells also. Still, since ovaries are 
naturally fibroblast-rich organ it is plausible that this holds true also in case of cancer. 
Thus, this slight increase in LKB1 levels could originate from the other stromal cells 
in which LKB1 level in retained. Thus, the level where fibroblast-specific LKB1wil set 
in ovarian cancer remains elusive. 
 In our iHOFs the knock-down efficiency reaches about 20-40%, which hits 
slightly harder compared to actual CAFs (above). Thus, it is important to repeat the 
experiments with either heterozygous iHOFs or with patient cell lines. This could also 
provide important evidence not only for the case of HGSOC but also PJS: to date 
there has been no direct (in vivo) or indirect (in vitro) evidence of mitochondrial 
dysfunction of fibroblasts in PJS-models. Speculation around metabolic changes in 
PJS fibroblasts are based on association analyses (in silico). Encouraging data is 
reported from other stromal cells though (hematopoietic and T-cell).  
 Nevertheless, after seeing such a good coverage between the LKB1-
responsive genes and OVCA-CAFs it is difficult to question the association between 
them. Interestingly though, many of the ECM components were observed 
downregulated in the LKB1-iHOFs whereas they were upregulated in the OVCA 
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stroma. This might be due to number of reasons. One explanation for this might come 
from the culturing conditions: LKB1-null fibroblasts secrete different ECM 
components depending on whether plated on plastic or situating in their native 
environment. A more mechanistic idea comes from LKB1’s function as a TGFB 
inhibitor. Reduced TGFB-signaling would be observed as decrease in ECM 
component expression. We didn’t however see big changes in TGFB-signaling 
component (SMAD9, TGFBI, TGFBR3) so further investigation on this is in place. 
 Another interesting finding regarding endometrial loss-of LKB1 was that it 
induced stromal expansion of aSMA expressing myofibroblasts (CAFs). Interestingly, 
we did not observe such increase in proliferation in LKB1-null iHOFs. This highlights 
the role of tumor microenvironment. Induction hyperproliferative program would 
require other cells types and their signaling components. Still, metabolic changes 
were readily observable after loss-of LKB1 alone. This suggests LKB1’s role as a 
metabolic caretaker, in fibroblasts as-a-whole, seems highly conserved.  
 Whether de novo LKB1 downregulation is achieved though paracrine regulation 
of genetic silencing is not known. OVCA stroma is reported not to be mutated [51]. 
This further supports the idea that some of the tumor microenvironmental phenotypes 
might decay once the epithelial effectors are removed. Thus, also metabolic rewiring 
could be potentially reverse merely by identifying the critical signaling component. Of 
course, stroma might face epigenetic pressure, and through that, change its gene 
expression permanently even without mutational load. Furthermore, fibroblasts 
originating through EMT might experience mutations, and thus, selective advantage 
and expand.  
 A question that is still completely open is through which of the substrates LKB1 
might conduct its effects in HGSOC. Many of ARKs have been discovered to play a 
role in ovarian cancer development but mostly from the epithelial point-of-view and 
the LKB1-dependency is hardly proven.  
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7. Future Directions 
We are planning to explore the AMPKa1/2 double knock-out MEF dataset against 
current data. With it we hope to dissect some interdependencies and feed-back/-
forward mechanisms. Luckily these data also include energy stress samples that can 
help us to understand how the mitochondrial mechanisms are behaving in more 
physiologically active circumstances. We will consider sequencing of BRSKs as the 
shear expression levels in MEFs does not seen to justify ruling them out. We will also 
plan rescue experiments in LKB1-deficient MEFs with add-back of at least AMPKa1, 
MARK1/3 and SIKs. We will also try mitochondrial experiments with LKB1-null MEFs 
with treatment of AMPK-activators (AICAR, A76, metformin etc.). We are also 
planning rescue experiments with chemical agonists/antagonists of other substrates. 
We would also want to look into the mitochondrial fission and fusion dynamics in 
addition to brute mass. There are currently plenty of good antibodies suitable for this 
task. Also, we are considering performing the mitochondrial assay with heterozygous 
deletion of LKB1: currently we have primary intestinal fibroblasts and MEFs suitable 
for the task. We are also considering similar type of assay in iHOFs or primary HOFs. 
We are also considering looking more into detail how are pathways such as b-
oxidation, nucleotide metabolism and gluconeogenesis within MEF-system. We will 
aim to further filter, fitting and merging the publicly available datasets with the aim to 
improve the handling of large deviation between among the samples. With the 
expertise from single-cell technologies we will try to normalize the samples according 
to different covariates. Currently available cancer transcriptomic databases are 
primarily only epithelial samples. Thus, we find this type of cancer stroma repository 
particularly interesting.  
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8. Methods 
8.1 Cell Lines and Cell Culture Mouse embryonic fibroblasts were generated 
by dissecting E13.5 wild type embryos on petri dish. Tissue pieces were trypsinized 
into single-cell suspension at +37°C. Media was changed shortly after trypsin 
neutralization, thus flushing unattached epithelial cells away. MEFs were grown in 
DMEM (10% FBS, 5% L-glutamine, 5% Pen/Strep = DMEMcomp) to confluency and 
stored in liquid nitrogen. Human ovarian fibroblasts (ScienCell™, #7330) were 
grown on fully supplemented fibroblast media (ScienCell™, #2301) on uncoated 
plates. Immortalization was achieved through transfection of C-terminal tp53. 
HEK293FT cells were used for virus production. 293s were maintained in DMEMcomp. 
Patient cell lines were grown in fibroblast media without immortalization. Cells were 
culture in standard conditions (+37C°C).  
 
8.2 Lentivirus Production and Transfection 
Virus production: HEK293FT cells were transfected using Lipofectamine2000® 
(Thermo Fisher Scientific, 11668019) following manufacturer’s transfection protocol 
for 6/10cm culture plates. For lentiviral constructs and viral particle sequences, refer 
to Appendix II. pLKO.1 expression vector, pCMV-dR8.9 and VSVG were mixed 
according the RNAi Consortium recommendations 
(http://www.broadinstitute.org/rnai/public/resources/protocols). Transfected cells 
were grown 48 hours before virus containing media was collected. Media was filtered 
through 20µm filter. Viral vials were stored in -70°C.  
Transduction: 2x105 MEFs/HOFs were plated in 6-wells 24 hours prior transduction 
in 2ml of DMEMcomp/fibroblast media. 24 hours post plating 1ml of media was 
removed and supplemented with viral media along with 8µg/ml of polybrene (Merck 
Millipore, TR-1003-G). 24 hours later all media was changed to fresh. 24 hours later 
(48 hours post plating) cells were split 1:2 and adding 1µg/ml of puromycin for 
selection. 48 hours later cells were split once more and puromycin was added at 
higher, 2µg/ml concentration. For prolonged culture cells were maintained in 2µg/ml 
puromycin.  
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8.3 RT-PCR RNA was extracted using Macherey-Nagel NucleoSpin® RNA Plus 
extraction kit (740984.250) following manufacturer’s protocol. RNA concentration 
was measured with Nanodrop ND-1000 spectrophotometer (Thermo Fisher 
Scientific, ND-1000). 400ng of RNA was reverse transcribed into cDNA using 
Taqman reverse transcription kit (Applied Biosciences). 20ng of cDNA was applied 
for each RT-PCR reaction master mix (KAPA, SYBR® FAST, KK4617). 
Measurement was performed with StepOnePlus Real-Time PCR system (Applied 
Biosystems). No-template controls were included for each of the probes and no-
reverse-transcriptase controls in case the RNA concentration was seemingly low 
(<20ng/µl). For PCR primer sequences, refer to Appendix I. 
 
8.4 Western-Blotting Protein samples were collected by lysing the cells in SDS-
lysis buffer (250mM Tris-HCl, 2.5V/V-% SDS, 0.5 mM PMSF, 10mM Glycerol-2-
phosphate, 5mM NaF, 1mM DTT, 1 µg/ml Leupeptin, heated +98°C). Samples were 
incubated 10 minutes in +98°C and passed through 25G needle 10 times. Samples 
were centrifuged 30 minutes at full speed and the supernatants were transferred into 
clean tubes. Protein concentration were measured with DC™ protein assay (BioRad) 
FLUOstar Omega spectrophotometer (ORDIOR). Samples were denatured in SDS-
loading buffer with bromophenol blue, and heated with another 5 minutes in +98°C.  
 Proteins were separated on SDS-page gel and transferred to nitrocellulose 
membrane. Protein loading was assessed with Ponceau staining. Membranes were 
blocking in skim milk for 1 hour (5%-w/V in 0.05%TBS-Tween-20® = milk). After quick 
was in TBST membranes were incubated in primary antibodies over-night at +4°C 
(AMPKa1, Abcam, ab110036; AMPKa2, Abcam, ab3760; Lkb1, Abcam, ab15095; 
phospho-ACC, Cell Signaling, #3661L; aSMA, Abcam, ab5694; CAV-1, Cell 
Signaling, #D46G3; MMP-9, Cell Signaling, #13667; NDUFB8, Abcam, ab110242; 
Vinculin, Cell Signaling, #4650). After washing with TBST, membranes were 
incubated in HRP secondary antibodies diluted in milk for 1 hour in room temperature. 
After washing, membranes were incubated in chemiluminescent solution (ECL) for 3 
minutes following luminescent detection in dark room with autoradiograph films.  
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8.5 RNA-sequencing and GSEA Analysis RNA quality was assessed with 
Bioanalyzer 2100 (Agilent). Only samples with RIN-value above 10 were accepted 
for library preparation. Library preparation (NEBNext® Ultra™ Directional RNA 
Library Prep Kit for Illumina®), sequencing (Illumina Next Seq500) and data 
demultiplexing, were done by FuGU (Biomedicum Functional Genomics Unit). 
Messenger RNA was enriched using poly-A beads. All together 1µg of RNA was 
sequenced per sample. 
 FASTQ files were processed through standardized RNA-sequencing pipeline 
(Appendix IV). Raw reads were mapped to mouse reference genome (GRCm38.p6) 
with STAR [163]. Mapped reads were counted using htseq [164]. Read counts were 
imported to R environment where differential expression analysis was conducted 
using limma and edger software’s (Appendix V) [165,166]. Principal component 
analysis was performed with limma and hierarchical clustering with heatmap2. Unix 
pipeline was conducted in CSC’s (IT-Center for Science, Finland) TAITO 
environment.  
 For GSEA ((V.4.0.3)) [167], human orthologs were fetched with Biomart [168]. 
Ranked gene lists were compared against hallmark gene sets (V.7) from Molecular 
Signatures Database (MSigDB).   
 
8.6 Published Datasets Published stromal datasets were fetched from Gene 
Expression Omnibus (NIH-NCBI) and ArrayExpress (EMBL-EBI) repositories. For 
microarray data, if functional annotation data was available, Affymetrix® (Thermo 
Fisher Scientific) raw CEL-files were uploaded into R-environment. Raw data was 
background corrected, RMA-normalized, log-transformed, annotated and analyzed 
according to Appendix VIII (Applied from 
http://homer.ucsd.edu/homer/basicTutorial/affymetrix.html). For other arrays and if 
no annotation files were found, differential expression was conducted with GEO2R 
browser analyzer inside GEO. Results were uploaded into R. Microarray probes were 
filtered according to the adjusted p-value. Gene symbols and orthologs were fetched 
using biomaRt (Bioconductor, Appendix IX). For sequencing data, if raw dead 
counts were not supplied to the repository, they were fetched using SRA-toolkit 
(Appendix IV, V). Sequencing pipeline was the same as above: STAR mapping to 
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human (GRCh38.p12)/mouse (GRCm38.p6) reference genomes, read counting with 
htseq and differential expression in R with limma/edger. 
 For clustering analyses, single datasets were merged into combined data 
(direct and indirect separately, Appendix X). 1000 Highest upregulated and 1000 
lowest downregulated genes were included into the clustering analyses which was 
conducted with heatmap2 in R. After cluster identification, subcluster datasets were 
re-merged and the expression values were averaged across into a single 
representative gene set (Appendix XI). 
 
8.7 Extracellular Flux Assay 24 hours prior measurement cells were plated on 
Seahorse® 96-well plates (Agilent, Seahorse XFe96 FluxPak, 102416) in normal 
growth media. For high cell density OCR and ECAR measurement 3x104 and for low 
cell density OCR 1x104 cell were used. At the day of measurement, cells were 
washed with PBS and supplemented with 80µl of supplemented Seahorse® media 
(pH7.4). For ECAR, glycose was omitted from Seahorse® media and the cells were 
starved for 1 hour. OCR and ECAR cells were incubated in +37°C, CO2-free incubator 
(VWR, INCU-Line) for at least 1 hour before measurement. Injections were calibrated 
in XF calibrant solution (Agilent, 100840-000). Measurement protocol for OCR: 3x 
baseline, 3x oligomycin (O4876), 3x FCCP (C2920) and 3x rotenone (557368) and 
antimycin (A8674). Measurement protocol for ECAR: 3x baseline, 3x glucose 
(A2494001), 3x oligomycin and 3x 2DG (D6134).  
 After measurement, wells were stained with crystal violet for 30 minutes and 
washed equally 5 times with 100 µl of PBS. Stained plates were scanned, and crystal 
violet stain was quantified using ImageJ (v1.51s). Seahorse results were normalized 
according to the crystal violet. Time course figures were generated with R, barplots 
with Microsoft Excel. Knock-down efficiencies were obtained from parallelly grown 
cells at the end of the experiment.   
 
8.8 ROS-Assay 24 hours prior measurement, 1x104 cells were plated on 96-well 
plates (PerkinElmer, ViewPlate-96) in normal growth media. At the day of 
measurement, wells were divided into treatments: DCFDA (2’,7’-
dichlorodihyfrofluorscein diacetate), DCFDA+NAC (N-acetyl cysteine), NAC and ‘no-
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treatment’. NAC-containing wells were treated with 10 mM NAC in PBS for 2 hours. 
NAC was removed and cells were washed once with PBS. DCFDA-containing wells 
were treated with 1µM DCFDA in PBS for 20 minutes. All wells were finally washed 
with PBS and incubated for 60 minutes in +37°C. Measurement was performed with 
EnSpire spectrophotometer (PerkinElmer) using 495/515nm filter. Blank corrected 
values were plotted using Microsoft Excel. DCFDA+NAC and NAC results functioned 
as additional controls. 
  
8.9 mtDNA DNA was extracted using QIAGEN Blood & Tissue Kit (QIAGEN, 
69506). DNA concentrations were measured using Nanodrop. Mitochondrial DNA 
content was measured using 12S ribosomal RNA (12SrRNA) as a mtDNA marker 
and RBM15 as an extra-mitochondrial control. Primer and DNA were mixed and 
measured using above RT-PCR protocol. Fraction of mtDNA versus overall DNA was 
calculated as suggested in [169]. For specific primer sequences, refer to Appendix 
II.  
 
8.10 Immunohistochemistry For immunofluorescence of MEFs, cells were 
washed with PBS, fixed with 4% PFA in PBS for 30 minutes and washed with PBS 
for 4 times. Cells were permeabilized with 0.3% Triton X-100 in PBS for 10 minutes. 
Cells were blocked with blocking buffer (10%-goat serum in 0.3% Triton X-100 in 
PBS) for 1 hour. Blocking buffer was removed and replaced with primary antibody 
(Tom20, Santa Cruz, sc-11415; Phalloidin-Alexa Fluor™-594 conjugated, Thermo 
Fisher Scientific, A12381) diluted in blocking buffer overnight in +4°C. Cells were 
washed 3 times with PBS and incubated in secondary antibodies (Thermo Fisher 
Scientific, Alexa Fluor™ Goat-a-Rabbit 488) diluted in blocking buffer. Cells were 
washed 3 times with PBS and incubated in Hoechst (1mg/ml) for 5 minutes. Cells 
were washed 2 times with PBS and mounted using Mowiol.  For 
immunohistochemical staining of paraffin embedded mouse reproductive 
tracts, mouse ovaries were obtained from CO2 euthanized mice. Excess fat was 
removed under stereomicroscope and FRTs were incubated in 4% PFA-PBS in +4°C, 
overnight. Next day, FRTs were placed in 70% ethanol or washed with PBS and 
placed into paraffin processing cassettes. Paraffin blocks were serially sectioned 
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using microtome (MICROM, HM 355 S).  5µm thick sections dried overnight in 37°C 
platform. Prior deparaffinization series, paraffin was melted by briefly incubating 
sections on +60°C platform. Antigen retrieval was performed by incubating sections 
in citrate buffer pH6 or Tris-EDTA pH9 (Dako, S169984-2 and S236784-2) in 95°C 
for 20 minutes following 30 minutes of cooldown. Sections were quickly washed in 
dH2O. Endogenous peroxidases were inactivated by incubating sections in 3%-H2O2 
diluted in PBS for 10 minutes following 2 washes in dH2O. Sections were blocked by 
incubating in TNB blocking buffer (TSA® Blocking Reagent diluted in 0.1%-TBS-
Tween20, PerkinElmer) for 1 hour in ambient temperature. Blocking buffer was 
replaces with primary antibody diluted (Lkb1, CST, #13031; Vimentin, DAKO, M0725; 
aSMA, Abcam, ab5694; phpsho-SMAD3, Abcam, ab51903) in blocking buffer and 
incubated in +4°C, overnight. Sections were washed 3 times in washing buffer (0.1%-
Tween20 in TBS). For IHC, 3 drops SignalStain® Boost Reagent (Cell Signaling 
Technology, #8114) was applied and incubated for 30 minutes in ambient 
temperature. Sections were washed 3 times in washing buffer. Detection was done 
using DAB substrate kit (Cell Signaling Technology, #8059). Sections were 
counterstained using haematoxylin, dehydrated and mounted. For 
immunofluorescent staining of paraffin sections, endogenous peroxidase 
depletion step was omitted. Primary antibodies (TdTomato, SCIGENE, AB8181-200; 
E-Cadherin, SCT, #3195) were recognized using Alexa Fluor conjugated secondary 
antibodies (Donkey anti-Goat, Alexa Fluor™-488/-594) and mounted section were 
mounted using ProLong™ Diamond (Thermo Fisher Scientific) mountant. 
   
8.11 Microscopy MEF mitochondrial content was imaged using Leica TCS SP8 
CARS confocal microscope (Biomedicum Imaging Unit). Paraffin sections scanned 
using 3DHISTECH Pannoramic 250 FLASH II digital slide scanner (Genome Biology 
Unit, HiLIFE‚ Faculty of Medicine, University of Helsinki, and Biocenter Finland). 
Scanned slides were analyzed using HistoQuant software (3DHISTECH). Images 
were exported and panels were generated using Adobe Photoshop.  
 
8.12 Patient Cells and Mouse Model Human samples were a gift from Pietilä E. 
(Genome-Scale Biology, Research Programs Unit, University of Helsinki, Helsinki, 
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Finland). Mouse samples were supplied by Doménech-Moreno E. (HiLIFE-Helsinki 
Institute of Life Science, University of Helsinki, Helsinki, Finland) and were collected 
in conjunction with polyposis analyses.  
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Fibro
blast 
Hu
man 
Cutaneous 
squamous 
cell 
carcinoma 
Cutaneou
s 
squamou
s cell 
carcinom
a (cSCC) 
0.42
756 1 
GSE
3773
8 
Indire
ct 
RDEB-
vs-
CNTRL   + 
Patient 
derived 
cell line 
Der
mis 
Fibro
blast 
Hu
man 
Recessive 
dystrophic 
epidermolysi
s bullosa 
Recessiv
e 
dystrophic 
epidermol
ysis 
bullosa 
(RDEB) 
0.37
044 1 
GSE
3773
8 
Indire
ct 
cSCC_R
DEB-vs-
CNTRL   + 
Patient 
derived 
cell line 
Der
mis 
Fibro
blast 
Hu
man Both 
cSCC and 
RDEB 
0.19
559
8 1 
GSE
7107
8 
Indire
ct 
CAF-vs-
CNTRL   + 
Patient 
derived 
cell line 
Der
mis 
Fibro
blast 
Hu
man 
BRCA1 
mosaic 
epimutation NA 
-
0.00
604
9 
0.99
556
9 
GSE
8331
4 
Indire
ct 
CAF-vs-
CNTRL   + 
Patient 
derived 
cell line 
Der
mis 
Fibro
blast 
Hu
man 
Head and 
neck SCC NA 
0.13
124
8 1 
GSE
1223
70 
Indire
ct 
CAF-vs-
CNTRL   + 
Patient 
derived 
cell line 
Der
mis 
Fibro
blast 
Hu
man Dermal SCC NA     
GSE
3851
7 
indirec
t 
CAF_ML
-vs-
CNTRL   + 
Patient 
derived 
cell line 
Ling
ual 
muc
osa 
Fibro
blast 
Hu
man Oral SCC 
CAFs 
grown in 
2D versus 
NFs 
grown in 
3D 
-
0.42
491
6 
0.06
854
4 
GSE
3851
7 
indirec
t 
CAF-vs-
CNTRL   + 
Patient 
derived 
cell line 
Ling
ual 
Fibro
blast 
Hu
man Oral SCC 
CAFs 
versus 
NFs 
-
0.15
0.39
402
3 
 104 
muc
osa 
938
4 
GSE
3851
7 
indirec
t 
DYSPL-
vs-
CNTRL   + 
Patient 
derived 
cell line 
Ling
ual 
muc
osa 
Fibro
blast 
Hu
man Oral SCC 
Dysplastic 
fibroblasts 
grown in 
3D versus 
NFs 
grown in 
3D 
-
0.15
178
2 
0.46
521
1 
GSE
7372
8 Direct 
day4_TD
LN-vs-
CNTRL   + 
Patient 
derived 
cell line 
Lym
ph 
nod
e 
Fibro
blast 
retic
ular 
cell 
Mou
se - 
Tumor 
draining 
effects on 
lymph 
node. 
Compare
d to PBS 
draining. 
Day 4     
GSE
7372
8 Direct 
day11_T
DLN-vs-
CNTRL   + 
Patient 
derived 
cell line 
Lym
ph 
nod
e 
Fibro
blast 
retic
ular 
cell 
Mou
se - 
Tumor 
draining 
effects on 
lymph 
node. 
Compare
d to PBS 
draining. 
Day 11     
Appendix I: Table of Published CAF-data sets. Table of published direct and indirect cancer stroma 
datasets used in figures Fig1A; Fig1B; Fig3 and FigS5. Color-coding according to tissue. 
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Gene_primer name orientation Primer sequence 5'-3' 
Mm_Oaz1b_F CGCACCATGCCGCTTCTTA 
Mm_Oaz1b_R ATCCCGCTGACTGTTCCCT 
Mm_Prkaa1_F GCA AAA TGG CAT TTG GGA AT 
Mm_Prkaa1_R CGA TAG TTG CTG ATG GAT CC 
Mm_Prkaa2_F CAC AGG CAT ATG GTT GTC CA 
Mm_Prkaa2_R CGG ATC TTC TTG AAG AGC GT 
Mm_Sik1D_F TCATGTCGGAGTTCAGTGCG 
Mm_Sik1D_R ACCTGCGTTTTGGTGACTCG 
Mm_Sik2_F GGCCGGAAGGTAGTGCACAG 
Mm_Sik2_R GAATCTTCCTTCTAAAACCC 
Mm_Sik3D_F GCCATCCACACATCATCAGAC 
Mm_Sik3D_R CCAAGTGGTCAAATATCTCCCC 
Mm_Mark1B_F GAAGAAACTGTTAGTGCTGA 
Mm_Mark1B_R  AGAAGGATGTAAGTAGCCAT 
Mm_Mark2B_F  CTACCCACGCTGAACGAAAGG 
Mm_Mark2B_R  GTAGTTGCCAATATGGGGCTG 
Mm_Mark3B_F  CCCTTTGCCAACGGTGAATG 
Mm_Mark3B_R  CCCTTGCCGATTGTTTTCAAC 
Mm_Mark4B_F  GGACACGCATGGCACATTG 
Mm_Mark4B_R  GCAGGAAGCGATAGAGTTCCG 
Mm_Nuak1C_F  TCCAACCTGTACCAGAAGGAC 
Mm_Nuak1C_R  GGGCATCGTTCCATAAATGAGA 
Mm_Nuak2C_F  ATCAAGTCGCCTAAACCTCTGA 
Mm_Nuak2C_R  AATCTCCCTCCGTATGTGCAG 
Mm_SnrkB_F  TTTAGGCGAGGATATGATGGGA 
Mm_SnrkB_R  GTCCAGCTTCGTCTTGTCAAT 
Mm_Oaz1b_F CGCACCATGCCGCTTCTTA 
Mm_Oaz1b_R ATCCCGCTGACTGTTCCCT 
Mm_Lkb1_F CCCTTTGGAGGGAAAAATTC 
Mm_Lkb1_R TTTATCCCTATTGCCCAGAAC 
Hs_GAPDH_F CGACCACTTTGTCAAGCTCA 
Hs_GAPDH_R AGGGGAGATTCAGTGTGGTG 
Hs_LKB1_F GCTCTTACGGCAAGGTGAAG 
Hs_LKB1_R TTTTGTGCCGTAACCTCCTC 
Hs_VDR_exon4_1_F GTGGACATCGGCATGATGAAG 
Hs_VDR_exon5_1_R GGTCGTAGGTCTTATGGTGGG 
Hs_TGFBI_exon4_1_F CTTCGCCCCTAGCAACGAG 
Hs_TGFBI_exon5_1_R TGAGGGTCATGCCGTGTTTC 
Hs_ADAMTS5_exon1_1_F ACTACGATGCAGCTATCCTGT 
Hs_ADAMTS5_exon2_1_R GTCCCAACGTCTGCCATTC 
Hs_ADAMTS5_exon3_2_F TCTAAGCCCTGGTCCAAATG 
Hs_ADAMTS5_exon4_2_R CAGATTCTCCCCTTTCCACA 
Hs_LIMCH1_exon17_1_F CAAAGCAGTGCCTATGCTGA 
Hs_LIMCH1_exon18_1_R GGCCACACCTTCAAACATCT 
Hs_PTGS1_exon5_1_F CTCTGTGCCTAAAGATTGCCC 
Hs_PTGS1_exon7_1_R GTCTCCATAAATGTGGCCGAG 
Hs_CXCR4_exon1_1_F ACTACACCGAGGAAATGGGCT 
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Hs_CXCR4_exon1_1_R CCCACAATGCCAGTTAAGAAGA 
Hs_ATP1A2_exon8_1_F TTCTTCGTGCTCTCCCTCAT 
Hs_ATP1A2_exon9_1_R GGTTCTTCACCAGGCAGTTC 
Hs_SNCA_exon2_1_F AAGAGGGTGTTCTCTATGTAGGC 
Hs_SNCA_exon4_1_R GCTCCTCCAACATTTGTCACTT 
Hs_ITM2A_exon3_1_F AATGACTGCTTACCTGGACTTG 
Hs_ITM2A_exon4_1_R TCCACAGCAACTAGGTCTTCT 
Hs_CDO1_exon3_1_F ACATTATTTGCCTGGCCTGA 
Hs_CDO1_exon4_1_R CAAGTGAAGGCTCACAGCAG 
Hs_HLA-MDA_exon2_1_F GCCAAAACTTGATGGGAAAA 
Hs_HLA-MDA_exon3_1_R CCATCGACAGCTGAGACAAA 
Hs_SLPI_exon2_1_F GAAATCTGCCCAGTGCCTTA 
Hs_SLPI_exon3_1_R GCATCAAACATTGGCCATAA 
Hs_C3_exon12_1_F GACCCTCAACGTCAACTTCC 
Hs_C3_exon13_1_R GCACCGATCAGCGTGTAGTA 
Hs_MAL2_exon2_1_F TCTTTCTGGGCATGTTCCTC 
Hs_MAL2_exon3_1_R GCCCGGTTATGGTTGTATTG 
Hs_KRT18_exon3_1_F TCGCAAATACTGTGGACAATGC 
Hs_KRT18_exon4_1_R GCAGTCGTGTGATATTGGTGT 
Hs_UCP2_exon5_1_F GGAGGTGGTCGGAGATACCAA 
Hs_UCP2_exon6_1_R ACAATGGCATTACGAGCAACAT 
Hs_CEMIP_exon13_1_F TAGTGATGGGGGAGATGGAG 
Hs_CEMIP_exon14_1_R AGCTGCTGTCCCATATGCTT 
Hs_THY1_exon3_1_F GAACCAACTTCACCAGCAAA 
Hs_THY1_exon4_1_R GCCCTCACACTTGACCAGTT 
Hs_IDH2_exon2_1_F CCCGTATTATCTGGCAGTTCATC 
Hs_IDH2_exon3_1_R ATCAGTCTGGTCACGGTTTGG 
Hs_STAT2_exon5_1_F GAGCCAGCAACATGAGATTGA 
Hs_STAT2_exon6_1_R GCCTGGATCTTATATCGGAAGCA 
Hs_MAP3K8_exon4_1_F CTCCCCAAAATGGACGTTACC 
Hs_MAP3K8_exon5_1_R GGATTTCCACATCAGATGGCTTA 
Hs_EMB_exon5_1_F CATGGGAAAAACAAGCCATT 
Hs_EMB_exon6_1_R CCCCATCTTCCTCCAAAAGT 
Hs_NLRC5_exon14_1_F GCTGGAAGATGAAGGCTGTC 
Hs_NLRC5_exon16_1_R TGGGCAAACATGAAGATCAC 
Hs_PLAU_exon5_1_F GCTTGTCCAAGAGTGCATGGT 
Hs_PLAU_exon6_1_R CAGGGCTGGTTCTCGATGG 
Hs_SLC7A7_exon2_1_F CCTTTGGAGGATTCCTTGCTT 
Hs_SLC7A7_exon3_1_R GTTCCCCATTTGACATAGGCA 
Hs_CDCA3_exon3_1_F GGAGCAACTGGAGGGTCTTA 
Hs_CDCA3_exon34_1_R GCTCTGGGGGAAGATTTGAT 
Hs_COL11A1_exon3_1_F TGGTGTTGAGGTTGGGAGAT 
Hs_COL11A1_exon4_1_R TCAAGTGGTTTCGTGGTTTTC 
Hs_SMAD9_exon5_1_F GAGTTGGGGAGACATTCCAG 
Hs_SMAD9_exon6_1_R AGATGCTGCTGTCACTCACG 
Hs_TGFBR3_exon10_1_F CCAAGATGAATGGCACACAC 
Hs_TGFBR3_exon11_1_R ATTTCAGGTCGGGTGAACAG 
Hs_IL7R_exon3_1_F CCCTCGTGGAGGTAAAGTGC 
Hs_IL7R_exon4_1_R CCTTCCCGATAGACGACACTC 
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Hs_IL10RA_exon2_1_F CCTCCGTCTGTGTGGTTTGAA 
Hs_IL10RA_exon3_1_R CACTGCGGTAAGGTCATAGGA 
Hs_MUC1_exon2_1_F CTCGGTCCCAGTCACCAG 
Hs_MUC1_exon3_1_R CCGAGGTGACATTGTGGA 
Hs_LYZ_exon2_1_F TCAATAGCCGCTACTGGTGTA 
Hs_LYZ_exon3_1_R ATCACGGACAACCCTCTTTGC 
Hs_SPP1_exon5_1_F GAAGTTTCGCAGACCTGACAT 
Hs_SPP1_exon6_1_R GTATGCACCATTCAACTCCTCG 
Hs_MXRA5_exon3_1_F CATCCCCGATGGAGCTTTAAG 
Hs_MXRA5_exon4_1_R TCAATGTGCAGCCTCATTAAGTT 
Hs_CXCL14_exon2_1_F CGCTACAGCGACGTGAAGAA 
Hs_CXCL14_exon3_1_R GTTCCAGGCGTTGTACCAC 
Hs_SLC1A3_exon6_1_F GTCATCGTCTTGCCACTCCT 
Hs_SLC1A3_exon7_1_R GTCCACGCCATTGTTCTCTT 
Hs_SLC40A1_exon7_1_F CCGGAGACAAGTCCTGAATC 
Hs_SLC40A1_exon8_1_R ACACCATTTATAATGCCTCTTTCA 
Hs_COL1A1_exon2_1_F GTGCGATGACGTGATCTGTGA 
Hs_COL1A1_exon3_1_R CGGTGGTTTCTTGGTCGGT 
Hs_COL6A2_exon10_1_F GAACGGGACCGATGGACAG 
Hs_COL6A2_exon13_1_R CCCTTGGCCCCGATTTCTC 
Hs_IL1R1_exon6_1_F GGCTGAAAAGCATAGAGGGAAC 
Hs_IL1R1_exon7_1_R CTGGGCTCACAATCACAGG 
Hs_ORAI2_exon3_1_F GTCACCTCTAACCACCACTCG 
Hs_ORAI2_exon4_1_R CGGGTACTGGTACTGCGTCT 
Hs_SYK_exon3_1_F CATGGAAAAATCTCTCGGGAAGA 
Hs_SYK_exon4_1_R GTCGATGCGATAGTGCAGCA 
Hs_PKD2_exon6_1_F TGGAAATTCGCATTCACAAA 
Hs_PKD2_exon7_1_R TGCTCAAAGTTGGGGAAAGT 
Hs_BPTF_exon1_1_F CTTCAGGAGCCATAGTACCTACA 
Hs_BPTF_exon2_1_R CAAGGGGCGGGATGTCTTTTT 
Hs_SRSF7_exon2_1_F CAGGATTTGCCTTTGTGGAA 
Hs_SRSF7_exon3_1_R GGGCAGGTGGTCTATCAAAA 
Hs_SENP6_exon7_1_F TCCTGTAAGGTTAAGTCGGCT 
Hs_SENP6_exon8_1_R AGATAGAGGAGGAGTAGGCTGAT 
Hs_GOSR1_exon4_1_F TACCAACAGTGCAGGTGTCC 
Hs_GOSR1_exon5_1_R TGATCCCATAAGATTCTCCCTTT 
Hs_FZD7_exon1_1_F GTGCCAACGGCCTGATGTA 
Hs_FZD7_exon1_1_R AGGTGAGAACGGTAAAGAGCG 
Hs_PAPOLA_exon18_1_F GCAGCATCTGTGACCAACAT 
Hs_PAPOLA_exon19_1_R CAACTCTGGAGACCGTAGGC 
Hs_KPNB1_exon3_1_F AGGCACAATATCAGCAGAGGT 
Hs_KPNB1_exon4_1_R ACTAGGCCGGTAAGTTTCTGTA 
Hs_SNAI2_exon2_1_F TGTGACAAGGAATATGTGAGCC 
Hs_SNAI2_exon3_1_R TGAGCCCTCAGATTTGACCTG 
Hs_PWP1_exon3_1_F GGATGACAGGACGCTTGATGA 
Hs_PWP1_exon4_1_R CGTAGACCGTAAGACCCAAGA 
Hs_DKK3_exon2_1_F AGGAACTGATGGAGGACACG 
Hs_DKK3_exon3_1_R TTCCAACCTTCGTGTCTGTG 
Hs_RABL6_exon9_1_F ATCCTCTGTGCCCCCTGTA 
Hs_RABL6_exon10_R CGGTCGTCAGGAACAAAGTC 
Hs_CCL11_exon2_1_F CCCCTTCAGCGACTAGAGAG 
 108 
Hs_CCL11_exon3_1_R TCTTGGGGTCGGCACAGAT 
Hs_GFPT2_exon4_1_F AGACACACTTCGGCATTGC 
Hs_GFPT2_exon6_1_R TTGGCGATGGTCTCTGTATCT 
Hs_KCNE4_exon1_1_F AGCAGCGGAGTTGTCAGAG 
Hs_KCNE4_exon2_1_R GCTGTTCAGAGGCTCCATTT 
Hs_SERPINB9_exon2_1_F AATGCAAGTGGTACTTTTGCCA 
Hs_SERPINB9_exon3_1_R AAGCCCGATGAATGTCTTCCT 
Hs_TNFAIP6_exon2_1_F TCTGGCAAATACAAGCTCACC 
Hs_TNFAIP6_exon3_1_R CTGCCCTTAGCCATCCATCC 
Mm_RMB15_F GGACAGTTTTCTTGGGCAAC 
Mm_RMB15_F AGTTTGGCCCTGTGAGACAT 
Mm_12srRNA_F AGGAGGCTGTTCTATAATCGATAAA 
Mm_12srRNA_R GATGGCGGTATATAGGCCGAA 
Appendix II: PCR-primers. Blue: Murine Stk11 and ARKs (FigS8). Red: Human STK11 and GAPDH (Fig1C; 
Fig1D). Purple: Human ovarian cancer responsive genes (Fig1C). Brown: Murine mitochondrial DNA primers 
(Fig4C; FigS6E). Housekeeping primers written in bold. 
 
 
 
Target Identifier 
shPRKAA1 TRCN0000220672 
shPRKAA2 TRCN0000220719 
shMARK1 TRCN0000024173 
shMARK2 TRCN0000220661 
shMARK3 TRCN0000221202 
shMARK4 TRCN0000024281 
shNUAK1 TRCN0000221208 
shNUAK2 TRCN0000024271 
shSIK1 TRCN0000221194 
shSIK2 TRCN0000024288 
shSIK3 TRCN0000079132 
shSNRK TRCN0000024290 
shLKB1 TRCN0000221241 
shLKB1_#8 TRCN0000000408 
shLKB1_#9 TRCN0000000409 
shLKB1_#11 TRCN0000000411 
Appendix III: The RNAi  
consortium (TRC) construct  
identifiers for mouse  
(Yellow) and human (Green) 
 LKB1 and ARKs. 
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# APPENDIX IV 
 
#--------------------------------------------------------# 
# Mapping and read counting for mouse trascriptomic data # 
# GRCm38.p6                                     # 
# Single-end reads                  # 
#--------------------------------------------------------# 
 
# Location of reference genomes: 
ftp://ftp.ncbi.nlm.nih.gov/genomes/all/GCF/000/001/635/GCF_000001635.26_GRCm
38.p6/ 
#-> gunzip them 
#--> samtools faidx *.fna 
#--> mkdir genomedir_GRCm38.p6_RefSeq 
 
module load biokit 
 
STAR --runMode genomeGenerate --genomeDir 
/wrk/pekkajpp/DONOTREMOVE/reference/GRCm38.p6_RefSeq/genomedir_GRCm38.p6_Ref
Seq --genomeFastaFiles 
/wrk/pekkajpp/DONOTREMOVE/reference/GRCm38.p6_RefSeq/GCF_000001635.26_GRCm38
.p6_genomic.fna --sjdbGTFfile 
/wrk/pekkajpp/DONOTREMOVE/reference/GRCm38.p6_RefSeq/GCF_000001635.26_GRCm38
.p6_genomic.gff --sjdbOverhang 100 --runThreadN 2 
 
# Mapping 
nohup STAR --genomeDir 
/wrk/pekkajpp/DONOTREMOVE/reference/GRCm38.p6_RefSeq/genomedir_GRCm38.p6_Ref
Seq --readFilesIn 
/wrk/pekkajpp/DONOTREMOVE/starjob2/filename_concatenated.fastq --
outFilterType BySJout --outFilterMultimapNmax 20 --alignSJoverhangMin 8 --
alignSJDBoverhangMin 1 --outFilterMismatchNmax 999 --
outFilterMismatchNoverLmax 0.04 --alignIntronMin 20 --alignIntronMax 1000000 
--outFileNamePrefix filename_concatenated --chimSegmentMin 30 --outSAMtype 
BAM Unsorted SortedByCoordinate --runThreadN 12 & 
 
# Formatting 
nohup samtools view -h -o filename_concatenated.sorted.sam 
filename_concatenatedAligned.sortedByCoord.out.bam & 
 
Read counting 
#HTSeq 
module load python-env/3.5.3 
pip install htseq 
 
nohup python -m HTSeq.scripts.count -s no -i gene -t exon 
filename_concatenated.sorted.sam 
/wrk/pekkajpp/DONOTREMOVE/reference/GRCm38.p6_RefSeq/GCF_000001635.26_GRCm38
.p6_genomic.gff > filename_counts.txt & 
 
#--------------------------------------------------------# 
# Mapping and read counting for human trascriptomic data # 
# GRCh38.p12                            # 
# Single-end reads         # 
#--------------------------------------------------------# 
 
prefetch -v -O /wrk/pekkajpp/DONOTREMOVE/GSE_identifier SRR_identifier.sra 
 
 110 
fastq-dump --outdir /wrk/pekkajpp/DONOTREMOVE/GSE_identifier --split-files 
SRR_identifier.sra 
 
# Check the file size 
# https://stackoverflow.com/questions/25845057/unix-command-to-check-the-
filesize 
 
# Count the read number 
# https://www.biostars.org/p/139006/ 
 
echo $(cat yourfile.fastq|wc -l)/4|bc 
 
# Mapping 
 
nohup STAR --genomeDir 
/wrk/pekkajpp/DONOTREMOVE/reference/GRCh38.p12_RefSeq/genomedir_GRCh38.p12_R
efSeq --readFilesIn 
/wrk/pekkajpp/DONOTREMOVE/GSE_identifier/identifier_1.fastq --outFilterType 
BySJout --outFilterMultimapNmax 20 --alignSJoverhangMin 8 --
alignSJDBoverhangMin 1 --outFilterMismatchNmax 999 --
outFilterMismatchNoverLmax 0.04 --alignIntronMin 20 --alignIntronMax 1000000 
--outFileNamePrefix SRR_identifier --chimSegmentMin 30 --outSAMtype BAM 
Unsorted SortedByCoordinate --runThreadN 12 & 
 
# HTseq-count 
 
nohup samtools view -h -o SRR_identifier.sorted.sam 
SRR_identifierAligned.sortedByCoord.out.bam & 
 
module load python-env/3.5.3 
pip install htseq 
 
nohup python -m HTSeq.scripts.count -s no -i gene -t exon 
SRR_identifier.sorted.sam 
/wrk/pekkajpp/DONOTREMOVE/reference/GRCh38.p12_RefSeq/GCF_000001405.38_GRCh3
8.p12_genomic.gff > SRR_identifier_counts.txt & 
 
#--------------------------------------------------------# 
# Mapping and read counting for human trascriptomic data # 
# GRCh38.p12         # 
# Paired-end reads                  # 
#--------------------------------------------------------# 
 
Human, paired 
 
prefetch -v -O /wrk/pekkajpp/DONOTREMOVE/GSE_identifier SRR_identifier.sra 
 
fastq-dump --outdir /wrk/pekkajpp/DONOTREMOVE/GSE_identifier --split-files 
SRR_identifier.sra 
 
# Check the file size 
# https://stackoverflow.com/questions/25845057/unix-command-to-check-the-
filesize 
 
# Count the read number 
# https://www.biostars.org/p/139006/ 
 
echo $(cat yourfile.fastq|wc -l)/4|bc 
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# Mapping 
 
nohup STAR --genomeDir 
/wrk/pekkajpp/DONOTREMOVE/reference/GRCh38.p12_RefSeq/genomedir_GRCh38.p12_R
efSeq --readFilesIn /wrk/pekkajpp/DONOTREMOVE/GSE76125/filename_1.fastq 
filename_2.fastq --outFilterType BySJout --outFilterMultimapNmax 20 --
alignSJoverhangMin 8 --alignSJDBoverhangMin 1 --outFilterMismatchNmax 999 --
outFilterMismatchNoverLmax 0.06 --alignIntronMin 20 --alignIntronMax 1000000 
--outFileNamePrefix SRR3_filename --chimSegmentMin 30 --outSAMtype BAM 
Unsorted SortedByCoordinate --runThreadN 12 & 
 
 
# HTseq-count 
 
nohup samtools view -h -o SRR_filename.sorted.sam 
SRR_filenameAligned.sortedByCoord.out.bam & 
 
module load python-env/3.5.3 
pip install htseq 
 
nohup python -m HTSeq.scripts.count -s no -i gene -t exon -r pos 
SRR_filename.sorted.sam 
/wrk/pekkajpp/DONOTREMOVE/reference/GRCh38.p12_RefSeq/GCF_000001405.38_GRCh3
8.p12_genomic.gff > SRR_filename_counts.txt & 
Appendix IV: Unix-script for genome mapping, read counting and SRA-toolkit fetching. 
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# APPENDIX V 
# Upload the counts 
counts1<-read.delim(file = "counts1.txt", header = FALSE, col.names = 
c('Transcript_ID','counts1')) 
counts2<-read.delim(file = "counts2.txt", header = FALSE, col.names = 
c('Transcript_ID','counts2')) 
counts3<-read.delim(file = "counts3.txt", header = FALSE, col.names = 
c('Transcript_ID','counts3')) 
counts4<-read.delim(file = "counts4.txt", header = FALSE, col.names = 
c('Transcript_ID','counts4')) 
 
merged1<-merge(counts1,counts2,all = TRUE) 
merged1<-merge(merged1,counts3,all = TRUE) 
merged1<-merge(merged1,counts4,all = TRUE) 
 
write.table(x = merged1, file = 'countmatrix.txt', sep = '\t', row.names = 
FALSE, quote = FALSE) 
 
# Annotation: This step might drop out some (significantly expressed 
genes!!!)  
#--------------------------------------------------------------------------- 
dataframe <- merged1 
library(biomaRt) 
ensembl = useMart("ensembl") 
ensembl = useMart("ensembl") 
datasets = listDatasets(ensembl) 
ensembl = useDataset("mmusculus_gene_ensembl", useMart("ensembl")) 
genes = dataframe$Transcript_ID 
data = dataframe[,2:5] 
G_list <- getBM(attributes= 
c('mgi_symbol','entrezgene','ensembl_gene_id','ensembl_transcript_id','descr
iption'),  
                filters= 'mgi_symbol',                                                     
                values=genes,  
                mart= ensembl) 
mergedData <- merge(x = dataframe,  
                    y = G_list,  
                    by.x = "Transcript_ID",  
                    by.y = "mgi_symbol" 
) 
write.table(mergedData, "/Volumes//merged_annotated.txt", sep = "\t") 
 
#--------------------------------------------------------------------------- 
# Differential expression with edgeR/Limma 
 
library(edgeR) 
rawData2 <- merged1 
rawData2 <- unique(rawData2) 
 
# We then create a DGEList object: 
y <- DGEList(counts = rawData2[,2:5], genes = rawData2[,1]) 
y$samples 
# Filtering 
keep <- rowSums(cpm(y)>0.2) >= 4 
table(keep) 
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y <- y[keep, , keep.lib.sizes = FALSE] 
 
# Normalization 
y <- calcNormFactors(y) 
y$samples 
 
# PCA (edgeR) 
plotMDS(y, col=rep(1:4, each=4)) 
 
# Design matrix 
exp_design <- data.frame(row.names = colnames(rawData2[,2:5]), 
                         names = colnames(rawData2[,2:5]), 
                         kd = factor(c(rep("wt", 2), rep("mutant", 2))) 
) 
exp_design$kd 
 
design <- model.matrix(~0+exp_design$kd) 
 
rownames(design) <- colnames(y) 
colnames(design) <- c("mutant", "wt") 
 
# DE 
vwts <- voomWithQualityWeights(y, design = design, normalize.method = 
"quantile", plot = FALSE) 
fit <- lmFit(vwts, design) 
 
# Make contrasts: 
my.contrasts <- makeContrasts( 
  mutant = mutant - wt, 
  levels = design 
) 
 
fit.de <- contrasts.fit(fit, my.contrasts) 
fit.de <- eBayes(fit.de) 
 
summary(decideTests(fit.de, adjust.method = "fdr", p.value = 0.05)) 
 
for (i in 1:1) { 
  res <- topTable(fit.de, coef = i, number = Inf, adjust.method = "fdr") 
  #require(xlsx) 
  write.table(res, file = paste(colnames(my.contrasts)[i], "vsWT_genes.txt", 
sep = ""), row.names = TRUE, sep = "\t", quote = FALSE) 
} 
 
data <- read.table(file = 'mutantvsWT_genes.txt', header = TRUE, sep = '\t', 
stringsAsFactors = FALSE) 
 
#--------------------------------------------------------------------------- 
# Ranked file for GSEA 
 
df <- data 
attach(df) 
df <- df[order(genes),] 
df <- df[c(1,2)] 
df <- unique(df) 
write.table(x = df, file = "df.musmusculus.rnk.txt", sep = "\t", quote = 
FALSE, row.names = FALSE) 
Appendix V: R-script for differential expression analysis. 
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#APPENDIX VI 
 
library(readxl) 
library(dplyr) 
 
# Input files: 
AMPKa1 <- read.delim("AMPKa1vsSCR_genes_20190323.txt", check.names = FALSE, 
stringsAsFactors = FALSE) 
AMPKa1 <- AMPKa1[,c(1,2,6)] 
AMPKa1 <- data.frame(AMPKa1) 
AMPKa2 <- read.delim("AMPKa2vsSCR_genes_20190323.txt", check.names = FALSE, 
stringsAsFactors = FALSE) 
AMPKa2 <- AMPKa2[,c(1,2,6)] 
AMPKa2 <- data.frame(AMPKa2) 
LKB1 <- read.table("LKB1vsSCR_genes_20190323.txt", check.names = FALSE, 
stringsAsFactors = FALSE) 
LKB1 <- LKB1[,c(1,3,7)] 
LKB1 <- data.frame(LKB1) 
 
# Copy the excel sheet to clipboard 
All_genes_all_KD_ST_RNAseqdata_merged <- read_excel(path = 
'All_genes_all_KD_ST_RNAseqdata_merged.xlsx') 
All_genes_all_KD_ST_RNAseqdata_merged <- 
data.frame(All_genes_all_KD_ST_RNAseqdata_merged) 
# If you import with 'read_excel' you need to transform the data into 
data.frame object. 
ST_LKB1 <- All_genes_all_KD_ST_RNAseqdata_merged[, c(1, 5, 6)] 
ST_LKB1 <- data.frame(ST_LKB1)  
NUAK1 <- All_genes_all_KD_ST_RNAseqdata_merged[, c(1, 8, 9)] 
NUAK2 <- All_genes_all_KD_ST_RNAseqdata_merged[, c(1, 11, 12)] 
MRK1 <- All_genes_all_KD_ST_RNAseqdata_merged[, c(1, 14, 15)] 
MRK2 <- All_genes_all_KD_ST_RNAseqdata_merged[, c(1, 17, 18)] 
MRK3 <- All_genes_all_KD_ST_RNAseqdata_merged[, c(1, 20, 21)] 
MRK4 <- All_genes_all_KD_ST_RNAseqdata_merged[, c(1, 23, 24)] 
SIK1 <- All_genes_all_KD_ST_RNAseqdata_merged[, c(1, 26, 27)] 
SIK2 <- All_genes_all_KD_ST_RNAseqdata_merged[, c(1, 29, 30)] 
SIK3 <- All_genes_all_KD_ST_RNAseqdata_merged[, c(1, 32, 33)] 
SNRK <- All_genes_all_KD_ST_RNAseqdata_merged[, c(1, 35, 36)] 
 
############################################################################ 
# These vectors include only genes unique for LKB1_1 and LKB1_2 dataframes 
respectively 
unique_for_PP <- setdiff(LKB1[,1], ST_LKB1[,1]) 
length(unique_for_PP) 
unique_for_PP_frame <- LKB1[LKB1[,1] %in% unique_for_PP, ] 
#2235 
unique_for_ST <- setdiff(ST_LKB1[,1], LKB1[,1]) 
length(unique_for_ST) 
unique_for_ST_frame <- ST_LKB1[ST_LKB1[,1] %in% unique_for_ST, ] 
#1846 
colnames(unique_for_ST_frame) <- colnames(unique_for_PP_frame) 
 
# These FILTERED dataframes include only common genes 
LKB1_filtered <- LKB1[!(LKB1[,1] %in% unique_for_PP),] 
ST_LKB1_filtered <- ST_LKB1[!(ST_LKB1[,1] %in% unique_for_ST),] 
# Total common de genes: 
# 13139 
colnames(ST_LKB1_filtered) <- colnames(LKB1_filtered) 
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# Sorting the dataframes according to gene names 
LKB1_sorted <- with(LKB1_filtered, LKB1_filtered[order(LKB1_filtered[,1]) , 
]) 
ST_LKB1_sorted <- with(ST_LKB1_filtered, 
ST_LKB1_filtered[order(ST_LKB1_filtered[,1]) , ]) 
colnames(ST_LKB1_sorted) <- colnames(LKB1_sorted)  # Matching the col.names 
 
LKB1_sorted <- LKB1_sorted[!duplicated(LKB1_sorted[,1]),] 
rownames(LKB1_sorted) <- LKB1_sorted[,1] 
LKB1_sorted <- LKB1_sorted[,c(2,3)] 
ST_LKB1_sorted <- ST_LKB1_sorted[!duplicated(ST_LKB1_sorted[,1]),] 
rownames(ST_LKB1_sorted) <- ST_LKB1_sorted[,1] 
ST_LKB1_sorted <- ST_LKB1_sorted[,c(2,3)] 
 
# Check for similarity between the two LKB1 datasets with respect to brute-
directionality 
interceptUP <- NULL    # This 'll contain rows from highest upregalated LKB1 
datasets REGARDLESS of p-value.  
interceptDOWN <- NULL  # This 'll contain rows from lowest downregulated 
LKB1 datasets REGARDLESS of p-value. 
for (i in 1:(dim(LKB1_sorted)[1])) { 
    if (((ST_LKB1_sorted[i,1] >= 0) & (LKB1_sorted[i,1] >= 0)) & 
(ST_LKB1_sorted[i,1] >= LKB1_sorted[i,1])) { 
      interceptUP <- rbind(interceptUP, ST_LKB1_sorted[i,])   
    } else if (((ST_LKB1_sorted[i,1] >= 0) & (LKB1_sorted[i,1] >= 0)) & 
(ST_LKB1_sorted[i,1] < LKB1_sorted[i,1])) { 
      interceptUP <- rbind(interceptUP, LKB1_sorted[i,]) 
    } else if (((ST_LKB1_sorted[i,1] <= 0) & (LKB1_sorted[i,1] <= 0)) & 
(ST_LKB1_sorted[i,1] > LKB1_sorted[i,1])) { 
      interceptDOWN <- rbind(interceptDOWN, LKB1_sorted[i,]) 
    } else if (((ST_LKB1_sorted[i,1] <= 0) & (LKB1_sorted[i,1] <= 0)) & 
(ST_LKB1_sorted[i,1] <= LKB1_sorted[i,1])) { 
      interceptDOWN <- rbind(interceptDOWN, ST_LKB1_sorted[i,]) 
    } 
} 
common <- rbind(interceptUP, interceptDOWN) 
# interceptUP: 4716  
# interceptDOWN:  4645 
# Total: 9361 -> 71.24591% show the same directionality 
 
############################################################################ 
# COMPARING HOW DOES ALL THE SUBSTRATES CONTRIBUTE TO THE OVERALL LKB1-
SIGNATURE TOGETHER AND INDIVIDUALLY (UNIQUELY EXPRESSED GENES WITHIN SINGLE 
SUBSTRATE) 
 
LKB1_adjPVal0.05_logFC0.59 <- subset(LKB1, ((LKB1[,2] >= 0.59 & LKB1[,3] <= 
0.05) | (LKB1[,2] <= -1 & LKB1[,3] <= 0.05))) 
ST_LKB1_adjPVal0.05_logFC0.59 <- subset(ST_LKB1, ((ST_LKB1[,2] >= 0.59 & 
ST_LKB1[,3] <= 0.05) | (ST_LKB1[,2] <= -1 & ST_LKB1[,3] <= 0.05))) 
 
signfUniqPekka <- setdiff(LKB1_adjPVal0.05_logFC0.59[,1], 
ST_LKB1_adjPVal0.05_logFC0.59[,1]) 
signfUniqPekka <- LKB1[LKB1[,1] %in% signfUniqPekka, ] 
signfUniqPekka <- signfUniqPekka[order(signfUniqPekka[,1]) , ] 
 
signfUniqSushil <- setdiff(ST_LKB1_adjPVal0.05_logFC0.59[,1], 
LKB1_adjPVal0.05_logFC0.59[,1]) 
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signfUniqSushil <- ST_LKB1[ST_LKB1[,1] %in% signfUniqSushil, ] 
signfUniqSushil <- signfUniqSushil[order(signfUniqSushil[,1]) , ] 
 
signfCommonPekka <- 
LKB1_adjPVal0.05_logFC0.59[!(LKB1_adjPVal0.05_logFC0.59[,1] %in% 
signfUniqPekka[,1]) , ] 
signfCommonPekka <- signfCommonPekka[order(signfCommonPekka[,1]) , ] 
signfCommonSushil <- 
ST_LKB1_adjPVal0.05_logFC0.59[!(ST_LKB1_adjPVal0.05_logFC0.59[,1] %in% 
signfUniqSushil[,1]) , ] 
signfCommonSushil <- signfCommonSushil[order(signfCommonSushil[,1]) , ] 
colnames(signfCommonSushil) <- colnames(signfCommonPekka) 
 
# How many of the "common" signicant genes are actually COMMON? That is, 
that also share the same directioanlity! 
commonSignfDOWN <- NULL  # 130 ## 25 
commonSignfUP <- NULL  # 178 ## 178 
for (i in 1:dim(signfCommonPekka)[1]) { 
  for (j in 1:dim(signfCommonSushil)[1]) { 
    if ((signfCommonPekka[i,1] == signfCommonSushil[j,1]) & 
(signfCommonPekka[i,2] > 0) & (signfCommonSushil[j,2] > 0) & 
(signfCommonPekka[i,2] > signfCommonSushil[j,2])) { 
      commonSignfUP <- rbind(commonSignfUP, signfCommonPekka[i,]) 
    } else if ((signfCommonPekka[i,1] == signfCommonSushil[j,1]) & 
(signfCommonPekka[i,2] > 0) & (signfCommonSushil[j,2] > 0) & 
(signfCommonPekka[i,2] < signfCommonSushil[j,2])) { 
      commonSignfUP <- rbind(commonSignfUP, signfCommonSushil[j,])  
    } else if ((signfCommonPekka[i,1] == signfCommonSushil[j,1]) & 
(signfCommonPekka[i,2] < 0) & (signfCommonSushil[j,2] < 0) & 
(signfCommonPekka[i,2] < signfCommonSushil[j,2])) { 
      commonSignfDOWN <- rbind(commonSignfDOWN, signfCommonPekka[i,]) 
    } else if ((signfCommonPekka[i,1] == signfCommonSushil[j,1]) & 
(signfCommonPekka[i,2] < 0) & (signfCommonSushil[j,2] < 0) & 
(signfCommonPekka[i,2] > signfCommonSushil[j,2])) { 
      commonSignfDOWN <- rbind(commonSignfDOWN, signfCommonSushil[j,]) 
    } 
  } 
} 
 
# nonSignfPekka <- LKB1[!(LKB1[,1] %in% LKB1_adjPVal0.05_logFC0.59[,1]), ] 
# nonSignfPekka <- nonSignfPekka[order(nonSignfPekka[,1]) , ] 
# nonSignfSushil <- ST_LKB1[!(ST_LKB1[,1] %in% 
ST_LKB1_adjPVal0.05_logFC0.59[,1]), ] 
# nonSignfSushil <- nonSignfSushil[order(nonSignfSushil[,1]) , ] 
# colnames(nonSignfSushil) <- colnames(nonSignfPekka) 
 
# How many of uniquely significant genes in Sushil's LKB1 dataset is 
directionally similar to non-significant genes in  my LKB1 dataset 
commonDOWN_Pekka <- NULL  # 40 
commonUP_Pekka <- NULL    # 88 
nonSignfPekka <- LKB1[(LKB1[,1] %in% signfUniqSushil[,1]) , ] 
nonSignfPekka <- nonSignfPekka[order(nonSignfPekka[,1]) , ] 
for (i in 1:dim(nonSignfPekka)[1]) { 
  for (j in 1:dim(signfUniqSushil)[1]) { 
    if ((nonSignfPekka[i,1] == signfUniqSushil[j,1]) & (nonSignfPekka[i,2] 
>= 0) & (signfUniqSushil[j,2] > 0)) { 
      commonUP_Pekka <- rbind(commonUP_Pekka, nonSignfPekka[i,])   
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    } else if ((nonSignfPekka[i,1] == signfUniqSushil[j,1]) & 
(nonSignfPekka[i,2] <= 0) & (signfUniqSushil[j,2] < 0)) { 
      commonDOWN_Pekka <- rbind(commonDOWN_Pekka, nonSignfPekka[i,]) 
    } 
  } 
} 
# How many of uniquely significant genes in my LKB1 dataset is directionally 
similar to non-significant genes in Sushil's LKB1 dataset 
commonDOWN_Sushil <- NULL  # 91 
commonUP_Sushil <- NULL  # 271 
nonSignfSushil <- ST_LKB1[(ST_LKB1[,1] %in% signfUniqPekka[,1]) , ] 
colnames(nonSignfSushil) <- colnames(nonSignfPekka) 
for (i in 1:dim(nonSignfSushil)[1]) { 
  for (j in 1:dim(signfUniqPekka)[1]) { 
    if ((nonSignfSushil[i,1] == signfUniqPekka[j,1]) & (nonSignfSushil[i,2] 
>= 0) & (signfUniqPekka[j,2] > 0)) { 
      commonUP_Sushil <- rbind(commonUP_Sushil, nonSignfSushil[i,])   
    } else if ((nonSignfSushil[i,1] == signfUniqPekka[j,1]) & 
(nonSignfSushil[i,2] <= 0) & (signfUniqPekka[j,2] < 0)) { 
      commonDOWN_Sushil <- rbind(commonDOWN_Sushil, nonSignfSushil[i,]) 
    } 
  } 
} 
 
# This vector will contain all the significantly and similarly expressed 
(pVal<0.05,  
# log2FC either <-1 or +0.59<) between LKB1_1 and LKB1_2 dataset AND 
# similarly expressed genes between unique significant genes from either 
LKB1_1 or LKB1_2 dataset 
# and the non-significant (outside adjPVal0.05_logFC0.59) from the other 
dataset: 
LKB1comp <- rbind(commonSignfDOWN, 
           commonSignfUP, 
           commonDOWN_Pekka, 
           commonUP_Pekka, 
           commonDOWN_Sushil, 
           commonUP_Sushil) 
# Then use the 'commonWithLkb1' -function from below 
commonWithLkb1(NUAK1, LKB1comp, pValue = 0.05, log2FC = 0.59) 
## Total common up/down genes: 174 / 36 ( 210 )  
## Total up+down genes in NUAK1 : 1573  
## Fraction of all NUAK1 genes: 0.1335029 
commonWithLkb1(NUAK2, LKB1comp, pValue = 0.05, log2FC = 0.59) 
## Total common up/down genes: 112 / 8 ( 120 )  
## Total up+down genes in NUAK2 : 847  
## Fraction of all NUAK2 genes: 0.1416765 
commonWithLkb1(MRK1, LKB1comp, pValue = 0.05, log2FC = 0.59) 
## Total common up/down genes: 33 / 3 ( 36 )  
## Total up+down genes in MRK1 : 433  
## Fraction of all MRK1 genes: 0.08314088 
commonWithLkb1(MRK2, LKB1comp, pValue = 0.05, log2FC = 0.59) 
## Total common up/down genes: 179 / 36 ( 215 )  
## Total up+down genes in MRK2 : 2479  
## Fraction of all MRK2 genes: 0.08672852 
commonWithLkb1(MRK3, LKB1comp, pValue = 0.05, log2FC = 0.59) 
## Total common up/down genes: 73 / 12 ( 85 )  
## Total up+down genes in MRK3 : 1176  
##Fraction of all MRK3 genes: 0.07227891 
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commonWithLkb1(MRK4, LKB1comp, pValue = 0.05, log2FC = 0.59) 
## Total common up/down genes: 25 / 1 ( 26 )  
## Total up+down genes in MRK4 : 406  
## Fraction of all MRK4 genes: 0.06403941 
commonWithLkb1(SIK1, LKB1comp, pValue = 0.05, log2FC = 0.59) 
## Total common up/down genes: 71 / 17 ( 88 )  
## Total up+down genes in SIK1 : 1261  
## Fraction of all SIK1 genes: 0.06978588 
commonWithLkb1(SIK2, LKB1comp, pValue = 0.05, log2FC = 0.59) 
## Total common up/down genes: 31 / 4 ( 35 )  
## Total up+down genes in SIK2 : 773  
## Fraction of all SIK2 genes: 0.04527814 
commonWithLkb1(SIK3, LKB1comp, pValue = 0.05, log2FC = 0.59) 
## Total common up/down genes: 71 / 6 ( 77 )  
## Total up+down genes in SIK3 : 946  
## Fraction of all SIK3 genes: 0.08139535 
commonWithLkb1(SNRK, LKB1comp, pValue = 0.05, log2FC = 0.59) 
## Total common up/down genes: 63 / 7 ( 70 )  
## Total up+down genes in SNRK : 1091  
## Fraction of all SNRK genes: 0.06416132 
commonWithLkb1(AMPKa1, LKB1comp, pValue = 0.05, log2FC = 0.59) 
## Total common up/down genes: 113 / 14 ( 127 )  
## Total up+down genes in AMPKa1 : 2006  
## Fraction of all AMPKa1 genes: 0.06331007 
commonWithLkb1(AMPKa2, LKB1comp, pValue = 0.05, log2FC = 0.59) 
## Total common up/down genes: 157 / 22 ( 179 )  
## Total up+down genes in AMPKa2 : 1150  
## Fraction of all AMPKa2 genes: 0.1556522 
 
x <- subset(SNRK, ((SNRK[,2] > 0.59 & SNRK[,3] <= 0.05) | (SNRK[,2] < -1 & 
SNRK[,3] <= 0.05))) 
write.table(x = x, file = 'SNRK.txt', quote = FALSE, sep = '\t', row.names = 
FALSE, col.names = TRUE) 
 
allGenesFromSubstrates <- c(AMPKa1commonAll, AMPKa2commonAll, 
NUAK1commonAll, NUAK2commonAll, MRK1commonAll, 
                            MRK2commonAll, MRK3commonAll, MRK4commonAll, 
SIK1commonAll, SIK2commonAll, SIK3commonAll, 
                            SNRKcommonAll) 
allGenesFromSubstrates <- unique(allGenesFromSubstrates) 
length(allGenesFromSubstrates)/dim(LKB1comp)[1] 
# >>> 77.34% explained 
 
############################################################################ 
#This for checking the exclusive gene contribution of each substrate 
# From this dataframe you can easily see what genes come from what 
substrates! 
df1 <- data.frame(col = NUAK1commonAll, NUAK1commonAll) 
df2 <- data.frame(col = NUAK2commonAll, NUAK2commonAll) 
df3 <- data.frame(col = MRK1commonAll, MRK1commonAll) 
df4 <- data.frame(col = MRK2commonAll, MRK2commonAll) 
df5 <- data.frame(col = MRK3commonAll, MRK3commonAll) 
df6 <- data.frame(col = MRK4commonAll, MRK4commonAll) 
df7 <- data.frame(col = SIK1commonAll, SIK1commonAll) 
df8 <- data.frame(col = SIK2commonAll, SIK2commonAll) 
df9 <- data.frame(col = SIK3commonAll, SIK3commonAll) 
df10 <- data.frame(col = SNRKcommonAll, SNRKcommonAll) 
df11 <- data.frame(col = AMPKa1commonAll, AMPKa1commonAll) 
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df12 <- data.frame(col = AMPKa2commonAll, AMPKa2commonAll) 
allSubstrates <- Reduce(function(x, y) merge(x, y, all=TRUE), list(df1, df2, 
df3, df4, df5, df6, df7, df8, df9, df10, df11, df12)) 
genes <- allSubstrates[,1]  # < This is just to set the 'allSubstrates' -
genes as the row names 
genes <- as.character(genes) # < The same continues here... 
row.names(allSubstrates) <- genes # < ...and here 
allSubstrates <- allSubstrates[,c(2:13)] # Deleting the first column (all 
genes) 
allSubstrates <- data.matrix(allSubstrates) # data.frame >> data.matrix 
allSubstrates <- ifelse(is.na(allSubstrates), 0, 1) # Renaming the values 
from the data.matrix so that each hit is 1 and miss is 0. 
rivisummat <- rowSums(allSubstrates) == 1 # Check which rows has only one 
substrate! 
table(rivisummat) 
#rivisummat 
#FALSE  TRUE  
#513   268  
rivisummat1 <- allSubstrates[rivisummat, ] 
pylvassummat <- colSums(rivisummat1) # <<< This'll show how many UNIQUE 
genes each substrate has together with LKB1 
 
           # NUAK1commonAll  NUAK2commonAll   MRK1commonAll   MRK2commonAll   
MRK3commonAll   MRK4commonAll   SIK1commonAll  SIK2commonAll   SIK3commonAll   
SNRKcommonAll AMPKa1commonAll AMPKa2commonAll  
# -1;+0.59 # 32              12               2               33              
15              4               11             3               11              
8             20              18     
 
############################################################################ 
# Function for substrate-wise contribution 
commonWithLkb1 <- function(knockdown, comparedTo, pValue, log2FC) { 
  name1 <- deparse(substitute(knockdown)) 
   
  downInKnock <- subset(knockdown, (knockdown[,2] < -(1) & knockdown[,3] <= 
pValue)) 
  upInKnock <- subset(knockdown, (knockdown[,2] > log2FC & knockdown[,3] <= 
pValue)) 
  downInLkb1Union <- subset(comparedTo, (comparedTo[,2] < 0)) 
  upInLkb1Union <- subset(comparedTo, (comparedTo[,2] > 0)) 
  commonDownInKnock <- downInKnock[(downInKnock[,1] %in% 
downInLkb1Union[,1]),] 
  commonUpInKnock <- upInKnock[(upInKnock[,1] %in% upInLkb1Union[,1]),] 
   
  commonAllInKnock <- c(commonDownInKnock[,1], commonUpInKnock[,1]) 
  x <- (dim(commonDownInKnock)[1] + 
dim(commonUpInKnock)[1])/(dim(downInKnock)[1] + dim(upInKnock)[1]) 
   
  assign(paste(deparse(substitute(knockdown)),"commonDOWN", sep = ""), 
commonDownInKnock, .GlobalEnv) 
  assign(paste(deparse(substitute(knockdown)),"commonUP", sep = ""), 
commonUpInKnock, .GlobalEnv) 
  assign(paste(deparse(substitute(knockdown)),"commonAll", sep = ""), 
commonAllInKnock, .GlobalEnv) 
  return(cat("Total common up/down 
genes:",dim(commonUpInKnock)[1],"/",dim(commonDownInKnock)[1],'(',sum(dim(co
mmonUpInKnock)[1],dim(commonDownInKnock)[1]),')',"\n", 
 120 
             "Total up+down genes in",name1,":",(dim(downInKnock)[1] + 
dim(upInKnock)[1]),"\n", 
             "Fraction of all",name1,"genes:",x) 
         ) 
} 
Appendix VI: Gene-by-gene analysis of LKB1 batches and substrate-wise contribution. 
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# APPENDIX VII 
 
library(VennDiagram) 
library(readxl) 
library(RColorBrewer) 
library(tidyverse) 
library(hrbrthemes) 
library(tm) 
library(proustr) 
# Prior plotting prepare excel-sheet with substrates information about 
log2FC, AdjPValue and transcript identifiers 
 
df <- read_excel(path = 'All.xlsx', sheet = 2) 
df <- data.frame(df) 
 
AMPKa1 <- df[,1] 
AMPKa1 <- AMPKa1[complete.cases(AMPKa1)] 
AMPKa2 <- df[,4] 
AMPKa2 <- AMPKa2[complete.cases(AMPKa2)] 
MARK1 <- df[,13] 
MARK1 <- MARK1[complete.cases(MARK1)] 
MARK2 <- df[,16] 
MARK2 <- MARK2[complete.cases(MARK2)] 
MARK3 <- df[,19] 
MARK3 <- MARK3[complete.cases(MARK3)] 
MARK4 <- df[,22] 
MARK4 <- MARK4[complete.cases(MARK4)] 
NUAK1 <- df[,7] 
NUAK1 <- NUAK1[complete.cases(NUAK1)] 
NUAK2 <- df[,10] 
NUAK2 <- NUAK2[complete.cases(NUAK2)] 
SIK1 <- df[,25] 
SIK1 <- SIK1[complete.cases(SIK1)] 
SIK2 <- df[,28] 
SIK2 <- SIK2[complete.cases(SIK2)] 
SIK3 <- df[,31] 
SIK3 <- SIK3[complete.cases(SIK3)] 
SNRK <- df[,34] 
SNRK <- SNRK[complete.cases(SNRK)] 
 
venn.diagram( 
  x = list(AMPKa1, AMPKa2), 
  category.names = c("AMPKa1" , "AMPKa2"), 
  filename = 'AMPK_2_venn_diagramm.png', 
  output=FALSE, 
   
  imagetype="png" , 
  height = 1200 ,  
  width = 1200 ,  
  resolution = 500, 
  compression = "lzw", 
  lwd = 1.5, 
  col = c('#404040', '#404040'), 
  fill = c(alpha("#BF9650",0.9), alpha('#71839A',0.9)), 
  cex = 0.8, 
  fontfamily = "sans", 
  cat.cex = 1, 
  cat.fontface = "bold", 
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  cat.default.pos = "outer", 
  cat.pos = c(0, 0), 
  cat.dist = c(0.055, 0.055), 
  cat.fontfamily = "sans", 
  cat.col = c("#404040", '#404040') 
) 
 
venn.diagram( 
  x = list(NUAK1, NUAK2), 
  category.names = c("NUAK1" , "NUAK2"), 
  filename = 'NUAK_venn_diagramm.png', 
  output=FALSE, 
   
  imagetype="png" , 
  height = 1200 ,  
  width = 1200 ,  
  resolution = 500, 
  compression = "lzw", 
  lwd = 1.5, 
  col = c('#404040', '#404040'), 
  fill = c(alpha("#BF9650",0.9), alpha('#71839A',0.9)), 
  cex = 0.8, 
  fontfamily = "sans", 
  cat.cex = 1, 
  cat.fontface = "bold", 
  cat.default.pos = "outer", 
  cat.pos = c(0, 0), 
  cat.dist = c(0.055, 0.055), 
  cat.fontfamily = "sans", 
  cat.col = c("#404040", '#404040') 
) 
 
venn.diagram( 
  x = list(MARK1, MARK2, MARK3, MARK4), 
  category.names = c("MARK1" , "MARK2", "MARK3", "MARK4"), 
  filename = 'MARK_venn_diagramm.png', 
  output=FALSE, 
  imagetype="png" , 
  height = 1600 ,  
  width = 1800 ,  
  resolution = 500, 
  compression = "lzw", 
  lwd = 1, 
  col = c('#404040', '#404040','#404040', '#404040'), 
  fill = c(alpha("#BF9650",0.9), alpha('#71839A',0.9), alpha('#6A5E40',0.9), 
alpha('#AA6E29',0.9)), 
  cex = 0.8, 
  fontfamily = "sans", 
  cat.cex = 1, 
  cat.fontface = "bold", 
  cat.default.pos = "outer", 
  cat.pos = c(-10, 10, 0, 0), 
  cat.dist = c(0.23, 0.23,0.12, 0.12), 
  cat.fontfamily = "sans", 
  cat.col = c("#404040", '#404040','#404040', '#404040') 
) 
 
venn.diagram( 
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  x = list(SIK1, SIK2, SIK3), 
  category.names = c("SIK1" , "SIK2", "SIK3"), 
   
  filename = 'SIK_venn_diagramm.png', 
  output=FALSE, 
   
  imagetype="png" , 
  height = 1200 ,  
  width = 1200 ,  
  resolution = 500, 
  compression = "lzw", 
  lwd = 1, 
  col = c('#404040', '#404040','#404040'), 
  fill = c(alpha("#BF9650",0.9), alpha('#71839A',0.9), 
alpha('#6A5E40',0.9)), 
  cex = 0.8, 
  fontfamily = "sans", 
  cat.cex = 1, 
  cat.fontface = "bold", 
  cat.default.pos = "outer", 
  cat.pos = c(-10, 10, 0), 
  cat.dist = c(0.05, 0.05,-0.45), 
  cat.fontfamily = "sans", 
  cat.col = c('#404040','#404040', '#404040') 
) 
Appendix VII: Substrate Venn-diagrams. 
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# Appendix VIII: 
# R-script is applied from HOMER 
(http://homer.ucsd.edu/homer/basicTutorial/affymetrix.html) 
# source("http://bioconductor.org/biocLite.R") 
#  
# biocLite('affy') 
# biocLite('oligo') 
# biocLite('limma') 
 
################################################# 
### Microarray analsysis                        # 
### Affymetrix Human Genome U133 Plus 2.0 Array # 
################################################# 
# load the oligo library 
library(oligo) 
library(limma) 
library(readxl) 
library(biomaRt) 
# Read in the CEL files in the directory 
celFiles <- list.celfiles() 
affyRaw <- read.celfiles(celFiles) 
# You might need to install and load a package for the specific array you 
are using (this example is mouse gene 2.0 ST) 
# It may try to load it automatically, but may fail.  Install & load the 
library manually if this happens. 
 
#library(pd.hg.u133.plus.2)  
#library(pd.hg.u133.plus.2) 
#library(pd.hg.u133a) 
#library(pd.hg.u133a.2) 
#library(pd.ht.hg.u133.plus.pm) 
#library(pd.hugene.1.0.st.v1) 
#library(pd.mouse430.2) 
#library(pd.huex.1.0.st.v2) 
 
eset <- rma(affyRaw) #RMA normalization 
 
# Finally, save the data to an output file to be used by other programs, etc 
(Data will be log2 transformed and normalized) 
write.exprs(eset,file="filename_data_ALL.txt") 
 
#library(hgu133plus2.db)  
#library(hgu133a.db) 
#library(hgu133a2.db) 
#library(mouse4302.db) 
#library("mogene10sttranscriptcluster.db") 
#library(huex10stprobeset.db) 
 
# Strategy is to create data frame objects and merge them together - put 
expression info into a data frame 
 
my_frame <- data.frame(exprs(eset)) 
 
# Put annotation information in a data frame.  To get specific fields, use 
packageNameSYMBOL, where the caps part names the type of data you're after 
# To get a list of available annotation information, run the packagename 
with () at the end, i.e. mogene20sttranscriptcluster() 
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# Example 
Annot <- data.frame(ACCNUM=sapply(contents(hgu133plus2ACCNUM), paste, 
collapse=", "),  
                    SYMBOL=sapply(contents(hgu133plus2SYMBOL), paste, 
collapse=", "),  
                    DESC=sapply(contents(hgu133plus2GENENAME), paste, 
collapse=", ")) 
 
# Merge data frames together (like a database table join) 
all <- merge(Annot, my_frame, by.x=0, by.y=0, all=T) 
 
# Write out to a file: 
write.table(all,file="filename_data.ann_ALL.txt",sep="\t") 
 
############################################################################ 
### DE analsysis 
############################################################################ 
# Example analysis: GSE26910. It contains data from breast and prostate 
cancer stromas. 
df <- read.table(file = 'GSE26910_data.ann_ALL.txt', header = TRUE, sep = 
'\t', stringsAsFactors = FALSE) 
 
library(edgeR) 
 
y <- DGEList(counts = df[,5:28], genes = df[,1:4]) 
 
# Design matrix 
exp_design <- data.frame(row.names = colnames(df[5:28]), 
                         names = colnames(df[5:28]), 
                         kd = factor(c('PNF', 'PCAF','PNF', 'PCAF','PNF', 
'PCAF','PNF', 'PCAF','PNF', 'PCAF','PNF', 'PCAF', 
                                       'BNF', 'BCAF','BNF', 'BCAF','BNF', 
'BCAF','BNF', 'BCAF','BNF', 'BCAF','BNF', 'BCAF')) 
) 
 
design <- model.matrix(~0+exp_design$kd) 
 
rownames(design) <- colnames(y) 
colnames(design) <- c('BreastTumor', 'BreastNormal', 'ProstateTumor', 
'ProstateNormal') 
 
#vwts <- voomWithQualityWeights(y, design = design, normalize.method = 
"quantile") 
fit <- lmFit(my_frame, design) 
 
# This would filter in only the highest intesity probe when multiple 
sequences are present for a single gene 
# o <- order(fit$Amean, decreasing=TRUE) # 
https://support.bioconductor.org/p/43745/ 
# dup <- duplicated(fit$genes$SYMBOL[o]) 
# fit.unique <- fit[o,][!dup,] 
 
# Make contrasts: 
my.contrasts <- makeContrasts( 
  ProstateTumor = ProstateTumor - ProstateNormal, 
  BreastTumor = BreastTumor - BreastNormal, 
  levels = design 
) 
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fit.de <- contrasts.fit(fit, my.contrasts) 
fit.de <- eBayes(fit.de) 
 
summary(decideTests(fit.de, adjust.method = "fdr", p.value = 0.05)) 
 
for (i in 1:2) { 
  res <- topTable(fit.de, coef = i, number = Inf, adjust.method = "fdr") 
  write.table(res, file = paste(colnames(my.contrasts)[i], 
"vsNormal_ALL.txt", sep = ""), row.names = TRUE, sep = "\t", quote = FALSE) 
} 
 
############################################################################ 
### Post-annotation 
############################################################################ 
 
df2 <- read.delim("ProstateTumorvsNormal_ALL.txt", check.names = FALSE, 
stringsAsFactors = FALSE) 
df2 <- read.delim("BreastTumorvsNormal_ALL.txt", check.names = FALSE, 
stringsAsFactors = FALSE) 
 
df2 <- merge(Annot, df2, by.x=0, by.y=0, all=T) 
write.table(df2, file = "BreastTumorvsNormal_ALL.txt", row.names = TRUE, sep 
= "\t", quote = FALSE) # Re-save the DE-dataframe with annotations to the 
sane file-name. 
 
############################################################################ 
### Probe filtering 
############################################################################ 
 
df3 <- read.delim("ProstateTumorvsNormal_ALL.txt", check.names = FALSE, 
stringsAsFactors = FALSE) 
df3 <- read.delim("BreastTumorvsNormal_ALL.txt", check.names = FALSE, 
stringsAsFactors = FALSE) 
 
df3 <- df3[,c(1,3,5:10)] 
 
# Remove genes named 'NA'; some probes didn't contain any annotated gene 
symbol at all. 
df3 <- df3[complete.cases(df3[,2]),] 
 
unique_genes_in_df4 <- unique(df3[,2]) 
 
result <- NULL 
for (i in 1:length(unique_genes_in_df4)) { 
  gene <- unique_genes_in_df4[i] 
  genes_in_df4 <- df3[df3[,2] %in% gene, ] 
  genes_in_df4 <- genes_in_df4[order(genes_in_df4[,7]) , ] 
  result <- rbind(result, genes_in_df4[1,]) 
} 
 
write.table(x = result, file = 
'ProstateTumorvsNormal_probefiltered_ALL.txt', row.names = F, sep = "\t", 
quote = FALSE) 
write.table(x = result, file = 'BreastTumorvsNormal_probefiltered_ALL.txt', 
row.names = F, sep = "\t", quote = FALSE) 
 
############################################################################ 
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### GSEA file formatting: 
### *.rnk.txt 
### *.500_ALL.gmx 
############################################################################ 
 
df4 <- read.table(file = 'ProstateTumorvsNormal_probefiltered_ALL.txt', 
header = TRUE, sep = '\t', stringsAsFactors = FALSE) 
df4 <- read.table(file = 'BreastTumorvsNormal_probefiltered_ALL.txt', header 
= TRUE, sep = '\t', stringsAsFactors = FALSE) 
 
 
# GSEA-file 
GSEA_file <- df4[order(df4[,3]) , ] 
GSEA_file <- GSEA_file[,c(2,3)] 
 
write.table(x = GSEA_file, file = 
'GSE26910_ProstateTumorvsNormal_GSEA_Hs.rnk.txt', row.names = FALSE, sep = 
"\t", quote = FALSE) 
write.table(x = GSEA_file, file = 
'GSE26910_BreastTumorvsNormal_GSEA_Hs.rnk.txt', row.names = FALSE, sep = 
"\t", quote = FALSE) 
 
GSEA_file <- read.table(file = 
'GSE26910_BreastTumorvsNormal_GSEA_Hs.rnk.txt', header = T, sep = '\t', 
stringsAsFactors = F) 
 
result_signf_up <-  GSEA_file[1:250,]# Total 250 
result_signf_down <- GSEA_file[((dim(GSEA_file)[1])-
250+1):(dim(GSEA_file)[1]),] # Total 250 
result_signf_1 <- rbind(result_signf_up, result_signf_down) 
 
result_signf_up <-  GSEA_file[1:500,]# Total 250 
#result_signf_down <- GSEA_file[15684:15933,] # Total 250 
result_signf_2 <- rbind(result_signf_up) 
 
#result_signf_up <-  GSEA_file[1:250,]# Total 250 
result_signf_down <- GSEA_file[((dim(GSEA_file)[1])-
500+1):(dim(GSEA_file)[1]),] # Total 250 
result_signf_3 <- rbind(result_signf_down) 
 
result_GSEA_names_1 <- result_signf_1[,c(1)] 
result_GSEA_names_2 <- result_signf_2[,c(1)] 
result_GSEA_names_3 <- result_signf_3[,c(1)] 
 
write.table(x = result_GSEA_names_1, file = 
'GSE26910_BreastTumorvsNormal_500_ALL.gmx', row.names = FALSE, sep = "\t", 
quote = FALSE) 
write.table(x = result_GSEA_names_2, file = 
'GSE26910_BreastTumorvsNormal_500_DOWN_ALL.gmx', row.names = FALSE, sep = 
"\t", quote = FALSE) 
write.table(x = result_GSEA_names_3, file = 
'GSE26910_BreastTumorvsNormal_500_UP_ALL.gmx', row.names = FALSE, sep = 
"\t", quote = FALSE) 
Appendix VIII: Example R-script for microarray data analysis. Example analysis of GSE26910. 
Script contains filtering, background correction, annotating, DE-analysis and GSEA-file formatting (ranked 
gene list and (Top-/Bottom- and overall-) gene set). 
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# Appendix IX: 
# Input the GEO2R generated differential expression table and filter 
ambiguous expressions: 
df <- read.table(file = 'filename.txt', header = TRUE, sep = '\t', 
stringsAsFactors = FALSE) 
df <- df[,c(8,6,3,2)] 
df[,1] <- gsub("/.*","",df[,1]) 
 
#df$'refseq_mRNA' <- sub("\\..*", "", df[,1]) 
#df <- df[,c(5,2:4)] 
df <- df[complete.cases(df[,1]) , ] 
df <- df[!(df[,1]==""), ] 
 
# Include the array-probes with the highest statisticl significance: 
unique_genes_in_df4 <- unique(df[,1]) 
 
result <- NULL 
for (i in 1:length(unique_genes_in_df4)) { 
  gene <- unique_genes_in_df4[i] 
  genes_in_df4 <- df[df[,1] %in% gene, ] 
  genes_in_df4 <- genes_in_df4[order(genes_in_df4[,3]) , ] 
  result <- rbind(result, genes_in_df4[1,]) 
} 
 
#--------------------------------------------------------------------------- 
# biomaRt homolog fetching; the script depends on what kind of identifiers 
the original arrya was using. 
 
library(biomaRt) 
# ensembl = useMart("ensembl") 
# datasets = listDatasets(ensembl) 
# genes = result$GB_ACC 
#  
# human = useMart("ensembl", dataset = "hsapiens_gene_ensembl") 
# mouse = useMart("ensembl", dataset = "mmusculus_gene_ensembl") 
# G_list <- getLDS(attributes = c('mgi_symbol','refseq_mrna'), 
#                  filters = "refseq_mrna", values = genes,mart = mouse, 
#                  attributesL = c("hgnc_symbol"), martL = human) 
#  
# mergedData <- merge(x = df, 
#                     y = G_list, 
#                     by.x = "GB_ACC", 
#                     by.y = "RefSeq.mRNA.ID" 
# ) 
 
#-- 
#----- 
#-- 
 
ensembl = useDataset("hsapiens_gene_ensembl", useMart("ensembl")) 
 
#result[,1] <- gsub("[.].*$", "", result[,1]) 
genes = result[,1] 
 
G_list <- getBM(attributes= c('hgnc_symbol','refseq_mrna'), 
                filters= 'refseq_mrna', 
                values=genes, 
                mart= ensembl) 
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mergedData <- merge(x = result, 
                    y = G_list, 
                    by.x = 'GB_ACC', 
                    by.y = "refseq_mrna" 
) 
# # #----------------------------------------------------------------------- 
mergedData <- mergedData[,c(5,2:4)] 
mergedData <- unique(mergedData) 
mergedData <- mergedData[!(mergedData$hgnc_symbol==""), ] 
mergedData <- mergedData[complete.cases(mergedData) , ] 
# Re-do filtering 
unique_genes_in_df4 <- unique(mergedData[,1]) 
result <- NULL 
for (i in 1:length(unique_genes_in_df4)) { 
  gene <- unique_genes_in_df4[i] 
  genes_in_df4 <- mergedData[mergedData[,1] %in% gene, ] 
  genes_in_df4 <- genes_in_df4[order(genes_in_df4[,3]) , ] 
  result <- rbind(result, genes_in_df4[1,]) 
} 
write.table(x = result, file = 'filename_probefiltered_ALL.txt', row.names = 
F, sep = "\t", quote = FALSE) 
 
#--------------------------------------------------------------------------- 
# GSEA file formatting: 
 
df2 <- read.table(file = 'filename_probefiltered_ALL.txt', header = TRUE, 
sep = '\t', stringsAsFactors = FALSE) 
# GSEA-file 
GSEA_file <- df2[order(df2[,2]) , ] 
GSEA_file <- GSEA_file[,c(1,2)] 
# Optional filtering 
# GSEA_file_new <- gsub("/.*","",GSEA_file[,1]) 
# GSEA_file_new <- gsub("//.*","",GSEA_file_new) 
# GSEA_file_new <- gsub("///.*","",GSEA_file_new) 
# GSEA_file_new <- gsub("////.*","",GSEA_file_new) 
# GSEA_file_new <- gsub("@.*","",GSEA_file_new) 
# GSEA_file[,3] <- GSEA_file_new 
# GSEA_file <- GSEA_file[,c(3,2)] 
# GSEA_file_new <- GSEA_file[ grep("//", GSEA_file$Gene.symbol, invert = 
TRUE) , ] 
write.table(x = GSEA_file, file = 'GSE90505_CAF-vs-CNTRL_GSEA_Hs.rnk.txt', 
row.names = FALSE, sep = "\t", quote = FALSE) 
 
# Gene set file generation: bottom, down 
GSEA_file <- read.table(file = 'filename_GSEA_Hs.rnk.txt', header = T, sep = 
'\t', stringsAsFactors = F) 
 
result_signf_up <-  GSEA_file[1:250,]# Total 250 
result_signf_down <- GSEA_file[18753:19002,] # Total 250 
result_signf_1 <- rbind(result_signf_up, result_signf_down) 
 
result_signf_up <-  GSEA_file[1:500,]# Total 250 
#result_signf_down <- GSEA_file[18503:19002,] # Total 250 
result_signf_2 <- rbind(result_signf_up) 
 
#result_signf_up <-  GSEA_file[1:250,]# Total 250 
result_signf_down <- GSEA_file[18503:19002,] # Total 250 
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result_signf_3 <- rbind(result_signf_down) 
 
result_GSEA_names_1 <- result_signf_1[,c(1)] 
result_GSEA_names_2 <- result_signf_2[,c(1)] 
result_GSEA_names_3 <- result_signf_3[,c(1)] 
 
write.table(x = result_GSEA_names_1, file = 'filename_500_ALL.gmx', 
row.names = FALSE, sep = "\t", quote = FALSE) 
write.table(x = result_GSEA_names_2, file = 'filename__500_DOWN_ALL.gmx', 
row.names = FALSE, sep = "\t", quote = FALSE) 
write.table(x = result_GSEA_names_3, file = 'filename__500_UP_ALL.gmx', 
row.names = FALSE, sep = "\t", quote = FALSE) 
Appendix IX: Example R-script for GEO2R DE-table analysis. Here, the differential expression is 
conducted inside the browser-based analysis tool (Gene Expression Omnibus) and the expression table is 
saved and imported into the R-environment for further formatting. The script depends on the also on the input 
file (array type, species, identifiers etc.).  
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# APPENDIX X 
library(gplots) 
library(pheatmap) 
library(readxl) 
library(ggplot2) 
library(DESeq2) 
library(data.table) 
library(pheatmap); library("RColorBrewer") 
library(cluster) 
library(dplyr) 
 
##################################### 
###   Import file and             ### 
###   generate common dataframe   ### 
##################################### 
 
file_list <- list.files() 
 
# Format the files to fit together 
for (file in file_list){ 
   
  temp_dataset <-read.table(file, header=TRUE, sep="\t" 
                            , col.names = c('ID',as.character(file)) 
                            ) 
  temp_dataset[,1] <- gsub("/.*","",temp_dataset[,1]) 
  temp_dataset[,1] <- gsub(";.*$", "", temp_dataset[,1]) 
  temp_dataset[,1] <- gsub("_.*$", "", temp_dataset[,1]) 
   
  if (length(unique(temp_dataset[,1])) == dim(temp_dataset)[1]) { 
    row.names(temp_dataset)<-temp_dataset[,1] 
    temp_dataset<-data.frame(temp_dataset) 
    assign(paste(file), temp_dataset, .GlobalEnv) 
    rm(temp_dataset) 
   
  } else { 
    unique_genes_in_df4 <- unique(temp_dataset[,1]) 
    result <- NULL 
    for (i in 1:length(unique_genes_in_df4)) { 
      gene <- unique_genes_in_df4[i] 
      genes_in_df4 <- temp_dataset[temp_dataset[,1] %in% gene, ] 
      genes_in_df4 <- genes_in_df4[order(genes_in_df4[,2]) , ] 
      result <- rbind(result, genes_in_df4[1,]) 
    } 
     
    temp_dataset<-result 
    row.names(temp_dataset)<-temp_dataset[,1] 
    temp_dataset<-data.frame(temp_dataset) 
    assign(paste(file), temp_dataset, .GlobalEnv) 
    rm(temp_dataset) 
  } 
} 
 
flightsList<-list(GSE101665_CAFvsNF_GSEA.Hs.rnk.txt, `GSE114056_CAF-vs-
CNTRL_GSEA_Hs.rnk.txt`, `GSE116167_44As3-vs-NF_GSEA_Hs.rnk.txt`, 
                  `GSE116167_HSC44PE-vs-NF_GSEA_Hs.rnk.txt`,`GSE116679_HIGH-
vs-LOW_GSEA_Hs.rnk.txt`, GSE118624_GSEA.rnk.txt, 
                  GSE1724_FASScvsCNTRL_GSEA_Hs.rnk.txt, 
GSE1724_IPFvsCNTRL_GSEA_Hs.rnk.txt, GSE20086_CAFvsNF_GSEA_Hs.rnk.txt, 
 132 
                  GSE22862_CAFvsNF_GSEA_Hs.rnk.txt, 
                  GSE29270_CAFvsNF_GSEA_Hs.rnk.txt, 
GSE34312_CancerVSnormal_GSEA_Hs.rnk.txt, `GSE35364_CAF-vs-
CNTRL_GSEA_Hs.rnk.txt`, 
                  `GSE35364_coCAF-vs-
CNTRL_GSEA_Hs.rnk.txt`,GSE37738_cSCCvsNF_GSEA_Hs.rnk.txt, 
GSE37738_RDEBcSCCvsNF_GSEA_Hs.rnk.txt, 
                  GSE37738_RDEBvsNF_GSEA_Hs.rnk.txt, 
GSE38517_CAF_MLvsNF_GSEA_Hs.rnk.txt, GSE38517_CAFvsNF_GSEA_Hs.rnk.txt, 
                  GSE38517_DysplasticvsNF_GSEA_Hs.rnk.txt, 
GSE40839_IntPneumvsNF_GSEA_Hs.rnk.txt, 
GSE40839_ScleroCAFvsNF_GSEA_Hs.rnk.txt, 
                  GSE43770_CAFvsNF.Hs.rnk.txt, `GSE44723_rapidIPF-vs-
CNTRL_GSEA_Hs.rnk.txt`, `GSE44723_stableIPF-vs-CNTRL_GSEA_Hs.rnk.txt`, 
                  `GSE45256_ADENO-vs-NF_GSEA_Hs.rnk.txt`, `GSE45256_CAF-vs-
NF_GSEA_Hs.rnk.txt`, `GSE45256_HYP-vs-NF_GSEA_Hs.rnk.txt`, 
                  `GSE45686_IPF-vs-CNTRL_GSEA_Hs.rnk.txt`, 
GSE46824_GSEA.rnk.txt, `GSE48397_CAF-vs-CNTRL_GSEA_Hs.rnk.txt`, 
`GSE62740_CAF-vs-CNTRL_GSEA_Hs.rnk.txt`, 
                  GSE67250_GSEA_Hs.rnk.txt, 
GSE68164_CAFvsNF_GSEA_Hs.rnk.txt, GSE70468_CAFvsNF_GSEA_Hs.rnk.txt, 
                  GSE71078_CAFvsNF_GSEA_Hs.rnk.txt, `GSE71351_RAPID_IPF-vs-
CNTRL_GSEA_Hs.rnk.txt`, `GSE71351_SLOW_IPF-vs-CNTRL_GSEA_Hs.rnk.txt`, 
                  GSE73728_day11_TCLNvsPBS_GSEA_Hs.rnk.txt, 
GSE73728_day4_TCLNvsPBS_GSEA_Hs.rnk.txt, GSE79786_PAHvsCNTL_GSEA_Hs.rnk.txt, 
                  GSE83314_MUTvsWT_GSEA.Hs.rnk.txt, 
GSE83834_MUTvsWT_GSEA.Hs.rnk.txt, `GSE85606_CAF-vs-CNTRL_GSEA.Hs.rnk.txt`, 
                  `GSE86256_CAF-vs-CNTRL_GSEA_Hs.rnk.txt`, 
GSE90607_INFLvsNF_GSEA_Hs.rnk.txt, GSE90607_STENOvsNF_GSEA_Hs.rnk.txt, 
                  `GSE93313_TRANSWELL-vs-3D_GSEA.Hs.rnk.txt`, 
`GSE99816_INFL-vs-CNTRL_GSEA_Hs.rnk.txt`, `GSE99816_NON_INFL-vs-
CNTRL_GSEA_Hs.rnk.txt`, 
                  `GSE99816_STENO-vs-CNTRL_GSEA_Hs.rnk.txt`) 
 
# Merge the DE dataframes 
df<-Reduce(function(x, y) merge(x, y, all=TRUE), flightsList) 
 
df1<-df 
#df <- df1 
df <- df[-c(1) , ] 
 
# Filter out genes which are out in majority of arrays/sequencings 
na_count <- apply(df, 1, function(x) sum(is.na(x))) 
 
# Taking into account that not all the transcripts are identified in all of 
the samples. 
# If a gene is expressed in more the 90% of samples, it is accepted; sample 
that do not  
# express the gene in this 90% will be denoted as zeroes (NA values are not 
accepted 
# in hierarchical clustering). 
rows<-NULL 
for (i in 1:dim(df)[1]) { 
  if (na_count[i] <= 5) { 
    df[i,][is.na(df[i,] ) ] <- 0 
    rows<-rbind(rows, df[i,1]) 
  } 
} 
 133 
 
df2 <- df[df$ID %in% rows, ] 
row.names(df2)<-df2[,1] 
#write.table(x = df2, file = 'df2_IndirectCAF.txt', row.names = FALSE, sep = 
"\t", quote = FALSE) 
df2<-df2[,-c(1)] 
 
# (Convert to Z-scores???) 
commonDF<-df2 
commonDF<-data.matrix(commonDF) 
commonDF<-commonDF[order(rowSums(commonDF),decreasing=T),] 
# Only include to TOP/BOTTOM1000 expressed genes 
commonDFup <-  commonDF[1:1000,] 
commonDFdown <- commonDF[7654:8653,] 
commonDF <- rbind(commonDFup, commonDFdown) 
 
#--------------------------------------------------------------------------- 
############################################################################ 
###    k-means clusteirng                                                         
###    http://girke.bioinformatics.ucr.edu/GEN242/mydoc_Rclustering_4.html        
############################################################################ 
 
yscaled <- t(scale(t(commonDF))) 
apply(yscaled, 1, sd) 
 
dist(commonDF[1:4,], method = "euclidean") 
 
# Correlation matrix 
c <- cor(t(commonDF), method="pearson")  
#as.matrix(c)[1:4,1:4] 
 
# Correlation-based distance matrix 
d <- as.dist(1-c) 
#as.matrix(d)[1:4,1:4] 
 
#------------------------ 
# Hierarchical clustering 
 
hr <- hclust(d, method = "complete", members=NULL) 
names(hr) 
 
#par(mfrow = c(1, 2)); plot(hr, hang = 0.1); plot(hr, hang = -1)  
 
hc <- hclust(as.dist(1-cor(yscaled, method="spearman")), method="complete") 
#mycol <- colorpanel(40, "darkblue", "yellow", "white") 
 
colfunc <- colorRampPalette(c("#d36000", "white", "#00306e")) 
 
#---------------------------- 
# K-Means Clustering with PAM 
 
pamy <- pam(d, 4) 
(kmcol <- pamy$clustering) 
 
heatmap.2(commonDF, 
          Rowv=as.dendrogram(hr), 
          Colv=as.dendrogram(hc), 
          #col = brewer.pal(9,"PuOr"), 
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          col = colfunc(45), 
          scale="row", 
          density.info="none", 
          trace="none", 
          #RowSideColors=as.character(kmcol), 
          labRow = F, 
          margins = c(12, 1), 
          cexCol = 0.95, 
          srtCol = 35, 
          lhei = c(0.6,5) 
) 
Appendix X: R-script for hierarchical cluster of published CAF-datasets (Fig3B). As an example 
the indirect patient samples. Hierarchical clustering was performed similarly in MEF-samples (Fig2A), direct 
patient samples (Fig3A) and with curated CAF-genes (FigS4). 
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# APPENDIX XI 
library(gplots) 
library(pheatmap) 
library(readxl) 
library(ggplot2) 
library(DESeq2) 
library(data.table) 
library(pheatmap); library("RColorBrewer") 
library(cluster) 
library(dplyr) 
 
##################################### 
###   Import file and             ### 
###   generate common dataframe   ### 
##################################### 
 
inFilePaths = list.files(path=".", pattern=glob2rx("*"), full.names=TRUE) 
 
for (inFilePath in inFilePaths) { 
  inFileData = read.csv(inFilePath) 
  print(inFilePath) 
} 
#--------------------------------------------------------------------------- 
# Apparently there are still some dublicated rows. These are not allowed 
when merging the dataframes, thus need to be removed 
# (internal for-loop) 
file_list <- list.files() 
 
for (file in file_list){ 
   
  temp_dataset <-read.table(file, header=TRUE, sep="\t", col.names = 
c('ID',as.character(file))) 
  temp_dataset[,1] <- gsub("/.*","",temp_dataset[,1]) 
  temp_dataset[,1] <- gsub(";.*$", "", temp_dataset[,1]) 
  temp_dataset[,1] <- gsub("_.*$", "", temp_dataset[,1]) 
   
  if (length(unique(temp_dataset[,1])) == dim(temp_dataset)[1]) { 
    row.names(temp_dataset)<-temp_dataset[,1] 
    temp_dataset<-data.frame(temp_dataset) 
    assign(paste(file), temp_dataset, .GlobalEnv) 
    rm(temp_dataset) 
   
  } else { 
    unique_genes_in_df4 <- unique(temp_dataset[,1]) 
    result <- NULL 
    for (i in 1:length(unique_genes_in_df4)) { 
      gene <- unique_genes_in_df4[i] 
      genes_in_df4 <- temp_dataset[temp_dataset[,1] %in% gene, ] 
      genes_in_df4 <- genes_in_df4[order(genes_in_df4[,2]) , ] 
      result <- rbind(result, genes_in_df4[1,]) 
    } 
     
    temp_dataset<-result 
    row.names(temp_dataset)<-temp_dataset[,1] 
    temp_dataset<-data.frame(temp_dataset) 
    assign(paste(file), temp_dataset, .GlobalEnv) 
    rm(temp_dataset) 
  } 
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} 
 
flightsList<-list(GSE101665_CAFvsNF_GSEA.Hs.rnk.txt, `GSE114056_CAF-vs-
CNTRL_GSEA_Hs.rnk.txt`, `GSE116167_44As3-vs-NF_GSEA_Hs.rnk.txt`, 
                  `GSE116167_HSC44PE-vs-NF_GSEA_Hs.rnk.txt`, 
GSE118624_GSEA.rnk.txt, GSE20086_CAFvsNF_GSEA_Hs.rnk.txt, 
                  `GSE35364_CAF-vs-CNTRL_GSEA_Hs.rnk.txt`, 
GSE37738_cSCCvsNF_GSEA_Hs.rnk.txt, GSE37738_RDEBcSCCvsNF_GSEA_Hs.rnk.txt, 
                  GSE37738_RDEBvsNF_GSEA_Hs.rnk.txt, 
GSE38517_CAF_MLvsNF_GSEA_Hs.rnk.txt, GSE40839_IntPneumvsNF_GSEA_Hs.rnk.txt, 
                  GSE40839_ScleroCAFvsNF_GSEA_Hs.rnk.txt, 
`GSE44723_rapidIPF-vs-CNTRL_GSEA_Hs.rnk.txt`, `GSE44723_stableIPF-vs-
CNTRL_GSEA_Hs.rnk.txt`, 
                  GSE46824_GSEA.rnk.txt, GSE70468_CAFvsNF_GSEA_Hs.rnk.txt, 
GSE83834_MUTvsWT_GSEA.Hs.rnk.txt, 
                  `GSE99816_INFL-vs-CNTRL_GSEA_Hs.rnk.txt`, 
`GSE99816_NON_INFL-vs-CNTRL_GSEA_Hs.rnk.txt`, `GSE99816_STENO-vs-
CNTRL_GSEA_Hs.rnk.txt`) 
 
# Merge the DE dataframes 
df<-Reduce(function(x, y) merge(x, y, all=TRUE), flightsList) 
 
df1<-df 
df <- df[-c(1) , ] 
 
# Filter out genes which are out in majority of arrays/sequencings 
na_count <- apply(df, 1, function(x) sum(is.na(x))) 
 
rows<-NULL 
for (i in 1:dim(df)[1]) { 
  if (na_count[i] <= 2) { 
    df[i,][is.na(df[i,] ) ] <- 0 
    rows<-rbind(rows, df[i,1]) 
  } 
} 
 
#df$na_count_2 <- apply(df, 1, function(x) sum(is.na(x))) 
 
df2 <- df[df$ID %in% rows, ] 
row.names(df2)<-df2[,1] 
#write.table(x = df2, file = 
'CommonGenes_Cluster1_PatientDerivedDirect.txt', row.names = FALSE, sep = 
"\t", quote = FALSE) 
df2<-df2[,-c(1)] 
 
# Z-scoring, though his didn't seem to result anything meaningfull since 
normalized values sum up to zero. Extremely small values etc. not good for 
ranking the genes. 
# df2_scaled <- scale(t(df2)) 
# df2_scaled <- t(df2_scaled) 
# df2_scaled <- data.frame(df2_scaled) 
# df2_scaled$'SUM'<-rowSums(df2_scaled) 
# df2$'Zscores' <- rowSums(df2_scaled)/13 
 
df2$'Average'<-rowSums(df2)/21 
df2$'ID'<-row.names(df2) 
 
df3<-df2[,c(23,22)] 
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df3<-df3[order(df3[,2]) , ] 
write.table(x = df3, file = 'CommonGenes_Cluster1_2.0_NEW_Hs.GSEA.rnk.txt', 
row.names = FALSE, sep = "\t", quote = FALSE) 
df3<-read.table(file = 'CommonGenes_Cluster1_2.0_NEW_Hs.GSEA.rnk.txt', 
header = T, sep = '\t', stringsAsFactors = F) 
 
df4UP <-  df3[1:250,] 
write.table(x = df4UP, file = 
'PatientDerivedIndirect_2.0_NEW_CommonGenes_Cluster1_DOWN_Hs.GSEA.rnk.txt', 
row.names = FALSE, sep = "\t", quote = FALSE) 
df4DOWN <- df3[10014:10263,] 
write.table(x = df4DOWN, file = 
'PatientDerivedIndirect_2.0_NEW_CommonGenes_Cluster1_UP_Hs.GSEA.rnk.txt', 
row.names = FALSE, sep = "\t", quote = FALSE) 
Appendix XI: Merging and GSEA-formatting of patient CAF-clusters. After 
identification of patient clusters with Appendix X, the individual CAF-data and dinned 
according to hierarchical clustering. As in Appendix X, cluster-specific data are combined 
and merged (averaged). Finally ranked GSEA-gene list and Top-/Bottom-gene sets are 
generated for following enrichment analyses. As an example is patient derived, indirect 
cluster II. 
